



Our Ref. No.: NUVO-02CP

**METHODS OF THERAPY AND DIAGNOSIS USING
TARGETING OF CELLS THAT EXPRESS KILLER
CELL IMMUNOGLOBULIN-LIKE RECEPTOR-LIKE
PROTEIN**

Express Mail Label No.: EV 331 981 099 US

**METHODS OF THERAPY AND DIAGNOSIS USING TARGETING OF CELLS
THAT EXPRESS KILLER CELL IMMUNOGLOBULIN-LIKE RECEPTOR-
LIKE PROTEIN**

5 **1. CROSS REFERENCE TO RELATED APPLICATIONS**

 This application is a continuation-in-part of U.S. Application Serial No.
10/414,539 filed on April 14, 2003, entitled "Methods of Therapy and Diagnosis Using
Targeting of Cells that Express Killer Cell Immunoglobulin-like Receptor-like Protein,;
Attorney Docket No. NUVO-02, which in turn is a continuation-in-part application of
10 PCT Application Serial No. PCT/US01/02623 filed on January 25, 2001, entitled "Novel
Nucleic Acids and Polypeptides," Attorney Docket No. 785CIP3/PCT, which in turn is a
continuation-in-part application of PCT Application Serial No. PCT/US01/02687 filed on
January 25, 2001, entitled "Novel Nucleic Acids and Polypeptides," Attorney Docket No.
785CIP2-2C/PCT, which in turn is a continuation-in-part application of U.S. Application
15 Serial No. 09/631,451 filed on August 03, 2000, entitled "Novel Nucleic Acids and
Polypeptides," Attorney Docket No. 785CIP2B, which in turn is a continuation-in-part
application of U.S. Application Serial No. 09/491,404 (now abandoned) filed on January
25, 2000, entitled "Novel Contigs Obtained from Various Libraries," Attorney Docket
No. 785. These and all other U.S. Patents and Patent Applications cited herein are hereby
20 incorporated by reference in their entirety.

2. BACKGROUND

2.1 TECHNICAL FIELD

 This invention relates to compositions and methods for targeting killer cell
25 immunoglobulin-like receptor-like protein (herein denoted KIRHy1)-expressing cells
using antibodies, polypeptides, polynucleotides, peptides, and small molecules and their
use in the therapy and diagnosis of various pathological states, including cancer,
autoimmune disease, organ transplant rejection, allergic reactions, and inflammatory
disorders.

30

2.2 BACKGROUND ART

Immunotherapy provides a method of harnessing the immune system to treat various pathological states, including cancer, autoimmune disease, transplant rejection, hyperproliferative conditions, allergic reactions, emphysema, and wound healing.

5 For example, antibody therapy for cancer involves the use of antibodies, or antibody fragments, against a tumor antigen to target antigen-expressing cells.

Antibodies, or antibody fragments, may have direct or indirect cytotoxic effects or may be conjugated or fused to cytotoxic moieties. Direct effects include the induction of apoptosis, the blocking of growth factor receptors, and anti-idiotypic antibody formation.

10 Indirect effects include antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-mediated cellular cytotoxicity (CMCC). When conjugated or fused to cytotoxic moieties, the antibodies, or fragments thereof, provide a method of targeting the cytotoxicity towards the tumor antigen expressing cells. (Green, *et al.*, *Cancer Treatment Reviews*, 26:269-286 (2000), incorporated herein by reference in its entirety).

15 Because antibody therapy targets cells expressing a particular antigen, there is a possibility of cross-reactivity with normal cells or tissue. Although some cells, such as hematopoietic cells, are readily replaced by precursors, cross-reactivity with many tissues can lead to detrimental results. Thus, considerable research has gone towards finding tumor-specific antigens. Such antigens are found almost exclusively on tumors or are
20 expressed at a greater level in tumor cells than the corresponding normal tissue. Tumor-specific antigens provide targets for antibody targeting of cancer, or other disease-related cells, expressing the antigen. Antibodies specific to such tumor-specific antigens can be conjugated to cytotoxic compounds or can be used alone in immunotherapy.

Immunotoxins target cytotoxic compounds to induce cell death. For example, anti-CD22
25 antibodies conjugated to deglycosylated ricin A may be used for treatment of B cell lymphoma that has relapsed after conventional therapy (Amlot, *et al.*, *Blood* 82:2624-2633 (1993), incorporated herein by reference in its entirety) and has demonstrated encouraging responses in initial clinical studies.

30 The immune system functions to eliminate organisms or cells that are recognized as non-self, including microorganisms, neoplasms and transplants. A cell-mediated host response to tumors includes the concept of immunologic surveillance, by which cellular

mechanisms associated with cell-mediated immunity, destroy newly transformed tumor cells after recognizing tumor-associated antigens (antigens associated with tumor cells that are not apparent on normal cells). Furthermore, a humoral response to tumor-associated antigens enables destruction of tumor cells through immunological processes triggered by the binding of an antibody to the surface of a cell, such as antibody-dependent cellular cytotoxicity (ADCC) and complement mediated lysis.

Recognition of an antigen by the immune system triggers a cascade of events including cytokine production, B-cell proliferation, and subsequent antibody production. Often tumor cells have reduced capability of presenting antigen to effector cells, thus impeding the immune response against a tumor-specific antigen. In some instances, the tumor-specific antigen may not be recognized as non-self by the immune system, preventing an immune response against the tumor-specific antigen from occurring. In such instances, stimulation or manipulation of the immune system provides effective techniques of treating cancers expressing one or more tumor-specific antigens.

For example, Rituximab (Rituxan®) is a chimeric antibody directed against CD20, a B cell-specific surface molecule found on >95% of B-cell non-Hodgkin's lymphoma (Press, *et al.*, *Blood* 69:584-591 (1987); Malony, *et al.*, *Blood* 90:2188-2195 (1997), both of which are incorporated herein in their entirety). Rituximab induces ADCC and inhibits cell proliferation through apoptosis in malignant B cells *in vitro* (Maloney, *et al.*, *Blood* 88:637a (1996), incorporated herein by reference in its entirety). Rituximab is currently used as a therapy for advanced stage or relapsed low-grade non-Hodgkin's lymphoma, which has not responded to conventional therapy.

Active immunotherapy, whereby the host is induced to initiate an immune response against its own tumor cells can be achieved using therapeutic vaccines. One type of tumor-specific vaccine uses purified idiotype protein isolated from tumor cells, coupled to keyhole limpet hemocyanin (KLH) and mixed with adjuvant for injection into patients with low-grade follicular lymphoma (Hsu, *et al.*, *Blood* 89:3129-3135 (1997), incorporated herein by reference in its entirety). Another type of vaccine uses antigen-presenting cells (APCs), which present antigen to naïve T cells during the recognition and effector phases of the immune response. Dendritic cells, one type of APC, can be used in a cellular vaccine in which the dendritic cells are isolated from the patient, co-cultured

with tumor antigen and then reinfused as a cellular vaccine (Hsu, *et al.*, *Nat. Med.* 2:52-58 (1996), incorporated herein by reference in its entirety). Immune responses can also be induced by injection of naked DNA. Plasmid DNA that expresses bicistronic mRNA encoding both the light and heavy chains of tumor idiotype proteins, such as those from B cell lymphoma, when injected into mice, are able to generate a protective, anti-tumor response (Singh, *et al.*, *Vaccine* 20:1400-1411 (2002)).

Thus, there exists a need in the art to identify and develop agents, such as peptide fragments, nucleic acids, small molecules or antibodies, that provide therapeutic compositions and diagnostic methods for treating and identifying cancer, hyperproliferative disorders, auto-immune diseases, and organ transplant rejection.

3. SUMMARY OF THE INVENTION

The invention provides therapeutic and diagnostic methods of targeting cells expressing killer cell immunoglobulin-like receptor (KIR)-like protein (herein denoted as KIRHy1) by using targeting elements such as KIRHy1 polypeptides, nucleic acids encoding KIRHy1 protein, and anti-KIRHy1 antibodies, including fragments or other modifications thereof, peptides and small molecules. The KIRHy1 protein is highly expressed in certain hematopoietic-based cancer cells relative to its expression in healthy cells. Thus, targeting of cells that express KIRHy1 will have a minimal effect on healthy tissues while destroying or inhibiting the growth of the hematopoietic-based cancer cells. Similarly, non-hematopoietic type tumors (solid tumors) can be targeted if they bear the KIRHy1 antigen. For example, inhibition of growth and/or destruction of KIRHy1-expressing cancer cells results from targeting such cells with anti-KIRHy1 antibodies. One embodiment of the invention is a method of destroying KIRHy1-expressing cells by conjugating anti-KIRHy1 antibodies with cytotoxic materials such as radioisotopes or other cytotoxic compounds.

The present invention provides a variety of targeting elements and compositions. One such embodiment is a composition comprising an anti-KIRHy1 antibody preparation. Exemplary antibodies include a single anti-KIRHy1 antibody, a combination of two or more anti-KIRHy1 antibodies, a combination of an anti-KIRHy1 antibody with a non-KIRHy1 antibody, a combination of an anti-KIRHy1 antibody and a

therapeutic agent, a combination of an anti-KIRHy1 antibody and a cytocidal agent, a bispecific anti-KIRHy1 antibody, Fab KIRHy1 antibodies or fragments thereof, including any fragment of an antibody that retains one or more CDRs that recognize KIRHy1, humanized anti-KIRHy1 antibodies that retain all or a portion of a CDR that recognizes
5 KIRHy1, anti-KIRHy1 conjugates, and anti-KIRHy1 antibody fusion proteins.

Another targeting embodiment of the invention is a composition comprising a KIRHy1 antigen, for example, a KIRHy1 polypeptide, or fragment thereof, and optionally comprising a suitable adjuvant.

Yet another targeting embodiment is a composition comprising a nucleic acid
10 encoding KIRHy1, or a fragment or variant thereof, optionally within a recombinant vector. A further targeting embodiment of the present invention is a composition comprising an antigen-presenting cell transformed with a nucleic acid encoding KIRHy1, or a fragment or variant thereof, optionally within a recombinant vector.

Yet another targeting embodiment of the invention is a preparation comprising a
15 KIRHy1 polypeptide or peptide fragment thereof. A further targeting embodiment of the present invention is a non-KIRHy1 polypeptide or peptide that binds a KIRHy1 polypeptide or polynucleotide of the invention.

Another targeting embodiment of the invention is a preparation comprising a small molecule that recognizes or binds to a KIRHy1 polypeptide or polynucleotide of
20 the invention.

The present invention further provides a method of targeting KIRHy1-expressing cells, which comprises administering a targeting element or composition in an amount effective to target KIRHy1-expressing cells. Any one of the targeting elements or compositions described herein may be used in such methods, including an anti-KIRHy1
25 antibody preparation, a KIRHy1 antigen comprising a KIRHy1 polypeptide, or a fragment thereof, a composition of a nucleic acid encoding KIRHy1, or a fragment or variant thereof, optionally within a recombinant vector, or a composition of an antigen-presenting cell transformed with a nucleic acid encoding KIRHy1, or fragment or variant thereof, optionally within a recombinant vector.

30 The present invention further provides a method of targeting KIRHy1-expressing cells, which comprises administering a targeting element or composition in an amount

effective to target KIRHy1-expressing cells. Any one of the targeting elements or compositions described herein may be used in such methods, including an anti-KIRHy1 antibody preparation, a KIRHy1 antigen comprising a KIRHy1 polypeptide, or a fragment or variant thereof, a composition of a nucleic acid encoding KIRHy1, or a
5 fragment or variant thereof, optionally with a recombinant vector, a composition of an antigen-presenting cell transformed with a nucleic acid encoding KIRHy1, or fragment thereof or variant, optionally within a recombinant vector, a KIRHy1 polypeptide, peptide fragment thereof, or a binding polypeptide, peptide or small molecule that binds to a KIRHy1 polypeptide or polynucleotide of the invention.

10 The invention also provides a method of inhibiting the growth of cancer cells, including hematopoietic-based cancer cells, KIRHy1-expressing cancer cells, which comprises administering a targeting element or a targeting composition in an amount effective to inhibit the growth of said hematopoietic-based cancer cells. Any one of the targeting elements or compositions described herein may be used in such methods,
15 including an anti-KIRHy1 antibody preparation, a KIRHy1 antigen comprising a KIRHy1 polypeptide, or fragment thereof, a composition of a nucleic acid encoding KIRHy1, or fragment or variant thereof, optionally within a recombinant vector, a composition of an antigen-presenting cell transformed with a nucleic acid encoding KIRHy1, or fragment or variant thereof, optionally within a recombinant vector, a
20 KIRHy1 polypeptide, peptide fragment thereof, or a binding polypeptide, peptide or small molecule that binds to a KIRHy1 polypeptide or polynucleotide of the invention.

The present invention further provides a method of treating disorders associated with the proliferation of KIRHy1-expressing cells in a subject in need thereof, comprising the step of administering a targeting element or targeting composition in a
25 therapeutically effective amount to treat disorders associated with KIRHy1-expressing cells. Any one of the targeting elements or compositions described herein may be used in such methods, including an anti-KIRHy1 antibody preparation, a KIRHy1 antigen comprising a KIRHy1 polypeptide, fragment thereof, a composition of a nucleic acid encoding KIRHy1, or fragment or variant thereof, optionally within a recombinant
30 vector, or a composition of an antigen-presenting cell comprising a nucleic acid encoding KIRHy1, or fragment or variant thereof, optionally within a recombinant vector, or a

KIRHy1 polypeptide, peptide fragment thereof, or a binding polypeptide, peptide or small molecule that binds to or recognizes a KIRHy1 polypeptide or polynucleotide of the invention.

5 Examples of disorders associated with the proliferation of KIRHy1-expressing cells include cancers, such as Hodgkin's Disease, non-Hodgkin's B-cell lymphomas, T-cell lymphomas, malignant lymphoma, lymphosarcoma leukemia, chronic lymphocytic leukemia, multiple myeloma, acute and chronic myeloid leukemia (also known as myelogenous leukemia), myelomonocytic leukemia, myelodysplastic syndromes, multiple myeloma, X-linked lymphoproliferative disorders; Epstein Barr Virus-related
10 conditions such as mononucleosis; hyperproliferative disorders; autoimmune disorders; wound healing; and organ and tissue transplantation rejection (including hyperacute, acute, chronic and xenograft transplant rejection). Non-hematopoietic tumors that bear the KIRHy1 antigen, such as esophageal cancer, stomach cancer, colon cancer, colorectal cancer, polyps associated with colorectal neoplasms, pancreatic cancer and gallbladder
15 cancer, cancer of the adrenal cortex, ACTH-producing tumor, bladder cancer, brain cancer including intrinsic brain tumors, neuroblastomas, astrocytic brain tumors, gliomas, and metastatic tumor cell invasion of the central nervous system, Ewing's sarcoma, head and neck cancer including mouth cancer and larynx cancer, kidney cancer including renal cell carcinoma, liver cancer, lung cancer including small and non-small cell lung cancers,
20 malignant peritoneal effusion, malignant pleural effusion, skin cancers including malignant melanoma, tumor progression of human skin keratinocytes, epithelial cell carcinoma, squamous cell carcinoma, basal cell carcinoma, and hemangiopericytoma, mesothelioma, Kaposi's sarcoma, bone cancer including osteomas and sarcomas such as fibrosarcoma and osteosarcoma, cancers of the female reproductive tract including
25 uterine cancer, endometrial cancer, ovarian cancer, ovarian (germ cell) cancer and solid tumors in the ovarian follicle, vaginal cancer, cancer of the vulva, and cervical cancer; breast cancer (small cell and ductal), penile cancer, prostate cancer, retinoblastoma, testicular cancer, thyroid cancer, trophoblastic neoplasms, and Wilms' tumor, can also be targeted. The invention further provides a method of modulating the immune system by
30 either suppression or stimulation of growth factors and cytokines, by administering the targeting elements or compositions of the invention. The invention also provides a

method of modulating the immune system through activation of immune cells (such as natural killer cells, T cells, B cells and myeloid cells), through the suppression of activation, or by stimulating or suppressing proliferation of these cells by KIRHy1 peptide fragments or KIRHy1 antibodies.

5 The present invention thereby provides a method of treating immune-related disorders by suppressing the immune system in a subject in need thereof, by administering the targeting elements or compositions of the invention. Such immune-related disorders include but are not limited to autoimmune disease and organ transplant rejection.

10 The present invention also provides a method of diagnosing disorders associated with KIRHy1-expressing cells comprising the step of measuring the expression patterns of KIRHy1 protein and/or its associated mRNA. Yet another embodiment of the invention provides a method of diagnosing disorders associated with KIRHy1-expressing cells comprising the step of detecting KIRHy1 expression using anti-KIRHy1 antibodies.
15 Expression levels or patterns may then be compared with a suitable standard indicative of the desired diagnosis. Such methods of diagnosis include compositions, kits and other approaches for determining whether a patient is a candidate for KIRHy1 therapy in which said KIRHy1 is targeted.

 The present invention also provides a method of enhancing the effects of
20 therapeutic agents and adjunctive agents used to treat and manage disorders associated with KIRHy1-expressing cells, by administering KIRHy1 preparations of said KIRHy1 with therapeutic and adjuvant agents commonly used to treat such disorders.

4. **BRIEF DESCRIPTION OF THE DRAWING**

25 Figure 1 depicts a BLASTP amino acid sequence alignment between the protein encoded by SEQ ID NO: 2 (*i.e.* SEQ ID NO: 3) KIRHy1 and human Natural Killer (NK) inhibitory receptor precursor (SEQ ID NO: 8), indicating that the two sequences share 94% similarity and 94% identity over the entire amino acid sequence of SEQ ID NO: 3.

 Figure 2 depicts a BLASTP amino acid sequence alignment between the protein
30 encoded by SEQ ID NO: 2 (*i.e.* SEQ ID NO: 3) KIRHy1 and human CMRF35-like protein (similar to CMRF35 leukocyte Ig-like receptor) (SEQ ID NO: 9), indicating that

the two sequences share 89% similarity and 89% identity over 149 amino acids of SEQ ID NO: 3.

Figure 3 shows the relative expression of KIRHy1 mRNA (as determined by RT-PCR) derived from healthy tissues, cell lines derived from acute monocytic leukemia (AML193), acute myeloid leukemia (AML565), acute myelogenous leukemia (KG1), anaplastic large T cell lymphoma (L5664), B cell lymphoma (RA1), chronic myelogenous leukemia (K562), diffuse large B cell lymphoma (L22601), follicular lymphoma grades II/III (L5856), histiocytic lymphoma (U937), Hodgkin's lymphoma (HD5664), large B cell lymphoma (DB), non-Hodgkin's lymphoma (RL), and plasmacytoma (RPMI), and tumor tissues derived from B cell lymphoma (H02-85T, H02-86T, H02-87T, H02-88T, H02-89T), follicular lymphoma (H02-74T, H02-75T, H02-76T, H02-77T, H02-78T), and myeloma (H02-79T, H02-80T, H02-81T, H02-82T, H02-83T, H02-84T).

5. DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to methods of targeting cells that express KIRHy1 using targeting elements, such as polypeptides, nucleic acids, antibodies, binding polypeptides, peptides and small molecules, including fragments or other modifications of any of these elements.

The present invention provides a novel approach for diagnosing and treating diseases and disorders associated with said KIRHy1. The method comprises administering an effective dose of targeting preparations such as KIRHy1 antigens, antigen presenting cells, or pharmaceutical compositions comprising the targeting elements, KIRHy1 polypeptides, nucleic acids encoding KIRHy1, anti-KIRHy1 antibodies, or binding polypeptides, peptides and small molecules that bind to KIRHy1 polypeptides or polynucleotides, described below. Targeting of KIRHy1 on the cell membranes is expected to inhibit the growth of or destroy such cells. An effective dose will be the amount of such targeting preparations necessary to target the cell surface KIRHy1 and inhibit the growth of or destroy the cells expressing KIRHy1 and/or metastasis.

A further embodiment of the present invention is to enhance the effects of therapeutic agents and adjunctive agents used to treat and manage disorders associated with said KIRHy1, by administering targeting preparations that recognize KIRHy1 with therapeutic and adjuvant agents commonly used to treat such disorders.

5 Chemotherapeutic agents useful in treating neoplastic disease and antiproliferative agents and drugs used for immunosuppression include alkylating agents, such as nitrogen mustards, alkyl sulfonates, nitrosoureas, triazenes; antimetabolites, such as folic acid analogs, pyrimidine analogs, and purine analogs; natural products, such as vinca
10 alkaloids, epipodophyllotoxins, antibiotics, and enzymes; miscellaneous agents such as polatinum coordination complexes, substituted urea, methyl hydrazine derivatives, and adrenocortical suppressant; and hormones and antagonists, such as adrenocorticosteroids, progestins, estrogens, androgens, and anti-estrogens (Calebresi and Parks, pp. 1240-1306 in, Eds. A.G Goodman, L.S. Goodman, T.W. Rall, and F. Murad, *The Pharmacological Basis of Therapeutics*, Seventh Edition, MacMillan Publishing Company, New York,
15 (1985), incorporated herein by reference in its entirety).

Adjunctive therapy used in the management of such disorders includes, for example, radiosensitizing agents, coupling of antigen with heterologous proteins, such as globulin or beta-galactosidase, or inclusion of an adjuvant during immunization.

High doses may be required for some therapeutic agents to achieve levels to
20 effectuate the target response, but may often be associated with a greater frequency of dose-related adverse effects. Thus, combined use of the targeting therapeutic methods of the present invention with agents commonly used to treat disorders associated with expression of KIRHy1 allows the use of relatively lower doses of such agents resulting in a lower frequency of adverse side effects associated with long-term administration of the
25 conventional therapeutic agents. Thus another indication for the targeting therapeutic methods of this invention is to reduce adverse side effects associated with conventional therapy of these disorders.

30 **5.1 TARGETING OF KIRHy1**

Immune system functions are governed by a complex network of cell surface interactions and associated signaling processes. When a cell surface receptor is activated

by its ligand a signal is sent into the cell; depending upon the signal transduction pathway that is engaged, the signal can be inhibitory or activating.

The cytolytic activity of Natural Killer (NK) cells is regulated by a balance between activating signals that initiate cell lysis and inhibitory signals which prevent cytotoxicity. NK cells recognize and kill certain tumor cells, virally-infected cells, MHC class I-disparate normal hematopoietic cells and mediate acute rejection of bone marrow grafts (Salmon-Divon *et al.*, *Bull. Math. Biol.* 65:199-218 (2003), herein incorporated by reference in its entirety). Target cells are killed when NK cells receive an excess of activation signals. If the target cell expresses cell surface MHC class I antigens for which the NK cell has a specific receptor (*i.e.* “self” MHC class I antigens), the NK cell is inhibited from killing the target cell. These specific NK cell receptors are of two types: killer cell immunoglobulin (Ig)-like receptors (KIRs) or C-type lectin-like Ly49 receptors. KIRs send a negative signal when engaged by their MHC ligand downregulating NK cell cytotoxicity activity. KIRs have immunoreceptor tyrosine-based inhibitory motifs (ITIM) in the cytoplasmic domain which are phosphorylated by tyrosine kinases. The ITIM motif common to many KIRs has the sequence I/L/VxYxxL/V, wherein “x” represents any amino acid (SEQ ID NO: 10) (Held *et al.*, *Curr. Opin. Immunol.* 15:233-237 (2003), herein incorporated by reference in its entirety).

Soluble forms of some of these membrane receptors, like FDF03 and CD54, are described and may serve as markers for pathologic conditions (Borges and Cosman *Cytokine and Growth Factor Reviews* 11:209-217 (2000), herein incorporated by reference in its entirety). Ig Variable domains are utilized to create a specific binding site while Ig Constant domains may serve as more conserved counter receptor binding module. Recently, CMRF-35 and PIGR-1 immunoglobulin members have been cloned that have only one Ig-variable domain (Shujian *et al* (1999). EP 0897981A1, incorporated herein by reference).

It is becoming apparent that inhibitory receptors are present on most of the haemopoietic cells, including dendritic cells, monocytes, CD19+ B cells; and CD3+ T cells (Borges and Cosman (2000) *supra*; De Maria *et al.*, *Proc. Natl. Acad. Sci. USA* 94:10285-88 (1997), herein incorporated by reference in its entirety). An

immunoreceptor expressed by mast cells is also known to downregulate cell activation signals (International Patent Application No. WO98/48017).

5 The receptors on NK and T cells have been shown to mediate innate immunity and play a major role in bone marrow graft rejection as well as in killing certain virus-infected and melanoma cells. Immunoglobulin receptors have also been implicated in mediating autoimmune reactions. More recently, they have also been shown to be required for development and maturation of dendritic cells (Fournier *et al.*, *J. Immunol.* 165:1197-1209 (2000), herein incorporated by reference in its entirety). It has been shown that addition of an anti-Ig receptor monoclonal antibody to T cells induced their
10 cytolytic activity for HIV infected target cells. It is apparent that the down regulation of an inhibitory receptor could lead to generalized activation of NK/T cells, which may cause autoimmune disorders like rheumatoid arthritis, multiple sclerosis (MS), systemic lupus erythematosus (SLE), psoriasis, and inflammatory bowel disease (IBD) among others.

15 Clearly, the activating and inhibitory signals mediated by opposing kinases and phosphatases are very important for maintaining balance in the immune systems. Systems with a predominance of activatory signals will lead to autoimmunity and inflammation. Immune systems with a predominance of inhibitory signals are less able to challenge infected cells or cancer cells. Isolating new activatory or inhibitory receptors is
20 highly desirable for studying the biological signal(s) transduced via the receptor. Additionally, identifying such molecules provides a means of regulating and treating diseased states associated with autoimmunity, inflammation and infection.

For example, engaging a cell surface receptor having ITIM motifs, such as KIRHy1, with an agonistic antibody or ligand can be used to downregulate a cell function
25 in disease states in which the immune system is overactive and excessive inflammation or immunopathology is present. On the other hand, using an antagonistic antibody specific to KIRHy1 or a soluble form of KIRHy1 can be used to block the interaction of the cell surface receptor with the receptor's ligand to activate the specific immune function in disease states associated with suppressed immune function.

30 The KIRHy1 protein of the invention, a homolog of the human NK inhibitory receptor precursor (gi 20502982), is highly expressed in certain hematopoietic-based

cancers, but not by most non-hematopoietic, healthy cells. Thus, targeting of cells that express KIRHy1 will have a minimal effect on healthy tissues while destroying or inhibiting the growth of cancer cells. Similarly, non-hematopoietic type tumors (*i.e.* solid tumors) can be targeted if they bear the KIRHy1 antigen. Targeting of KIRHy1 can also be used to treat disorders associated with the proliferation of KIRHy1-expressing cells. Examples of disorders associated with the proliferation of KIRHy1-expressing cells include cancers such as non-Hodgkin's B cell lymphomas, B cell leukemias, T cell lymphomas, acute myelogenous leukemia, acute myelomonocytic leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, B cell large cell lymphoma, multiple myeloma, myelodysplastic syndromes, X-linked proliferative disorders and Epstein Barr Virus-related conditions, such as mononucleosis; autoimmune disorders such as systemic lupus erythematosus; hyperproliferative disorders; organ and tissue transplant rejection; and certain allergic reactions. Non-hematopoietic tumors, such as breast colon, prostate, squamous cell or epithelial cell carcinomas that bear the KIRHy1 antigen can also be targeted.

KIRHy1 polypeptides and polynucleotides encoding such polypeptides are disclosed in co-owned U.S. Patent Application Serial Nos. 09/631,451 and 09/491,404 which correspond to International Publication Nos. WO 01/55437 and WO 01/55437, respectively. These and all other U.S. patents and patent applications, foreign patents and International publications cited herein are hereby incorporated by reference in their entirety. U.S. Patent Application Serial No. 09/491,404 incorporated by reference herein in its entirety relates, in general to a collection or library of at least one novel nucleic acid sequences, specifically contigs, assembled from expressed sequence tags (ESTs). U.S. Patent Application Serial No. 09/631,451, incorporated by reference herein in its entirety, (specifically including all sequences in the sequence listing) discloses KIRHy1 polypeptides, isolated polynucleotides encoding such polypeptides, including recombinant molecules, cloned genes or degenerate variants thereof, especially naturally occurring variants such as allelic variants, fragments or analogs or variants of such polynucleotides or polypeptides, antisense polynucleotide molecules, and antibodies that specifically recognize one or more epitopes present on such polypeptides, including polyclonal, monoclonal, single chain, bispecific, fragment, human and humanized

antibodies, as well as hybridomas producing monoclonal antibodies, and diagnostic and therapeutic uses and screening assays associated with such polynucleotides, polypeptides and antibodies.

The KIRHy1 polypeptide of SEQ ID NO: 3 is an approximately 305 amino acid protein with a predicted molecular weight of 33 kD unglycosylated. The initial methionine starts at position 114 of SEQ ID NO: 2 and the putative stop codon begins at position 1028 of SEQ ID NO: 2. A predicted approximately 17 residue signal peptide is encoded from approximately residue 1 to residue 17 of SEQ ID NO: 3 (*i.e.* SEQ ID NO: 4). The signal peptide region was predicted using the Neural Network SignalP V1.1 program (Nielsen *et al.*, *Int. J. Neural Syst.* 8:581-599 (1997), herein incorporated by reference in its entirety). One of skill in the art will recognize that the actual cleavage site may be different than that predicted by the computer program. A predicted transmembrane domain is encoded from approximately residue 159 to residue 186 of SEQ ID NO: 3 (*i.e.* SEQ ID NO: 6). The transmembrane domain was predicted using the Kyte-Doolittle hydrophobicity prediction algorithm (*J. Mol. Biol.* 157:105-131 (1982), herein incorporated by reference in their entirety). One of skill in the art will recognize that the actual domain may be different than that predicted by the computer program. Using the Pfam software program (Sonnhammer *et al.*, *Nucl. Acids Res.* 26:320-322 (1998), herein incorporated by reference in its entirety), KIRHy1 is predicted to contain one immunoglobulin (Ig) domain spanning amino acids 33 to 110 (SEQ ID NO: 5). The soluble portion of KIRHy1 is represented by SEQ ID NO: 7.

Protein database searches with the BLASTP algorithm (Altschul *et al.*, *J. Mol. Evol.* 36:290-300 (1993); Altschul *et al.*, *J. Mol. Biol.* 21:403-410 (1990), both of which are herein incorporated by reference in their entirety) indicate that SEQ ID NO: 3 is homologous to human NK inhibitory receptor precursor (gi 20502982) and a human CMRF35 homolog ("similar to CMRF35 leukocyte Ig-like receptor," gi 20380183). An alignment of SEQ ID NO: 3 with human NK inhibitory receptor precursor (SEQ ID NO: 8) is shown in Figure 1 indicating that the two sequences share 94% similarity and 94% identity over the entire amino acid sequence of SEQ ID NO: 3, wherein A=Alanine, C=Cysteine, D=Aspartic Acid, E= Glutamic Acid, F=Phenylalanine, G=Glycine, H=Histidine, I=Isoleucine, K=Lysine, L=Leucine, M=Methionine, N=Asparagine,

P=Proline, Q=Glutamine, R=Arginine, S=Serine, T=Threonine, V=Valine, W=Tryptophan, Y=Tyrosine. Gaps are presented as dashes. An alignment of SEQ ID NO: 3 with the CMRF35 homolog (SEQ ID NO: 9) is shown in Figure 2, indicating that the two sequences share 89% similarity and 89% identity over 149 amino acids of SEQ ID NO: 3, wherein A=Alanine, C=Cysteine, D=Aspartic Acid, E= Glutamic Acid, F=Phenylalanine, G=Glycine, H=Histidine, I=Isoleucine, K=Lysine, L=Leucine, M=Methionine, N=Asparagine, P=Proline, Q=Glutamine, R=Arginine, S=Serine, T=Threonine, V=Valine, W=Tryptophan, Y=Tyrosine. Gaps are presented as dashes.

The gene corresponding to SEQ ID NO: 3 was localized to chromosome 17 (see Example 3). The CMRF35 family has also been localized to chromosome 17 near the psoriasis susceptibility locus (PSORS2), which may overlap with loci for atopic dermatitis and rheumatoid arthritis (Clark *et al.*, *Tissue Antigens* 57:415-423 (2001); Speckman *et al.*, *Hum. Genet.* 112:34-41 (2003), both of which are herein incorporated by reference in their entirety). Thus, KIRHy1 and the CMRF35 family members may play a role in psoriasis, atopic dermatitis and rheumatoid arthritis as well as in autoimmune diseases in general.

KIRHy1 is expressed in certain hematopoietic-based cancers, including B cell lymphoma, follicular lymphoma, diffuse large B cell lymphoma, anaplastic large T cell lymphoma, multiple myeloma, acute myeloid leukemia, T cell leukemia, acute myelogenous leukemia, acute myelomonocytic leukemia, acute myeloid leukemia, chronic myelogenous leukemia, histiocytic lymphoma, plasmacytoma, non-Hodgkin's lymphoma, and Hodgkin's lymphoma, while most non-hematopoietic, healthy cells fail to express KIRHy1 or express it at low levels (see Figure 3). Thus, targeting KIRHy1 will be useful in treating hematopoietic cancers.

The KIRHy1 peptide itself may be used to target toxins or radioisotopes to tumor cells *in vivo*. KIRHy1 may be a homophilic adhesion protein which will bind to itself. In this case the extracellular domain of KIRHy1, or a fragment of this domain, may be able to bind to KIRHy1 expressed on tumor cells. This peptide fragment then may be used as a means to deliver cytotoxic agents to KIRHy1 bearing tumor cells. Much like an antibody, these fragments may specifically target cells expressing this antigen. Targeted delivery of these cytotoxic agents to the tumor cells would result in cell death and

suppression of tumor growth. An example of the ability of an extracellular fragment binding to and activating its intact receptor (by homophilic binding) has been demonstrated with the CD84 receptor (Martin, *et al.*, *J. Immunol*, 167:3668-3676 (2001), incorporated herein by reference in its entirety).

5 Extracellular fragments of the KIRHy1 receptor may also be used to modulate immune cells expressing the protein. Extracellular domain fragments of the receptor may bind to and activate its own receptor expressed on the cell surface. On cells bearing the KIRHy1 receptor (such as NK cells, T cells, B cells and myeloid cells) this may result in stimulating the release of cytokines (such as interferon gamma for example) that may
10 enhance or suppress the immune system. Additionally, binding of these fragments to cells bearing the KIRHy1 receptor may result in the activation of these cells and also may stimulate proliferation. Some fragments may bind to the intact KIRHy1 receptor and block activation signals and cytokine release by immune cells. These fragments would then have an immune suppressive effect. Fragments that activate and stimulate the
15 immune system may have anti-tumor properties. These fragments may stimulate an immunological response that can result in immune mediated tumor cell killing. The same fragments may result in stimulating the immune system to mount an enhance response to foreign invaders such as virus and bacteria. Fragments that suppress the immune response may be useful in treating lymphoproliferative disorders, auto-immune disease,
20 graft-vs-host disease, and inflammatory disorders such as emphysema.

5.2 DEFINITIONS

The term "fragment" of a nucleic acid refers to a sequence of nucleotide residues which are at least about 5 nucleotides, more preferably at least about 7 nucleotides, more
25 preferably at least about 9 nucleotides, more preferably at least about 11 nucleotides and most preferably at least about 17 nucleotides. The fragment is preferably less than about 500 nucleotides, preferably less than about 200 nucleotides, more preferably less than about 100 nucleotides, more preferably less than about 50 nucleotides and most preferably less than 30 nucleotides. Preferably the fragments can be used in polymerase
30 chain reaction (PCR), various hybridization procedures or microarray procedures to identify or amplify identical or related parts of mRNA or DNA molecules. A fragment or

segment may uniquely identify each polynucleotide sequence of the present invention. Preferably the fragment comprises a sequence substantially similar to a portion of SEQ ID NO: 2. A polypeptide "fragment " is a stretch of amino acid residues of at least about 5 amino acids, preferably at least about 7 amino acids, more preferably at least about 9 amino acids and most preferably at least about 17 or more amino acids. The peptide preferably is not greater than about 200 amino acids, more preferably less than 150 amino acids and most preferably less than 100 amino acids. Preferably the peptide is from about 5 to about 200 amino acids. To be active, any polypeptide must have sufficient length to display biological and/or immunological activity. The term "immunogenic" refers to the capability of the natural, recombinant or synthetic KIRHy1 peptide, or any peptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.

The term "KIRHy1 antigen" refers to a molecule that when introduced into an animal is capable of stimulating an immune response in said animal specific to the KIRHy1 polypeptide or fragment thereof, of the present invention.

The term "variant"(or "analog") refers to any polypeptide differing from naturally occurring polypeptides by amino acid insertions, deletions, and substitutions, created using, *e g.*, recombinant DNA techniques. Guidance in determining which amino acid residues may be replaced, added or deleted without abolishing activities of interest, may be found by comparing the sequence of the particular polypeptide with that of homologous peptides and minimizing the number of amino acid sequence changes made in regions of high homology (conserved regions) or by replacing amino acids with consensus sequence.

Alternatively, recombinant variants encoding these same or similar polypeptides may be synthesized or selected by making use of the "redundancy" in the genetic code. Various codon substitutions, such as the silent changes which produce various restriction sites, may be introduced to optimize cloning into a plasmid or viral vector or expression in a particular prokaryotic or eukaryotic system. Mutations in the polynucleotide sequence may be reflected in the polypeptide or domains of other peptides added to the polypeptide to modify the properties of any part of the polypeptide, to change

characteristics such as ligand-binding affinities, interchain affinities, or degradation/turnover rate.

The term "stringent" is used to refer to conditions that are commonly understood in the art as stringent. Stringent conditions can include highly stringent conditions (*i.e.*, hybridization to filter-bound DNA in 0.5 M NaHPO₄, 7% sodium dodecyl sulfate (SDS), 1 mM EDTA at 65°C, and washing in 0.1× SSC/0.1% SDS at 68°C), and moderately
5 stringent conditions (*i.e.*, washing in 0.2× SSC/0.1% SDS at 42°C). Other exemplary hybridization conditions are described herein in the examples.

In instances of hybridization of deoxyoligonucleotides, additional exemplary stringent hybridization conditions include washing in 6× SSC/0.05% sodium pyrophosphate at 37°C (for 14-base oligonucleotides), 48°C (for 17-base
10 oligonucleotides), 55°C (for 20-base oligonucleotides), and 60°C (for 23-base oligonucleotides).

5.3 TARGETING USING KIRHy1 ANTIGENS

One embodiment the present invention provides a composition comprising a
15 KIRHy1 polypeptide to stimulate the immune system against KIRHy1, thus targeting KIRHy1-expressing cells. Use of a tumor antigen in a composition for generating cellular and humoral immunity for the purpose of anti-cancer therapy is well known in the art. For example, one type of tumor-specific antigen composition uses purified
20 idiotype protein isolated from tumor cells, coupled to keyhole limpet hemocyanin (KLH) and mixed with adjuvant for injection into patients with low-grade follicular lymphoma (Hsu, *et al.*, *Blood* 89: 3129-3135 (1997), herein incorporated by reference in its entirety). U.S. Patent No. 6,312,718, herein incorporated by reference in its entirety, describes
25 methods for inducing immune responses against malignant B cells, in particular lymphoma, chronic lymphocytic leukemia, and multiple myeloma. The methods described therein utilize vaccines that include liposomes having (1) at least one B-cell malignancy-associated antigen, (2) IL-2 alone, or in combination with at least one other cytokine or chemokine, and (3) at least one lipid molecule. Methods of targeting KIRHy1 using a KIRHy1 antigen typically employ a KIRHy1 polypeptide, including fragments, analogs and variants.

As another example, dendritic cells, one type of antigen-presenting cell, can be used in a cellular vaccine in which the dendritic cells are isolated from the patient, co-cultured with tumor antigen and then reinfused as a cellular vaccine (Hsu, *et al.*, *Nat. Med.* 2:52-58 (1996), herein incorporated by reference in its entirety).

Combining this antigen therapy with other types of therapeutic agents in treatments such as chemotherapy or radiotherapy is also contemplated.

5.4 TARGETING USING NUCLEIC ACIDS

5.4.1 DIRECT DELIVERY OF NUCLEIC ACIDS

In some embodiments, a nucleic acid encoding KIRHy1, or encoding a fragment, analog or variant thereof, within a recombinant vector is utilized. Such methods are known in the art. For example, immune responses can be induced by injection of naked DNA. Plasmid DNA that expresses bicistronic mRNA encoding both the light and heavy chains of tumor idiotype proteins, such as those from B cell lymphoma, when injected into mice, are able to generate a protective, anti-tumor response (Singh, *et al.*, *Vaccine* 20:1400-1411 (2002), herein incorporated by reference in its entirety). KIRHy1 viral vectors are particularly useful for delivering nucleic acids encoding KIRHy1 of the invention to cells. Examples of vectors include those derived from influenza, adenovirus, vaccinia, herpes simplex virus, fowlpox, vesicular stomatitis virus, canarypox, poliovirus, adeno-associated virus, and lentivirus and sindbus virus. Of course, non-viral vectors, such as liposomes or even naked DNA, are also useful for delivering nucleic acids encoding KIRHy1 of the invention to cells.

Combining this type of therapy with other types of therapeutic agents or treatments such as chemotherapy or radiation is also contemplated.

5.4.2 NUCLEIC ACIDS EXPRESSED IN CELLS

In some embodiments, a vector comprising a nucleic acid encoding the KIRHy1 polypeptide (including a fragment, analog or variant) is introduced into a cell, such as a dendritic cell or a macrophage. When expressed in an antigen-presenting cell (APC), the KIRHy1 cell surface antigens are presented to T cells eliciting an immune response against KIRHy1. Such methods are also known in the art. Methods of introducing

tumor antigens into APCs and vectors useful therefore are described in U.S. Patent No. 6,300,090, herein incorporated by reference in its entirety. The vector encoding KIRHy1 may be introduced into the APCs *in vivo*. Alternatively, APCs are loaded with KIRHy1 or a nucleic acid encoding KIRHy1 *ex vivo* and then introduced into a patient to elicit an immune response against KIRHy1. In another alternative, the cells presenting KIRHy1 antigen are used to stimulate the expansion of anti-KIRHy1 cytotoxic T lymphocytes (CTL) *ex vivo* followed by introduction of the stimulated CTL into a patient. (U.S. Patent No. 6,306,388, herein incorporated by reference in its entirety).

Combining this type of therapy with other types of therapeutic agents or treatments such as chemotherapy or radiation is also contemplated.

5.4.3 ANTISENSE NUCLEIC ACIDS

Another aspect of the invention pertains to isolated antisense nucleic acid molecules that can hybridize to, or are complementary to, the nucleic acid molecule comprising the KIRHy1 nucleotide sequence, or fragments, analogs or derivatives thereof. An "antisense" nucleic acid comprises a nucleotide sequence that is complementary to a "sense" nucleic acid encoding a protein (*e.g.*, complementary to the coding strand of a double-stranded cDNA molecule or complementary to an mRNA sequence). In specific aspects, antisense nucleic acid molecules are provided that comprise a sequence complementary to at least about 10, 25, 50, 100, 250 or 500 nucleotides or an entire KIRHy1 coding strand, or to only a portion thereof. Nucleic acid molecules encoding fragments, homologs, derivatives and analogs of a KIRHy1 or antisense nucleic acids complementary to a KIRHy1 nucleic acid sequence of are additionally provided.

In one embodiment, an antisense nucleic acid molecule is antisense to a "coding region" of the coding strand of a nucleotide sequence encoding a KIRHy1 protein. The term "coding region" refers to the region of the nucleotide sequence comprising codons which are translated into amino acid residues. In another embodiment, the antisense nucleic acid molecule is antisense to a "conceding region" of the coding strand of a nucleotide sequence encoding the KIRHy1 protein. The term "conceding region" refers

to 5' and 3' sequences which flank the coding region that are not translated into amino acids (*i.e.*, also referred to as 5' and 3' untranslated regions).

Given the coding strand sequences encoding the KIRHy1 protein disclosed herein, antisense nucleic acids of the invention can be designed according to the rules of Watson and Crick or Hoogsteen base pairing. The antisense nucleic acid molecule can be complementary to the entire coding region of KIRHy1 mRNA, but more preferably is an oligonucleotide that is antisense to only a portion of the coding or noncoding region of KIRHy1 mRNA. For example, the antisense oligonucleotide can be complementary to the region surrounding the translation start site of KIRHy1 mRNA. An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 nucleotides in length. An antisense nucleic acid of the invention can be constructed using chemical synthesis or enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (*e.g.*, an antisense oligonucleotide) can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids (*e.g.*, phosphorothioate derivatives and acridine substituted nucleotides can be used).

Examples of modified nucleotides that can be used to generate the antisense nucleic acid include: 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxymethylaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (*v*), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (*v*), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)*w*, and 2,6-diaminopurine. Alternatively, the antisense nucleic acid can be produced biologically using an expression vector into which

a nucleic acid has been subcloned in an antisense orientation (*i.e.*, RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following section).

5 The antisense nucleic acid molecules of the invention are typically administered to a subject or generated *in situ* such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding a KIRHy1 protein to thereby inhibit expression of the protein (*e.g.*, by inhibiting transcription and/or translation). The hybridization can be by conventional nucleotide complementarity to form a stable duplex, or, for example, in the case of an antisense nucleic acid molecule that binds to DNA duplexes, through specific
10 interactions in the major groove of the double helix. An example of a route of administration of antisense nucleic acid molecules of the invention includes direct injection at a tissue site. Alternatively, antisense nucleic acid molecules can be modified to target selected cells and then administered systemically. For example, for systemic administration, antisense molecules can be modified such that they specifically bind to
15 receptors or antigens expressed on a selected cell surface (*e.g.*, by linking the antisense nucleic acid molecules to peptides or antibodies that bind to cell surface receptors or antigens). The antisense nucleic acid molecules can also be delivered to cells using the vectors described herein. To achieve sufficient nucleic acid molecules, vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong pol II or pol III promoter are preferred.
20

In yet another embodiment, the antisense nucleic acid molecule of the invention is an alpha-anomeric nucleic acid molecule. An alpha-anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual alpha-units, the strands run parallel to each other. See, *e.g.*, Gaultier, *et al.*,
25 *Nucl. Acids Res.* 15: 6625-6641 (1987). The antisense nucleic acid molecule can also comprise a 2'-o-methylribonucleotide (see, *e.g.*, Inoue, *et al.*, *Nucl. Acids Res.* 15: 6131-6148 (1987)) or a chimeric RNA-DNA analogue (see, *e.g.*, Inoue, *et al.*, *FEBS Lett.* 215: 327-330 (1987), all of which are herein incorporated by reference in their entirety.

30

5.4.4 RIBOZYMES AND PNA MOIETIES

In still another embodiment, an antisense nucleic acid of the invention is a ribozyme. Ribozymes are catalytic RNA molecules with ribonuclease activity that are capable of cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a complementary region. Thus, ribozymes (*e.g.*, hammerhead ribozymes (described in Haselhoff and Gerlach (1988) *Nature* 334:585-591)) can be used to catalytically cleave mRNA transcripts to thereby inhibit translation of an mRNA. A ribozyme having specificity for a nucleic acid of the invention can be designed based upon the nucleotide sequence of a DNA disclosed herein (*i.e.*, SEQ ID NO: 1-2). For example, a derivative of *Tetrahymena* L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in a mRNA. See, *e.g.*, Cech *et al.* U.S. Pat. No. 4,987,071; and Cech *et al.* U.S. Pat. No. 5,116,742. Alternatively, mRNA of the invention can be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. See, *e.g.*, Bartel *et al.*, (1993) *Science* 261:1411-1418.

Alternatively, gene expression can be inhibited by targeting nucleotide sequences complementary to the regulatory region (*e.g.*, promoter and/or enhancers) to form triple helical structures that prevent transcription of the gene in target cells. See generally, Helene. (1991) *Anticancer Drug Des.* 6: 569-84; Helene. *et al.* (1992) *Ann. N.Y. Acad. Sci.* 660:27-36; and Maher (1992) *Bioassays* 14: 807-15.

In various embodiments, the nucleic acids of the invention can be modified at the base moiety, sugar moiety or phosphate backbone to improve, *e.g.*, the stability, hybridization, or solubility of the molecule. For example, the deoxyribose phosphate backbone of the nucleic acids can be modified to generate peptide nucleic acids (see Hyrup *et al.* (1996) *Bioorg Med Chem* 4: 5-23). As used herein, the terms "peptide nucleic acids" or "PNAs" refer to nucleic acid mimics, *e.g.*, DNA mimics, in which the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone and only the four natural nucleobases are retained. The neutral backbone of PNAs has been shown to allow for specific hybridization to DNA and RNA under conditions of low ionic strength. The synthesis of PNA oligomers can be performed using standard solid phase peptide

synthesis protocols as described in Hyrup *et al.* (1996) above; Perry-O'Keefe *et al.* (1996) *PNAS* 93: 14670-675.

PNAs of the invention can be used in therapeutic and diagnostic applications. For example, PNAs can be used as antisense or antigene agents for sequence-specific modulation of gene expression by, *e.g.*, inducing transcription or translation arrest or inhibiting replication. PNAs of the invention can also be used, *e.g.*, in the analysis of single base pair mutations in a gene by, *e.g.*, PNA directed PCR clamping; as artificial restriction enzymes when used in combination with other enzymes, *e.g.*, S1 nucleases (Hyrup B. (1996) above); or as probes or primers for DNA sequence and hybridization (Hyrup *et al.* (1996), above; Perry-O'Keefe (1996), above).

In another embodiment, PNAs of the invention can be modified, *e.g.*, to enhance their stability or cellular uptake, by attaching lipophilic or other helper groups to PNA, by the formation of PNA-DNA chimeras, or by the use of liposomes or other techniques of drug delivery known in the art. For example, PNA-DNA chimeras can be generated that may combine the advantageous properties of PNA and DNA. Such chimeras allow DNA recognition enzymes, *e.g.*, RNase H and DNA polymerases, to interact with the DNA portion while the PNA portion would provide high binding affinity and specificity. PNA-DNA chimeras can be linked using linkers of appropriate lengths selected in terms of base stacking, number of bonds between the nucleobases, and orientation (Hyrup (1996) above). The synthesis of PNA-DNA chimeras can be performed as described in Hyrup (1996) above and Finn *et al.* (1996) *Nucl Acids Res* 24: 3357-63. For example, a DNA chain can be synthesized on a solid support using standard phosphoramidite coupling chemistry, and modified nucleoside analogs, *e.g.*, 5'-(4-methoxytrityl)amino-5'-deoxy-thymidine phosphoramidite, can be used between the PNA and the 5' end of DNA (Mag *et al.* (1989) *Nucl Acid Res* 17: 5973-88). PNA monomers are then coupled in a stepwise manner to produce a chimeric molecule with a 5' PNA segment and a 3' DNA segment (Finn *et al.* (1996) above). Alternatively, chimeric molecules can be synthesized with a 5' DNA segment and a 3' PNA segment. See, Petersen *et al.* (1975) *Bioorg Med Chem Lett* 5: 1119-11124.

In other embodiments, the oligonucleotide may include other appended groups such as peptides (*e.g.*, for targeting host cell receptors *in vivo*), or agents facilitating

transport across the cell membrane (see, *e.g.*, Letsinger *et al.*, 1989, *Proc. Natl. Acad. Sci. U.S.A.* 86:6553-6556; Lemaitre *et al.*, 1987, *Proc. Natl. Acad. Sci.* 84:648-652; PCT Publication No. W088/09810) or the blood-brain barrier (see, *e.g.*, PCT Publication No. W089/10134). In addition, oligonucleotides can be modified with hybridization triggered cleavage agents (See, *e.g.*, Krol *et al.*, 1988, *BioTechniques* 6:958-976) or intercalating agents. (See, *e.g.*, Zon, 1988, *Pharm. Res.* 5: 539-549). To this end, the oligonucleotide may be conjugated to another molecule, *e.g.*, a peptide, a hybridization triggered cross-linking agent, a transport agent, a hybridization-triggered cleavage agent, *etc.*

5.4.5 KIRHy1 NUCLEIC ACIDS

The isolated polynucleotides of the invention include, but are not limited to a polynucleotide comprising any of the nucleotide sequences of SEQ ID NO: 1-2; a fragment of SEQ ID NO: 1-2; a polynucleotide comprising the full length protein coding sequence of SEQ ID NO: 1-2 (for example coding for SEQ ID NO: 3, respectively); and a polynucleotide comprising the nucleotide sequence encoding the mature protein coding sequence of the polypeptides of any one of SEQ ID NO: 1-2. The polynucleotides of the present invention also include, but are not limited to, a polynucleotide that hybridizes under stringent conditions to (a) the complement of any of the nucleotides sequences of SEQ ID NO: 1-2; (b) a polynucleotide encoding any one of the polypeptides of SEQ ID NO: 3-7; (c) a polynucleotide which is an allelic variant of any polynucleotides recited above; (d) a polynucleotide which encodes a species homolog of any of the proteins recited above; or (e) a polynucleotide that encodes a polypeptide comprising a specific domain or truncation of the polypeptides of SEQ ID NO: 3-7. Domains of interest may depend on the nature of the encoded polypeptide; *e.g.*, domains in receptor-like polypeptides include ligand-binding, extracellular, transmembrane, or cytoplasmic domains, or combinations thereof; domains in immunoglobulin-like proteins include the variable immunoglobulin-like domains; domains in enzyme-like polypeptides include catalytic and substrate binding domains; and domains in ligand polypeptides include receptor-binding domains.

The polynucleotides of the invention include naturally occurring or wholly or partially synthetic DNA, *e.g.*, cDNA and genomic DNA, and RNA, *e.g.*, mRNA. The

polynucleotides may include the entire coding region of the cDNA or may represent a portion of the coding region of the cDNA.

The present invention also provides genes corresponding to the cDNA sequences disclosed herein. The corresponding genes can be isolated in accordance with known methods using the sequence information disclosed herein. Such methods include the preparation of probes or primers from the disclosed sequence information for identification and/or amplification of genes in appropriate genomic libraries or other sources of genomic materials. Further 5' and 3' sequence can be obtained using methods known in the art. For example, full length cDNA or genomic DNA that corresponds to any of the polynucleotides of SEQ ID NO: 1-2 can be obtained by screening appropriate cDNA or genomic DNA libraries under suitable hybridization conditions using any of the polynucleotides of SEQ ID NO: 1-2 or a portion thereof as a probe. Alternatively, the polynucleotides of SEQ ID NO: 1-2 may be used as the basis for suitable primer(s) that allow identification and/or amplification of genes in appropriate genomic DNA or cDNA libraries.

The nucleic acid sequences of the invention can be assembled from ESTs and sequences (including cDNA and genomic sequences) obtained from one or more public databases, such as dbEST, gbpri, and UniGene. The EST sequences can provide identifying sequence information, representative fragment or segment information, or novel segment information for the full-length gene.

The polynucleotides of the invention also provide polynucleotides including nucleotide sequences that are substantially equivalent to the polynucleotides recited above. Polynucleotides according to the invention can have, *e.g.*, at least about 65%, at least about 70%, at least about 75%, at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, or 89%, more typically at least about 90%, 91%, 92%, 93%, or 94% and even more typically at least about 95%, 96%, 97%, 98% or 99% sequence identity to a polynucleotide recited above.

Included within the scope of the nucleic acid sequences of the invention are nucleic acid sequence fragments that hybridize under stringent conditions to any of the nucleotide sequences of SEQ ID NO: 1-2, or complements thereof, which fragment is greater than about 5 nucleotides, preferably 7 nucleotides, more preferably greater than 9

nucleotides and most preferably greater than 17 nucleotides. Fragments of, *e.g.* 15, 17, or 20 nucleotides or more that are selective for (*i.e.* specifically hybridize to any one of the polynucleotides of the invention) are contemplated. Probes capable of specifically hybridizing to a polynucleotide can differentiate polynucleotide sequences of the invention from other polynucleotide sequences in the same family of genes or can differentiate human genes from genes of other species, and are preferably based on unique nucleotide sequences.

The sequences falling within the scope of the present invention are not limited to these specific sequences, but also include allelic and species variations thereof. Allelic and species variations can be routinely determined by comparing the sequence provided in SEQ ID NO: 1-2, a representative fragment thereof, or a nucleotide sequence at least 90% identical, preferably 95% identical, to SEQ ID NO: 1-2 with a sequence from another isolate of the same species. Furthermore, to accommodate codon variability, the invention includes nucleic acid molecules coding for the same amino acid sequences as do the specific ORFs disclosed herein. In other words, in the coding region of an ORF, substitution of one codon for another codon that encodes the same amino acid is expressly contemplated.

The nearest neighbor result for the nucleic acids of the present invention, including SEQ ID NO: 1-2, can be obtained by searching a database using an algorithm or a program. Preferably, a BLAST which stands for Basic Local Alignment Search Tool is used to search for local sequence alignments (Altshul, S.F., *J Mol. Evol.* 36 290-300 (1993) and Altschul S.F., *et al. J. Mol. Biol.* 21:403-410 (1990)).

Species homologs (or orthologs) of the disclosed polynucleotides and proteins are also provided by the present invention. Species homologs may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source from the desired species.

The invention also encompasses allelic variants of the disclosed polynucleotides or proteins; that is, naturally-occurring alternative forms of the isolated polynucleotide which also encodes proteins which are identical, homologous or related to that encoded by the polynucleotides.

The nucleic acid sequences of the invention are further directed to sequences which encode variants of the described nucleic acids. These amino acid sequence variants may be prepared by methods known in the art by introducing appropriate nucleotide changes into a native or variant polynucleotide. There are two variables in the construction of amino acid sequence variants: the location of the mutation and the nature of the mutation. Nucleic acids encoding the amino acid sequence variants are preferably constructed by mutating the polynucleotide to encode an amino acid sequence that does not occur in nature. These nucleic acid alterations can be made at sites that differ in the nucleic acids from different species (variable positions) or in highly conserved regions (constant regions). Sites at such locations will typically be modified in series, *e.g.*, by substituting first with conservative choices (*e.g.*, hydrophobic amino acid to a different hydrophobic amino acid) and then with more distant choices (*e.g.*, hydrophobic amino acid to a charged amino acid), and then deletions or insertions may be made at the target site. Amino acid sequence deletions generally range from about 1 to 30 residues, preferably about 1 to 10 residues, and are typically contiguous. Amino acid insertions include amino- and/or carboxyl-terminal fusions ranging in length from one to one hundred or more residues, as well as intrasequence insertions of single or multiple amino acid residues. Intrasequence insertions may range generally from about 1 to 10 amino residues, preferably from 1 to 5 residues. Examples of terminal insertions include the heterologous signal sequences necessary for secretion or for intracellular targeting in different host cells and sequences such as FLAG or poly-histidine sequences useful for purifying the expressed protein.

In a preferred method, polynucleotides encoding the novel amino acid sequences are changed via site-directed mutagenesis. This method uses oligonucleotide sequences to alter a polynucleotide to encode the desired amino acid variant, as well as sufficient adjacent nucleotides on both sides of the changed amino acid to form a stable duplex on either side of the site being changed. In general, the techniques of site-directed mutagenesis are well known to those of skill in the art and this technique is exemplified by publications such as, Edelman *et al.*, *DNA* 2:183 (1983). A versatile and efficient method for producing site-specific changes in a polynucleotide sequence was published by Zoller and Smith, *Nucleic Acids Res.* 10:6487-6500 (1982). PCR may also be used to

create amino acid sequence variants of the novel nucleic acids. When small amounts of template DNA are used as starting material, primer(s) that differs slightly in sequence from the corresponding region in the template DNA can generate the desired amino acid variant. PCR amplification results in a population of product DNA fragments that differ from the polynucleotide template encoding the polypeptide at the position specified by the primer. The product DNA fragments replace the corresponding region in the plasmid and this gives a polynucleotide encoding the desired amino acid variant.

A further technique for generating amino acid variants is the cassette mutagenesis technique described in Wells, *et al.*, *Gene* 34:315 (1985); and other mutagenesis techniques well known in the art, such as, for example, the techniques in Sambrook, *et al.*, *supra*, and *Current Protocols in Molecular Biology*, Ausubel, *et al.* Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be used in the practice of the invention for the cloning and expression of these novel nucleic acids. Such DNA sequences include those which are capable of hybridizing to the appropriate novel nucleic acid sequence under stringent conditions.

Polynucleotides encoding preferred polypeptide truncations of the invention can be used to generate polynucleotides encoding chimeric or fusion proteins comprising one or more domains of the invention and heterologous protein sequences.

The polynucleotides of the invention additionally include the complement of any of the polynucleotides recited above. The polynucleotide can be DNA (genomic, cDNA, amplified, or synthetic) or RNA. Methods and algorithms for obtaining such polynucleotides are well known to those of skill in the art and can include, for example, methods for determining hybridization conditions that can routinely isolate polynucleotides of the desired sequence identities.

In accordance with the invention, polynucleotide sequences comprising the mature protein coding sequences, coding for any one of SEQ ID NO: 3, or functional equivalents thereof, may be used to generate recombinant DNA molecules that direct the expression of that nucleic acid, or a functional equivalent thereof, in appropriate host cells. Also included are the cDNA inserts of any of the clones identified herein.

A polynucleotide according to the invention can be joined to any of a variety of other nucleotide sequences by well-established recombinant DNA techniques (see Sambrook, J. *et al.* (1989) *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory, NY). Useful nucleotide sequences for joining to polynucleotides include an
5 assortment of vectors, *e.g.*, plasmids, cosmids, lambda phage derivatives, phagemids, and the like, that are well known in the art. Accordingly, the invention also provides a vector including a polynucleotide of the invention and a host cell containing the polynucleotide. In general, the vector contains an origin of replication functional in at least one organism, convenient restriction endonuclease sites, and a selectable marker for the host cell.

10 Vectors according to the invention include expression vectors, replication vectors, probe generation vectors, and sequencing vectors. A host cell according to the invention can be a prokaryotic or eukaryotic cell and can be a unicellular organism or part of a multicellular organism.

The present invention further provides recombinant constructs comprising a
15 nucleic acid having any of the nucleotide sequences of SEQ ID NO: 1-2 or a fragment thereof or any other polynucleotides of the invention. In one embodiment, the recombinant constructs of the present invention comprise a vector, such as a plasmid or viral vector, into which a nucleic acid having any of the nucleotide sequences of SEQ ID NO: 1-2 or a fragment thereof is inserted, in a forward or reverse orientation. In the case
20 of a vector comprising one of the ORFs of the present invention, the vector may further comprise regulatory sequences, including for example, a promoter, operably linked to the ORF. Large numbers of suitable vectors and promoters are known to those of skill in the art and are commercially available for generating the recombinant constructs of the present invention. The following vectors are provided by way of example. Bacterial:
25 pBs, phagescript, PsiX174, pBluescript SK, pBs KS, pNH8a, pNH16a, pNH18a, pNH46a (Stratagene); pTrc99A, pKK223-3, pKK233-3, pDR540, pRIT5 (Pharmacia).
Eukaryotic: pWLneo, pSV2cat, pOG44, PXTI, pSG (Stratagene) pSVK3, pBPV, pMSG, and pSVL (Pharmacia).

The isolated polynucleotide of the invention may be operably linked to an
30 expression control sequence such as the pMT2 or pED expression vectors disclosed in Kaufman *et al.*, *Nucleic Acids Res.* 19:4485-4490 (1991), in order to produce the protein

recombinantly. Many suitable expression control sequences are known in the art. General methods of expressing recombinant proteins are also known and are exemplified in R. Kaufman, *Methods in Enzymology* 185:537-566 (1990). As defined herein "operably linked" means that the isolated polynucleotide of the invention and an
5 expression control sequence are situated within a vector or cell in such a way that the protein is expressed by a host cell which has been transformed (transfected) with the ligated polynucleotide/expression control sequence.

Promoter regions can be selected from any desired gene using CAT (chloramphenicol transferase) vectors or other vectors with selectable markers. Two
10 appropriate vectors are pKK232-8 and pCM7. Particular named bacterial promoters include lacI, lacZ, T3, T7, gpt, lambda PR, and trc. Eukaryotic promoters include CMV immediate early, HSV thymidine kinase, early and late SV40, LTRs from retrovirus, and mouse metallothionein-I. Selection of the appropriate vector and promoter is well within the level of ordinary skill in the art. Generally, recombinant expression vectors will
15 include origins of replication and selectable markers permitting transformation of the host cell, *e.g.*, the ampicillin resistance gene of *E. coli* and *S. cerevisiae* TRP1 gene, and a promoter derived from a highly expressed gene to direct transcription of a downstream structural sequence. Such promoters can be derived from operons encoding glycolytic enzymes such as 3-phosphoglycerate kinase (PGK), a-factor, acid phosphatase, or heat
20 shock proteins, among others. The heterologous structural sequence is assembled in appropriate phase with translation initiation and termination sequences, and preferably, a leader sequence capable of directing secretion of translated protein into the periplasmic space or extracellular medium. Optionally, the heterologous sequence can encode a fusion protein including an amino terminal identification peptide imparting desired
25 characteristics, *e.g.*, stabilization or simplified purification of expressed recombinant product. Useful expression vectors for bacterial use are constructed by inserting a structural DNA sequence encoding a desired protein together with suitable translation initiation and termination signals in operable reading phase with a functional promoter. The vector will comprise one or more phenotypic selectable markers and an origin of
30 replication to ensure maintenance of the vector and to, if desirable, provide amplification within the host. Suitable prokaryotic hosts for transformation include *E. coli*, *Bacillus*

subtilis, *Salmonella typhimurium* and various species within the genera *Pseudomonas*, *Streptomyces*, and *Staphylococcus*, although others may also be employed as a matter of choice.

As a representative but non-limiting example, useful expression vectors for bacterial use can comprise a selectable marker and bacterial origin of replication derived from commercially available plasmids comprising genetic elements of the well known cloning vector pBR322 (ATCC 37017). Such commercial vectors include, for example, pKK223-3 (Pharmacia Fine Chemicals, Uppsala, Sweden) and GEM 1 (Promega Biotech, Madison, WI, USA). These pBR322 "backbone" sections are combined with an appropriate promoter and the structural sequence to be expressed. Following transformation of a suitable host strain and growth of the host strain to an appropriate cell density, the selected promoter is induced or derepressed by appropriate means (*e.g.*, temperature shift or chemical induction) and cells are cultured for an additional period. Cells are typically harvested by centrifugation, disrupted by physical or chemical means, and the resulting crude extract retained for further purification.

Polynucleotides of the invention can also be used to induce immune responses. For example, as described in Fan, *et al.*, *Nat. Biotech.* 17:870-872 (1999), incorporated herein by reference, nucleic acid sequences encoding a polypeptide may be used to generate antibodies against the encoded polypeptide following topical administration of naked plasmid DNA or following injection, and preferably intramuscular injection of the DNA. The nucleic acid sequences are preferably inserted in a recombinant expression vector and may be in the form of naked DNA.

5.4.6 GENE THERAPY

Mutations in the polynucleotides of the invention gene may result in loss of normal function of the encoded protein. The invention thus provides gene therapy to restore normal activity of the polypeptides of the invention; or to treat disease states involving polypeptides of the invention. Delivery of a functional gene encoding polypeptides of the invention to appropriate cells is effected *ex vivo*, *in situ*, or *in vivo* by use of vectors, and more particularly viral vectors (*e.g.*, adenovirus, adeno-associated virus, or a retrovirus), or *ex vivo* by use of physical DNA transfer methods (*e.g.*,

liposomes or chemical treatments). See, for example, Anderson, *Nature*, 392(Suppl):25-20 (1998). For additional reviews of gene therapy technology see Friedmann, *Science*, 244: 1275-1281 (1989); Verma, *Scientific American*: 68-84 (1990); and Miller, *Nature*, 357: 455-460 (1992), all of which are herein incorporated by reference in their entirety.

5 Introduction of any one of the nucleotides of the present invention or a gene encoding the polypeptides of the present invention can also be accomplished with extrachromosomal substrates (transient expression) or artificial chromosomes (stable expression). Cells may also be cultured *ex vivo* in the presence of proteins of the present invention in order to proliferate or to produce a desired effect on or activity in such cells. Treated cells can
10 then be introduced *in vivo* for therapeutic purposes. Alternatively, it is contemplated that in other human disease states, preventing the expression of or inhibiting the activity of polypeptides of the invention will be useful in treating the disease states. It is contemplated that antisense therapy or gene therapy could be applied to negatively regulate the expression of polypeptides of the invention.

15 Other methods inhibiting expression of a protein include the introduction of antisense molecules to the nucleic acids of the present invention, their complements, or their translated RNA sequences, by methods known in the art. Further, the polypeptides of the present invention can be inhibited by using targeted deletion methods, or the insertion of a negative regulatory element such as a silencer, which is tissue specific.

20 The present invention still further provides cells genetically engineered *in vivo* to express the polynucleotides of the invention, wherein such polynucleotides are in operative association with a regulatory sequence heterologous to the host cell which drives expression of the polynucleotides in the cell. These methods can be used to increase or decrease the expression of the polynucleotides of the present invention.

25 Knowledge of DNA sequences provided by the invention allows for modification of cells to permit, increase, or decrease, expression of endogenous polypeptide. Cells can be modified (*e.g.*, by homologous recombination) to provide increased polypeptide expression by replacing, in whole or in part, the naturally occurring promoter with all or part of a heterologous promoter so that the cells express the protein at higher levels. The
30 heterologous promoter is inserted in such a manner that it is operatively linked to the desired protein encoding sequences. See, for example, PCT International Publication No.

WO 94/12650, PCT International Publication No. WO 92/20808, and PCT International Publication No. WO 91/09955, all of which are incorporated by reference in their entirety. It is also contemplated that, in addition to heterologous promoter DNA, amplifiable marker DNA (*e.g.*, *ada*, *dhfr*, and the multifunctional CAD gene which
5 encodes carbamyl phosphate synthase, aspartate transcarbamylase, and dihydroorotase) and/or intron DNA may be inserted along with the heterologous promoter DNA. If linked to the desired protein coding sequence, amplification of the marker DNA by standard selection methods results in co-amplification of the desired protein coding sequences in the cells.

10 In another embodiment of the present invention, cells and tissues may be engineered to express an endogenous gene comprising the polynucleotides of the invention under the control of inducible regulatory elements, in which case the regulatory sequences of the endogenous gene may be replaced by homologous recombination. As described herein, gene targeting can be used to replace a gene's existing regulatory region
15 with a regulatory sequence isolated from a different gene or a novel regulatory sequence synthesized by genetic engineering methods. Such regulatory sequences may be comprised of promoters, enhancers, scaffold-attachment regions, negative regulatory elements, transcriptional initiation sites, regulatory protein binding sites or combinations of said sequences. Alternatively, sequences which affect the structure or stability of the
20 RNA or protein produced may be replaced, removed, added, or otherwise modified by targeting. These sequences include polyadenylation signals, mRNA stability elements, splice sites, leader sequences for enhancing or modifying transport or secretion properties of the protein, or other sequences which alter or improve the function or stability of protein or RNA molecules.

25 The targeting event may be a simple insertion of the regulatory sequence, placing the gene under the control of the new regulatory sequence, *e.g.*, inserting a new promoter or enhancer or both upstream of a gene. Alternatively, the targeting event may be a simple deletion of a regulatory element, such as the deletion of a tissue-specific negative regulatory element. Alternatively, the targeting event may replace an existing element;
30 for example, a tissue-specific enhancer can be replaced by an enhancer that has broader or different cell-type specificity than the naturally occurring elements. Here, the

naturally occurring sequences are deleted and new sequences are added. In all cases, the identification of the targeting event may be facilitated by the use of one or more selectable marker genes that are contiguous with the targeting DNA, allowing for the selection of cells in which the exogenous DNA has integrated into the cell genome. The
5 identification of the targeting event may also be facilitated by the use of one or more marker genes exhibiting the property of negative selection, such that the negatively selectable marker is linked to the exogenous DNA, but configured such that the negatively selectable marker flanks the targeting sequence, and such that a correct homologous recombination event with sequences in the host cell genome does not result
10 in the stable integration of the negatively selectable marker. Markers useful for this purpose include the Herpes Simplex Virus thymidine kinase (TK) gene or the bacterial xanthine-guanine phosphoribosyl-transferase (gpt) gene.

The gene targeting or gene activation techniques which can be used in accordance with this aspect of the invention are more particularly described in U.S. Patent No.
15 5,272,071 to Chappel; U.S. Patent No. 5,578,461 to Sherwin *et al.*; International Application No. PCT/US92/09627 (WO93/09222) by Selden *et al.*; and International Application No. PCT/US90/06436 (WO91/06667) by Skoultchi *et al.*, each of which is incorporated by reference herein in its entirety.

20 **5.5 ANTI-KIRHy1 ANTIBODIES**

Alternatively, immunotargeting involves the administration of components of the immune system, such as antibodies, antibody fragments, or primed cells of the immune system against the target. Methods of immunotargeting cancer cells using antibodies or antibody fragments are well known in the art. U.S. Patent No. 6,306,393 describes the
25 use of anti-CD22 antibodies in the immunotherapy of B-cell malignancies, and U.S. Patent No. 6,329,503 describes immunotargeting of cells that express serpentine transmembrane antigens (both U.S. patents are herin incorporated by reference in their entirety).

KIRHy1 antibodies (including humanized or human monoclonal antibodies or
30 fragments or other modifications thereof, optionally conjugated to cytotoxic agents) may be introduced into a patient such that the antibody binds to KIRHy1 expressed by cancer

cells and mediates the destruction of the cells and the tumor and/or inhibits the growth of the cells or the tumor. Without intending to limit the disclosure, mechanisms by which such antibodies can exert a therapeutic effect may include complement-mediated cytotoxicity, antibody-dependent cellular cytotoxicity (ADCC), modulating the physiologic function of KIRHy1, inhibiting binding or signal transduction pathways, modulating tumor cell differentiation, altering tumor angiogenesis factor profiles, modulating the secretion of immune stimulating or tumor suppressing cytokines and growth factors, modulating cellular adhesion, and/or by inducing apoptosis. KIRHy1 antibodies conjugated to toxic or therapeutic agents, such as radioligands or cytosolic toxins, may also be used therapeutically to deliver the toxic or therapeutic agent directly to KIRHy1-bearing tumor cells.

KIRHy1 antibodies may be used to suppress the immune system in patients receiving organ transplants or in patients with autoimmune diseases such as arthritis. Healthy immune cells would be targeted by these antibodies leading their death and clearance from the system, thus suppressing the immune system.

KIRHy1 antibodies may be used as antibody therapy for solid tumors which express this action. Cancer immunotherapy using antibodies provides a novel approach to treating cancers associated with cells that specifically express KIRHy1. As described above, KIRHy1 These results demonstrate that KIRHy1 mRNA is highly expressed in cell lines derived from KIRHy1. These findings demonstrate KIRHy1 mRNA expression in KIRHy1 indicate that KIRHy1 may be used as an therapeutic antibody target and a diagnostic marker for certain cell types or disorders (*e.g.*, B-cell lymphomas, T cell lymphomas, myeloid leukemia, Hodgkin's disease). Cancer immunotherapy using antibodies has been previously described for other types of cancer, including but not limited to colon cancer (Arlen *et al.*, *Crit. Rev. Immunol.* 18:133-138 (1998)), multiple myeloma (Ozaki *et al.*, *Blood* 90:3179-3186 (1997); Tsunenari *et al.*, *Blood* 90:2437-2444 (1997)), gastric cancer (Kasprzyk *et al.*, *Cancer Res.* 52:2771-2776 (1992)), B cell lymphoma (Funakoshi *et al.*, *J. Immunother. Emphasisi Tumor Immunol.* 19:93-101 (1996)), leukemia (Zhong *et al.*, *Leuk. Res.* 20:581-589 (1996)), colorectal cancer (Moun *et al.*, *Cancer Res.* 54:6160-6166 (1994); Velders *et al.*, *Cancer Res.* 55:4398-4403

(1995)), and breast cancer (Shepard *et al.*, *J. Clin. Immunol.* 11:117-127 (1991), all of the above listed references are herein incorporated by reference in their entirety).

Although KIRHy1 antibody therapy may be useful for all stages of the foregoing
5 cancers, antibody therapy may be particularly appropriate in advanced or metastatic
cancers. Combining the antibody therapy method with a chemotherapeutic, radiation or
surgical regimen may be preferred in patients that have not received chemotherapeutic
treatment, whereas treatment with the antibody therapy may be indicated for patients who
have received one or more chemotherapies. Additionally, antibody therapy can also
10 enable the use of reduced dosages of concomitant chemotherapy, particularly in patients
that do not tolerate the toxicity of the chemotherapeutic agent very well. Furthermore,
treatment of cancer patients with KIRHy1 antibody with tumors resistant to
chemotherapeutic agents might induce sensitivity and responsiveness to these agents in
combination.

15 Prior to anti-KIRHy1 immunotargeting, a patient may be evaluated for the
presence and level of KIRHy1 expression by the cancer cells, preferably using
immunohistochemical assessments of tumor tissue, quantitative KIRHy1 imaging,
quantitative RT-PCR, or other techniques capable of reliably indicating the presence and
degree of KIRHy1 expression. For example, a blood or biopsy sample may be evaluated
20 by immunohistochemical methods to determine the presence of KIRHy1-expressing cells
or to determine the extent of KIRHy1 expression on the surface of the cells within the
sample. Methods for immunohistochemical analysis of tumor tissues or released
fragments of KIRHy1 in the serum are well known in the art.

Anti-KIRHy1 antibodies useful in treating cancers include those, which are
25 capable of initiating a potent immune response against the tumor and those, which are
capable of direct cytotoxicity. In this regard, anti-KIRHy1 mAbs may elicit tumor cell
lysis by either complement-mediated or ADCC mechanisms, both of which require an
intact Fc portion of the immunoglobulin molecule for interaction with effector cell Fc
receptor sites or complement proteins. In addition, anti-KIRHy1 antibodies that exert a
30 direct biological effect on tumor growth are useful in the practice of the invention.
Potential mechanisms by which such directly cytotoxic antibodies may act include

inhibition of cell growth, modulation of cellular differentiation, modulation of tumor angiogenesis factor profiles, and the induction of apoptosis. The mechanism by which a particular anti-KIRHy1 antibody exerts an anti-tumor effect may be evaluated using any number of *in vitro* assays designed to determine ADCC, ADMMC, complement-mediated cell lysis, and so forth, as is generally known in the art.

The anti-tumor activity of a particular anti-KIRHy1 antibody, or combination of anti-KIRHy1 antibody, may be evaluated *in vivo* using a suitable animal model. For example, xenogenic lymphoma cancer models wherein human lymphoma cells are introduced into immune compromised animals, such as nude or SCID mice. Efficacy may be predicted using assays, which measure inhibition of tumor formation, tumor regression or metastasis, and the like.

It should be noted that the use of murine or other non-human monoclonal antibodies, human/mouse chimeric mAbs may induce moderate to strong immune responses in some patients. In the most severe cases, such an immune response may lead to the extensive formation of immune complexes, which, potentially, can cause renal failure. Accordingly, preferred monoclonal antibodies used in the practice of the therapeutic methods of the invention are those which are either fully human or humanized and which bind specifically to the target KIRHy1 antigen with high affinity but exhibit low or no antigenicity in the patient.

The method of the invention contemplates the administration of single anti-KIRHy1 monoclonal antibodies (mAbs) as well as combinations, or "cocktails", of different mAbs. Two or more monoclonal antibodies that bind to KIRHy1 may provide an improved effect compared to a single antibody. Alternatively, a combination of an anti-KIRHy1 antibody with an antibody that binds a different antigen may provide an improved effect compared to a single antibody. Such mAb cocktails may have certain advantages inasmuch as they contain mAbs, which exploit different effector mechanisms or combine directly cytotoxic mAbs with mAbs that rely on immune effector functionality. Such mAbs in combination may exhibit synergistic therapeutic effects. In addition, the administration of anti-KIRHy1 mAbs may be combined with other therapeutic agents, including but not limited to various chemotherapeutic agents, androgen-blockers, and immune modulators (*e.g.*, IL-2, GM-CSF). The anti-KIRHy1

mAbs may be administered in their "naked" or unconjugated form, or may have therapeutic agents conjugated to them. Additionally, bispecific antibodies may be used. Such an antibody would have one antigenic binding domain specific for KIRHy1 and the other antigenic binding domain specific for another antigen (such as CD20 for example).
5 Finally, Fab KIRHy1 antibodies or fragments of these antibodies (including fragments conjugated to other protein sequences or toxins) may also be used as therapeutic agents.

Antibodies that specifically bind KIRHy1 are useful in compositions and methods for immunotargeting cells expressing KIRHy1 and for diagnosing a disease or disorder wherein cells involved in the disorder express KIRHy1. Such antibodies include
10 monoclonal and polyclonal antibodies, single chain antibodies, chimeric antibodies, bifunctional/bispecific antibodies, humanized antibodies, human antibodies, and complementary determining region (CDR)-grafted antibodies, including compounds that include CDR and/or antigen-binding sequences, which specifically recognize KIRHy1. Antibody fragments, including Fab, Fab', F(ab')₂, and F_v, are also useful.

15 The term "specific for" indicates that the variable regions of the antibodies recognize and bind KIRHy1 exclusively (*i.e.*, able to distinguish KIRHy1 from other similar polypeptides despite sequence identity, homology, or similarity found in the family of polypeptides), but may also interact with other proteins (for example, *S. aureus* protein A or other antibodies in ELISA techniques) through interactions with sequences
20 outside the variable region of the antibodies, and in particular, in the constant region of the molecule. Screening assays in which one can determine binding specificity of an anti-KIRHy1 antibody are well known and routinely practiced in the art. (Chapter 6, *Antibodies A Laboratory Manual*, Eds. Harlow, *et al.*, Cold Spring Harbor Laboratory; Cold Spring Harbor, NY (1988), herein incorporated by reference in its entirety).

25 KIRHy1 polypeptides can be used to immunize animals to obtain polyclonal and monoclonal antibodies that specifically react with KIRHy1. Such antibodies can be obtained using either the entire protein or fragments thereof as an immunogen. The peptide immunogens additionally may contain a cysteine residue at the carboxyl terminus, and are conjugated to a hapten such as keyhole limpet hemocyanin (KLH).
30 Methods for synthesizing such peptides have been previously described (Merrifield, *J. Amer. Chem. Soc.* 85, 2149-2154 (1963); Krstenansky, *et al.*, *FEBS Lett.* 211: 10 (1987),

both of which are incorporated by reference in their entirety). Techniques for preparing polyclonal and monoclonal antibodies as well as hybridomas capable of producing the desired antibody have also been previously disclosed (Campbell, *Monoclonal Antibodies Technology: Laboratory Techniques in Biochemistry and Molecular Biology*, Elsevier Science Publishers, Amsterdam, The Netherlands (1984); St. Groth, *et al.*, *J. Immunol.* 35:1-21 (1990); Kohler and Milstein, *Nature* 256:495-497 (1975)), the trioma technique, the human B-cell hybridoma technique (Kozbor, *et al.*, *Immunology Today* 4:72 (1983); Cole, *et al.*, in, *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc., pp. 77-96 (1985), all of which are incorporated by reference in their entirety).

Any animal capable of producing antibodies can be immunized with a KIRHy1 peptide or polypeptide. Methods for immunization include subcutaneous or intraperitoneal injection of the polypeptide. The amount of the KIRHy1 peptide or polypeptide used for immunization depends on the animal that is immunized, antigenicity of the peptide and the site of injection. The KIRHy1 peptide or polypeptide used as an immunogen may be modified or administered in an adjuvant in order to increase the protein's antigenicity. Methods of increasing the antigenicity of a protein are well known in the art and include, but are not limited to, coupling the antigen with a heterologous protein (such as globulin or β -galactosidase) or through the inclusion of an adjuvant during immunization.

For monoclonal antibodies, spleen cells from the immunized animals are removed, fused with myeloma cells, such as SP2/0-Ag14 myeloma cells, and allowed to become monoclonal antibody producing hybridoma cells. Any one of a number of methods well known in the art can be used to identify the hybridoma cell that produces an antibody with the desired characteristics. These include screening the hybridomas with an ELISA assay, Western blot analysis, or radioimmunoassay (Lutz, *et al.*, *Exp. Cell Res.* 175:109-124 (1988), herein incorporated by reference in its entirety). Hybridomas secreting the desired antibodies are cloned and the class and subclass is determined using procedures known in the art (Campbell, A.M., *Monoclonal Antibody Technology: Laboratory Techniques in Biochemistry and Molecular Biology*, Elsevier Science Publishers, Amsterdam, The Netherlands (1984), herein incorporated by reference in its entirety). Techniques described for the production of single chain antibodies can be

adapted to produce single chain antibodies to KIRHy1 (U.S. Patent 4,946,778, herein incorporated by reference in its entirety).

For polyclonal antibodies, antibody-containing antiserum is isolated from the immunized animal and is screened for the presence of antibodies with the desired specificity using one of the above-described procedures.

Because antibodies from rodents tend to elicit strong immune responses against the antibodies when administered to a human, such antibodies may have limited effectiveness in therapeutic methods of the invention. Methods of producing antibodies that do not produce a strong immune response against the administered antibodies are well known in the art. For example, the anti-KIRHy1 antibody can be a nonhuman primate antibody. Methods of making such antibodies in baboons are disclosed in PCT publication No. WO 91/11465 and Losman *et al.*, *Int. J. Cancer* 46:310-314 (1990), both of which are herein incorporated by reference in their entirety. In one embodiment, the anti-KIRHy1 antibody is a humanized monoclonal antibody. Methods of producing humanized antibodies have been previously described. (U.S. Patent Nos. 5,997,867 and 5,985,279, Jones *et al.*, *Nature* 321:522 (1986); Riechmann *et al.*, *Nature* 332:323(1988); Verhoeven *et al.*, *Science* 239:1534-1536 (1988); Carter *et al.*, *Proc. Nat'l Acad. Sci. USA* 89:4285-4289 (1992); Sandhu, *Crit. Rev. Biotech.* 12:437-462 (1992); and Singer, *et al.*, *J. Immun.* 150:2844-2857 (1993), all of which are herein incorporated by reference in their entirety). In another embodiment, the anti-KIRHy1 antibody is a human monoclonal antibody. Humanized antibodies are produced by transgenic mice that have been engineered to produce human antibodies. Hybridomas derived from such mice will secrete large amounts of human monoclonal antibodies. Methods for obtaining human antibodies from transgenic mice are described in Green, *et al.*, *Nature Genet.* 7:13-21(1994), Lonberg, *et al.*, *Nature* 368:856 (1994), and Taylor, *et al.*, *Int. Immun.* 6:579 (1994), all of which are herein incorporated by reference in their entirety.

The present invention also includes the use of anti-KIRHy1 antibody fragments. Antibody fragments can be prepared by proteolytic hydrolysis of an antibody or by expression in *E. coli* of the DNA coding for the fragment. Antibody fragments can be obtained by pepsin or papain digestion of whole antibodies. For example, antibody fragments can be produced by enzymatic cleavage of antibodies with pepsin to provide a

5S fragment denoted F(ab')₂. This fragment can be further cleaved using a thiol reducing agent, and optionally a blocking group for the sulfhydryl groups resulting from cleavage of disulfide linkages, to produce 3.5S Fab' monovalent fragments. Alternatively, an enzymatic cleavage using pepsin produces two monovalent Fab fragments and an Fc fragment directly. These methods have been previously described (U.S. Patent Nos. 4,036,945 and 4,331,647, Nisonoff, *et al.*, *Arch Biochem. Biophys.* 89:230 (1960); Porter, *Biochem. J.* 73:119 (1959), Edelman, *et al.*, *Meth. Enzymol.* 1:422 (1967), all of which are herein incorporated by reference in their entirety). Other methods of cleaving antibodies, such as separation of heavy chains to form monovalent light-heavy chain fragments, further cleavage of fragments, or other enzymatic, chemical or genetic techniques may also be used, so long as the fragments bind to the antigen that is recognized by the intact antibody. For example, Fv fragments comprise an association of V_H and V_L chains, which can be noncovalent (Inbar *et al.*, *Proc. Nat'l Acad. Sci. USA* 69:2659 (1972), herein incorporated by reference in its entirety). Alternatively, the variable chains can be linked by an intermolecular disulfide bond or cross-linked by chemicals such as glutaraldehyde.

In one embodiment, the Fv fragments comprise V_H and V_L chains that are connected by a peptide linker. These single-chain antigen binding proteins (sFv) are prepared by constructing a structural gene comprising DNA sequences encoding the V_H and V_L domains which are connected by an oligonucleotide. The structural gene is inserted into an expression vector, which is subsequently introduced into a host cell, such as *E. coli*. The recombinant host cells synthesize a single polypeptide chain with a linker peptide bridging the two V domains. Methods for producing sFvs have been previously described (U.S. Patent No. 4,946,778, Whitlow, *et al.*, *Methods: A Companion to Methods in Enzymology* 2:97 (1991), Bird, *et al.*, *Science* 242:423 (1988), Pack, *et al.*, *Bio/Technology* 11:1271 (1993), all of which are herein incorporated by reference in their entirety).

Another form of an antibody fragment is a peptide coding for a single complementarity-determining region (CDR). CDR peptides ("minimal recognition units") can be obtained by constructing genes encoding the CDR of an antibody of interest. Such genes are prepared, for example, by using the polymerase chain reaction to

synthesize the variable region from RNA of antibody-producing cells (Larrick, *et al.*, *Methods: A Companion to Methods in Enzymology* 2:106 (1991); Courtenay-Luck, pp. 166-179 in, *Monoclonal Antibodies Production, Engineering and Clinical Applications*, Eds. Ritter *et al.*, Cambridge University Press (1995); Ward, *et al.*, pp. 137-185 in, 5 *Monoclonal Antibodies Principles and Applications*, Eds. Birch *et al.*, Wiley-Liss, Inc. (1995), all of which are herein incorporated by reference in their entirety).

The present invention further provides the above- described antibodies in detectably labeled form. Antibodies can be detectably labeled through the use of radioisotopes, affinity labels (such as biotin, avidin, *etc.*), enzymatic labels (such as 10 horseradish peroxidase, alkaline phosphatase, *etc.*) fluorescent labels (such as FITC or rhodamine, *etc.*), paramagnetic atoms, *etc.* Procedures for accomplishing such labeling have been previously disclosed (Sternberger, *et al.*, *J. Histochem. Cytochem.* 18:315 (1970); Bayer, *et al.*, *Meth. Enzym.* 62:308 (1979); Engval, *et al.*, *Immunol.* 109:129 (1972); Goding, *J. Immunol. Meth.* 13:215 (1976), all of which are herein incorporated by 15 reference in their entirety).

The labeled antibodies can be used for *in vitro*, *in vivo*, and *in situ* assays to identify cells or tissues in which KIRHy1 is expressed. Furthermore, the labeled antibodies can be used to identify the presence of secreted KIRHy1 in a biological sample, such as a blood, urine, saliva samples.

20

5.5.1 ANTI-KIRHy1 ANTIBODY CONJUGATES

The present invention contemplates the use of “naked” anti-KIRHy1 antibodies, as well as the use of immunoconjugates. Immunoconjugates can be prepared by indirectly conjugating a therapeutic agent such as a cytotoxic agent to an antibody 25 component. Toxic moieties include, for example, plant toxins, such as abrin, ricin, modeccin, viscumin, pokeweed anti-viral protein, saporin, gelonin, momoridin, trichosanthin, barley toxin; bacterial toxins, such as *Diphtheria* toxin, *Pseudomonas* endotoxin and exotoxin, *Staphylococcal* enterotoxin A; fungal toxins, such as α -sarcin, restrictocin; cytotoxic RNases, such as extracellular pancreatic RNases; DNase I (Pastan, 30 *et al.*, *Cell* 47:641 (1986); Goldenberg, *Cancer Journal for Clinicians* 44:43 (1994), herein incorporated by reference in their entirety), calicheamicin, and radioisotopes, such

as ^{32}P , ^{67}Cu , ^{77}As , ^{105}Rh , ^{109}Pd , ^{111}Ag , ^{121}Sn , ^{131}I , ^{166}Ho , ^{177}Lu , ^{186}Re , ^{188}Re , ^{194}Ir , ^{199}Au (Illidge and Brock, *Curr Pharm. Design* 6:1399 (2000), herein incorporated by reference in its entirety). In humans, clinical trials are underway utilizing a yttrium-90 conjugated anti-CD20 antibody for B cell lymphomas (*Cancer Chemother Pharmacol* 48(Suppl 1):S91-S95 (2001), herein incorporated by reference in its entirety).

General techniques have been previously described (U.S. Patent Nos. 6,306,393 and 5,057,313, Shih, *et al.*, *Int. J. Cancer* 41:832-839 (1988); Shih, *et al.*, *Int. J. Cancer* 46:1101-1106 (1990), all of which are herein incorporated by reference in their entirety). The general method involves reacting an antibody component having an oxidized carbohydrate portion with a carrier polymer that has at least one free amine function and that is loaded with a plurality of drug, toxin, chelator, boron addends, or other therapeutic agent. This reaction results in an initial Schiff base (imine) linkage, which can be stabilized by reduction to a secondary amine to form the final conjugate.

The carrier polymer is preferably an aminodextran or polypeptide of at least 50 amino acid residues, although other substantially equivalent polymer carriers can also be used. Preferably, the final immunoconjugate is soluble in an aqueous solution, such as mammalian serum, for ease of administration and effective targeting for use in therapy. Thus, solubilizing functions on the carrier polymer will enhance the serum solubility of the final immunoconjugate. In particular, an aminodextran will be preferred.

The process for preparing an immunoconjugate with an aminodextran carrier typically begins with a dextran polymer, advantageously a dextran of average molecular weight of about 10,000-100,000. The dextran is reacted with an oxidizing agent to affect a controlled oxidation of a portion of its carbohydrate rings to generate aldehyde groups. The oxidation is conveniently effected with glycolytic chemical reagents such as NaIO_4 , according to conventional procedures. The oxidized dextran is then reacted with a polyamine, preferably a diamine, and more preferably, a mono- or polyhydroxy diamine. Suitable amines include ethylene diamine, propylene diamine, or other like polymethylene diamines, diethylene triamine or like polyamines, 1,3-diamino-2-hydroxypropane, or other like hydroxylated diamines or polyamines, and the like. An excess of the amine relative to the aldehyde groups of the dextran is used to ensure substantially complete conversion of the aldehyde functions to Schiff base groups. A

reducing agent, such as NaBH_4 , NaBH_3CN or the like, is used to effect reductive stabilization of the resultant Schiff base intermediate. The resultant adduct can be purified by passage through a conventional sizing column or ultrafiltration membrane to remove cross-linked dextrans. Other conventional methods of derivatizing a dextran to introduce amine functions can also be used, *e.g.*, reaction with cyanogen bromide, followed by reaction with a diamine.

The aminodextran is then reacted with a derivative of the particular drug, toxin, chelator, immunomodulator, boron addend, or other therapeutic agent to be loaded, in an activated form, preferably, a carboxyl-activated derivative, prepared by conventional means, *e.g.*, using dicyclohexylcarbodiimide (DCC) or a water soluble variant thereof, to form an intermediate adduct. Alternatively, polypeptide toxins such as pokeweed antiviral protein or ricin A-chain, and the like, can be coupled to aminodextran by glutaraldehyde condensation or by reaction of activated carboxyl groups on the protein with amines on the aminodextran.

Chelators for radiometals or magnetic resonance enhancers are well-known in the art. Typical are derivatives of ethylenediaminetetraacetic acid (EDTA) and diethylenetriaminepentaacetic acid (DTPA). These chelators typically have groups on the side chain by which the chelator can be attached to a carrier. Such groups include, *e.g.*, benzylisothiocyanate, by which the DTPA or EDTA can be coupled to the amine group of a carrier. Alternatively, carboxyl groups or amine groups on a chelator can be coupled to a carrier by activation or prior derivatization and then coupling, all by well-known means.

Boron addends, such as carboranes, can be attached to antibody components by conventional methods. For example, carboranes can be prepared with carboxyl functions on pendant side chains, as is well known in the art. Attachment of such carboranes to a carrier, *e.g.*, aminodextran, can be achieved by activation of the carboxyl groups of the carboranes and condensation with amines on the carrier to produce an intermediate conjugate. Such intermediate conjugates are then attached to antibody components to produce therapeutically useful immunoconjugates, as described below.

A polypeptide carrier can be used instead of aminodextran, but the polypeptide carrier should have at least 50 amino acid residues in the chain, preferably 100-5000

amino acid residues. At least some of the amino acids should be lysine residues or glutamate or aspartate residues. The pendant amines of lysine residues and pendant carboxylates of glutamine and aspartate are convenient for attaching a drug, toxin, immunomodulator, chelator, boron addend or other therapeutic agent. Examples of suitable polypeptide carriers include polylysine, polyglutamic acid, polyaspartic acid, copolymers thereof, and mixed polymers of these amino acids and others, *e.g.*, serines, to confer desirable solubility properties on the resultant loaded carrier and immunoconjugate.

Conjugation of the intermediate conjugate with the antibody component is effected by oxidizing the carbohydrate portion of the antibody component and reacting the resulting aldehyde (and ketone) carbonyls with amine groups remaining on the carrier after loading with a drug, toxin, chelator, immunomodulator, boron addend, or other therapeutic agent. Alternatively, an intermediate conjugate can be attached to an oxidized antibody component via amine groups that have been introduced in the intermediate conjugate after loading with the therapeutic agent. Oxidation is conveniently effected either chemically, *e.g.*, with NaIO_4 or other glycolytic reagent, or enzymatically, *e.g.*, with neuraminidase and galactose oxidase. In the case of an aminodextran carrier, not all of the amines of the aminodextran are typically used for loading a therapeutic agent. The remaining amines of aminodextran condense with the oxidized antibody component to form Schiff base adducts, which are then reductively stabilized, normally with a borohydride reducing agent.

Analogous procedures are used to produce other immunoconjugates according to the invention. Loaded polypeptide carriers preferably have free lysine residues remaining for condensation with the oxidized carbohydrate portion of an antibody component. Carboxyls on the polypeptide carrier can, if necessary, be converted to amines by, *e.g.*, activation with DCC and reaction with an excess of a diamine.

The final immunoconjugate is purified using conventional techniques, such as sizing chromatography on Sephacryl S-300 or affinity chromatography using one or more KIRHy1 epitopes.

Alternatively, immunoconjugates can be prepared by directly conjugating an antibody component with a therapeutic agent. The general procedure is analogous to the

indirect method of conjugation except that a therapeutic agent is directly attached to an oxidized antibody component. It will be appreciated that other therapeutic agents can be substituted for the chelators described herein. Those of skill in the art will be able to devise conjugation schemes without undue experimentation.

5 As a further illustration, a therapeutic agent can be attached at the hinge region of a reduced antibody component via disulfide bond formation. For example, the tetanus toxoid peptides can be constructed with a single cysteine residue that is used to attach the peptide to an antibody component. As an alternative, such peptides can be attached to the antibody component using a heterobifunctional cross-linker, such as N-succinyl 3-(2-
10 pyridyldithio)propionate (SPDP) (Yu, *et al.*, *Int. J. Cancer* 56:244 (1994), herein incorporated by reference in its entirety). General techniques for such conjugation have been previously described (Wong, *Chemistry of Protein Conjugation and Cross-linking*, CRC Press (1991); Upeslakis, *et al.*, pp. 187-230 in, *Monoclonal Antibodies Principles and Applications*, Eds. Birch *et al.*, Wiley-Liss, Inc. (1995); Price, pp. 60-84 in,
15 *Monoclonal Antibodies: Production, Engineering and Clinical Applications* Eds. Ritter, *et al.*, Cambridge University Press (1995), all of which are herein incorporated by reference in their entirety).

 As described above, carbohydrate moieties in the Fc region of an antibody can be used to conjugate a therapeutic agent. However, the Fc region may be absent if an
20 antibody fragment is used as the antibody component of the immunoconjugate. Nevertheless, it is possible to introduce a carbohydrate moiety into the light chain variable region of an antibody or antibody fragment (Leung, *et al.*, *J. Immunol.* 154:5919-5926 (1995); U.S. Pat. No. 5,443,953), both of which are herein incorporated by reference in their entirety. The engineered carbohydrate moiety is then used to attach a
25 therapeutic agent.

 In addition, those of skill in the art will recognize numerous possible variations of the conjugation methods. For example, the carbohydrate moiety can be used to attach polyethyleneglycol in order to extend the half-life of an intact antibody, or antigen-binding fragment thereof, in blood, lymph, or other extracellular fluids. Moreover, it is
30 possible to construct a "divalent immunoconjugate" by attaching therapeutic agents to a

carbohydrate moiety and to a free sulfhydryl group. Such a free sulfhydryl group may be located in the hinge region of the antibody component.

5.5.2 ANTI-KIRHy1 ANTIBODY FUSION PROTEINS

5 When the therapeutic agent to be conjugated to the antibody is a protein, the present invention contemplates the use of fusion proteins comprising one or more anti-KIRHy1 antibody moieties and an immunomodulator or toxin moiety. Methods of making antibody fusion proteins have been previously described (U.S. Patent No. 6,306,393, herein incorporated by reference in its entirety). Antibody fusion proteins
10 comprising an interleukin-2 moiety have also been previously disclosed (Boleti, *et al.*, *Ann. Oncol.* 6:945 (1995), Nicolet, *et al.*, *Cancer Gene Ther.* 2:161 (1995), Becker, *et al.*, *Proc. Nat'l Acad. Sci. USA* 93:7826 (1996), Hank, *et al.*, *Clin. Cancer Res.* 2:1951 (1996), Hu, *et al.*, *Cancer Res.* 56:4998 (1996) all of which are herein incorporated by reference in their entirety). In addition, Yang, *et al.*, *Hum. Antibodies Hybridomas* 6:129
15 (1995), herein incorporated by reference in its entirety, describe a fusion protein that includes an F(ab')₂ fragment and a tumor necrosis factor alpha moiety.

Methods of making antibody-toxin fusion proteins in which a recombinant molecule comprises one or more antibody components and a toxin or chemotherapeutic agent also are known to those of skill in the art. For example, antibody-*Pseudomonas*
20 exotoxin A fusion proteins have been described (Chaudhary, *et al.*, *Nature* 339:394 (1989), Brinkmann, *et al.*, *Proc. Nat'l Acad. Sci. USA* 88:8616 (1991), Batra, *et al.*, *Proc. Natl. Acad. Sci. USA* 89:5867 (1992), Friedman, *et al.*, *J. Immunol.* 150:3054 (1993), Wels, *et al.*, *Int. J. Can.* 60:137 (1995), Fominaya *et al.*, *J. Biol. Chem.* 271:10560 (1996), Kuan, *et al.*, *Biochemistry* 35:2872 (1996), Schmidt, *et al.*, *Int. J. Can.* 65:538
25 (1996), all of which are herein incorporated by reference in their entirety). Antibody-toxin fusion proteins containing a diphtheria toxin moiety have been described (Kreitman, *et al.*, *Leukemia* 7:553 (1993), Nicholls, *et al.*, *J. Biol. Chem.* 268:5302 (1993), Thompson, *et al.*, *J. Biol. Chem.* 270:28037 (1995), and Vallera, *et al.*, *Blood* 88:2342 (1996). Deonarain *et al.* (*Tumor Targeting* 1:177 (1995)), have described an
30 antibody-toxin fusion protein having an RNase moiety, while Linardou, *et al.* (*Cell Biophys.* 24-25:243 (1994), all of which are herein incorporated by reference in their

entirety), produced an antibody-toxin fusion protein comprising a DNase I component. Gelonin and *Staphylococcal* enterotoxin-A have been used as the toxin moieties in antibody-toxin fusion proteins (Wang, *et al.*, Abstracts of the 209th ACS National Meeting, Anaheim, Calif., Apr. 2-6, 1995, Part 1, BIOT005; Dohlsten, *et al.*, *Proc. Nat'l Acad. Sci. USA* 91:8945 (1994), both of which herein incorporated by reference in their entirety).

5.5.3 FAB FRAGMENTS AND SINGLE CHAIN KIRHy1 ANTIBODIES

According to the invention, techniques can be adapted for the production of single-chain antibodies specific to KIRHy1 (*see e.g.*, U.S. Patent No. 4,946,778). In addition, methods can be adapted for the construction of F_{ab} expression libraries (*see e.g.*, Huse, *et al.*, *Science* 246:1275-1281 (1989)) to allow rapid and effective identification of monoclonal F_{ab} fragments with the desired specificity for a protein or derivatives, fragments, analogs or homologs thereof. Antibody fragments that contain the idiotypes to a protein antigen may be produced by techniques known in the art including, but not limited to: (i) an F_(ab)₂ fragment produced by pepsin digestion of an antibody molecule; (ii) an F_{ab} fragment generated by reducing the disulfide bridges of an F_(ab)₂ fragment; (iii) an F_{ab} fragment generated by the treatment of the antibody molecule with papain and a reducing agent and (iv) F_v fragments.

5.5.4 BISPECIFIC KIRHy1 ANTIBODIES

Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens. In the present case, one of the binding specificities is for an antigenic protein of the invention. The second binding target is any other antigen, and advantageously is a cell-surface protein or receptor or receptor subunit.

Methods for making bispecific antibodies are known in the art. Traditionally, the recombinant production of bispecific antibodies is based on the co-expression of two immunoglobulin heavy-chain/light-chain pairs, where the two heavy chains have different specificities (Milstein and Cuello, *Nature*, 305:537-539 (1983)). Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas

(quadromas) produce a potential mixture of ten different antibody molecules, of which only one has the correct bispecific structure. The purification of the correct molecule is usually accomplished by affinity chromatography steps. Similar procedures are disclosed in WO 93/08829, published 13 May 1993, and in Traunecker *et al.*, 1991 *EMBO J.*, 10, 3655-3659.

Antibody variable domains with the desired binding specificities (antibody-antigen combining sites) can be fused to immunoglobulin constant domain sequences. The fusion preferably is with an immunoglobulin heavy-chain constant domain, comprising at least part of the hinge, CH2, and CH3 regions. It is preferred to have the first heavy-chain constant region (CH1) containing the site necessary for light-chain binding present in at least one of the fusions. DNAs encoding the immunoglobulin heavy-chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are co-transfected into a suitable host organism. For further details of generating bispecific antibodies see, for example, Suresh *et al.*, *Methods in Enzymology*, 121: 210 (1986).

According to another approach described in WO 96/27011, the interface between a pair of antibody molecules can be engineered to maximize the percentage of heterodimers that are recovered from recombinant cell culture. The preferred interface comprises at least a part of the CH3 region of an antibody constant domain. In this method, one or more small amino acid side chains from the interface of the first antibody molecule are replaced with larger side chains (*e.g.* tyrosine or tryptophan). Compensatory "cavities" of identical or similar size to the large side chain(s) are created on the interface of the second antibody molecule by replacing large amino acid side chains with smaller ones (*e.g.* alanine or threonine). This provides a mechanism for increasing the yield of the heterodimer over other unwanted end-products such as homodimers.

Bispecific antibodies can be prepared as full-length antibodies or antibody fragments (*e.g.* F(ab')₂ bispecific antibodies). Techniques for generating bispecific antibodies from antibody fragments have been described in the literature. For example, bispecific antibodies can be prepared using chemical linkage. Brennan *et al.*, *Science* 229:81 (1985) describe a procedure wherein intact antibodies are proteolytically cleaved

to generate $F(ab')_2$ fragments. These fragments are reduced in the presence of the dithiol complexing agent sodium arsenite to stabilize vicinal dithiols and prevent intermolecular disulfide formation. The Fab' fragments generated are then converted to thionitrobenzoate (TNB) derivatives. One of the Fab' -TNB derivatives is then
5 reconverted to the Fab' -thiol by reduction with mercaptoethylamine and is mixed with an equimolar amount of the other Fab' -TNB derivative to form the bispecific antibody. The bispecific antibodies produced can be used as agents for the selective immobilization of enzymes.

Additionally, Fab' fragments can be directly recovered from *E. coli* and
10 chemically coupled to form bispecific antibodies. Shalaby *et al.*, *J. Exp. Med.* 175:217-225 (1992) describe the production of a fully humanized bispecific antibody $F(ab')_2$ molecule. Each Fab' fragment was separately secreted from *E. coli* and subjected to directed chemical coupling *in vitro* to form the bispecific antibody. The bispecific antibody thus formed was able to bind to cells overexpressing the ErbB2 receptor and
15 normal human T cells, as well as trigger the lytic activity of human cytotoxic lymphocytes against human breast tumor targets.

Various techniques for making and isolating bispecific antibody fragments directly from recombinant cell culture have also been described. For example, bispecific antibodies have been produced using leucine zippers. Kostelny *et al.*, *J. Immunol.*
20 148:1547-1553 (1992). The leucine zipper peptides from the Fos and Jun proteins were linked to the Fab' portions of two different antibodies by gene fusion. The antibody homodimers were reduced at the hinge region to form monomers and then re-oxidized to form the antibody heterodimers. This method can also be utilized for the production of antibody homodimers. The "diabody" technology described by Hollinger *et al.*, *Proc.*
25 *Natl. Acad. Sci. USA* 90:6444-6448 (1993) has provided an alternative mechanism for making bispecific antibody fragments. The fragments comprise a heavy-chain variable domain (V_H) connected to a light-chain variable domain (V_L) by a linker which is too short to allow pairing between the two domains on the same chain. Accordingly, the V_H and V_L domains of one fragment are forced to pair with the complementary V_L and V_H
30 domains of another fragment, thereby forming two antigen-binding sites. Another

strategy for making bispecific antibody fragments by the use of single-chain Fv (sFv) dimers has also been reported. *See, Gruber et al., J. Immunol.* 152:5368 (1994).

Antibodies with more than two valencies are contemplated. For example, trispecific antibodies can be prepared. *Tutt et al., J. Immunol.* 147:60 (1991).

5 Exemplary bispecific antibodies can bind to two different epitopes, at least one of which originates in the protein antigen of the invention. Alternatively, an anti-antigenic arm of an immunoglobulin molecule can be combined with an arm which binds to a triggering molecule on a leukocyte such as a T-cell receptor molecule (*e.g.* CD2, CD3, CD28, or B7), or Fc receptors for IgG (FcγR), such as FcγRI (CD64), FcγRII (CD32) and
10 FcγRIII (CD16) so as to focus cellular defense mechanisms to the cell expressing the particular antigen. Bispecific antibodies can also be used to direct cytotoxic agents to cells which express a particular antigen. These antibodies possess an antigen-binding arm and an arm which binds a cytotoxic agent or a radionuclide chelator, such as EOTUBE, DPTA, DOTA, or TETA. Another bispecific antibody of interest binds the
15 protein antigen described herein and further binds tissue factor (TF).

5.5.5 HETEROCONJUGATE KIRHy1 ANTIBODIES

Heteroconjugate antibodies are also within the scope of the present invention. Heteroconjugate antibodies are composed of two covalently joined antibodies. Such
20 antibodies have, for example, been proposed to target immune system cells to unwanted cells (U.S. Patent No. 4,676,980), and for treatment of HIV infection (WO 91/00360; WO 92/200373; EP 03089). It is contemplated that the antibodies can be prepared *in vitro* using known methods in synthetic protein chemistry, including those involving crosslinking agents. For example, immunotoxins can be constructed using a disulfide
25 exchange reaction or by forming a thioether bond. Examples of suitable reagents for this purpose include iminothiolate and methyl-4-mercaptobutyrimidate and those disclosed, for example, in U.S. Patent No. 4,676,980.

5.5.6 EFFECTOR FUNCTION ENGINEERING

30 It can be desirable to modify the antibody of the invention with respect to effector function, so as to enhance, *e.g.*, the effectiveness of the antibody in treating cancer. For

example, cysteine residue(s) can be introduced into the Fc region, thereby allowing interchain disulfide bond formation in this region. The homodimeric antibody thus generated can have improved internalization capability and/or increased complement-mediated cell killing and antibody-dependent cellular cytotoxicity (ADCC). See Caron
5 *et al.*, *J. Exp Med.*, 176:1191-1195 (1992) and Shopes, *J. Immunol.*, 148:2918-2922 (1992). Homodimeric antibodies with enhanced anti-tumor activity can also be prepared using heterobifunctional cross-linkers as described in Wolff *et al. Cancer Research*, 53:2560-2565 (1993). Alternatively, an antibody can be engineered that has dual Fc regions and can thereby have enhanced complement lysis and ADCC capabilities. See
10 Stevenson *et al.*, *Anti-Cancer Drug Design*, 3:219-230 (1989).

5.6 KIRHy1 POLYPEPTIDES

The isolated polypeptides of the invention include, but are not limited to, a polypeptide comprising: the amino acid sequence set forth as any one of SEQ ID NO: 3-
15 7, or an amino acid sequence encoded by any one of the nucleotide sequences SEQ ID NO: 1-2 or the corresponding full length or mature protein. Polypeptides of the invention also include polypeptides preferably with biological or immunological activity that are encoded by: (a) a polynucleotide having any one of the nucleotide sequences set forth in the SEQ ID NO: 1-2 or (b) polynucleotides encoding any one of the amino acid
20 sequences set forth as SEQ ID NO: 3-7, or (c) polynucleotides that hybridize to the complement of the polynucleotides of either (a) or (b) under stringent hybridization conditions. The invention also provides biologically active or immunologically active variants of any of the polypeptide amino acid sequences set forth as SEQ ID NO: 3-7, or the corresponding full length or mature protein; and "substantial equivalents" thereof
25 (*e.g.*, with at least about 65%, at least about 70%, at least about 75%, at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, or 89%, more typically at least about 90%, 91%, 92%, 93%, or 94% and even more typically at least about 95%, 96%, 97%, 98% or 99%, most typically at least about 99% amino acid identity) that retain biological activity. Polypeptides encoded by allelic variants may have a similar, increased, or decreased
30 activity compared to polypeptides comprising SEQ ID NO: 3-7.

Fragments of the proteins of the present invention which are capable of exhibiting biological activity are also encompassed by the present invention. Fragments of the protein may be in linear form or they may be cyclized using known methods, for example, as described in H. U. Saragovi, *et al.*, *Bio/Technology* 10:773-778 (1992) and in
5 R. S. McDowell, *et al.*, *J. Amer. Chem. Soc.* 114:9245-9253 (1992), both of which are incorporated herein by reference. Such fragments may be fused to carrier molecules such as immunoglobulins for many purposes, including increasing the valency of protein binding sites.

The present invention also provides both full-length and mature forms (for
10 example, without a signal sequence or precursor sequence) of the disclosed proteins. The protein coding sequence is identified in the sequence listing by translation of the disclosed nucleotide sequences. The mature form of such protein may be obtained by expression of a full-length polynucleotide in a suitable mammalian cell or other host cell. The sequence of the mature form of the protein is also determinable from the amino acid
15 sequence of the full-length form. Where proteins of the present invention are membrane bound, soluble forms of the proteins are also provided. In such forms, part or all of the regions causing the proteins to be membrane bound are deleted so that the proteins are fully secreted from the cell in which it is expressed.

Protein compositions of the present invention may further comprise an acceptable
20 carrier, such as a hydrophilic, *e.g.*, pharmaceutically acceptable, carrier.

The present invention further provides isolated polypeptides encoded by the nucleic acid fragments of the present invention or by degenerate variants of the nucleic acid fragments of the present invention. By "degenerate variant" is intended nucleotide fragments which differ from a nucleic acid fragment of the present invention (*e.g.*, an
25 ORF) by nucleotide sequence but, due to the degeneracy of the genetic code, encode an identical polypeptide sequence. Preferred nucleic acid fragments of the present invention are the ORFs that encode proteins.

A variety of methodologies known in the art can be utilized to obtain any one of the isolated polypeptides or proteins of the present invention. At the simplest level, the
30 amino acid sequence can be synthesized using commercially available peptide synthesizers. The synthetically-constructed protein sequences, by virtue of sharing

primary, secondary or tertiary structural and/or conformational characteristics with proteins may possess biological properties in common therewith, including protein activity. This technique is particularly useful in producing small peptides and fragments of larger polypeptides. Fragments are useful, for example, in generating antibodies against the native polypeptide. Thus, they may be employed as biologically active or immunological substitutes for natural, purified proteins in screening of therapeutic compounds and in immunological processes for the development of antibodies.

The polypeptides and proteins of the present invention can alternatively be purified from cells which have been altered to express the desired polypeptide or protein. As used herein, a cell is said to be altered to express a desired polypeptide or protein when the cell, through genetic manipulation, is made to produce a polypeptide or protein which it normally does not produce or which the cell normally produces at a lower level. One skilled in the art can readily adapt procedures for introducing and expressing either recombinant or synthetic sequences into eukaryotic or prokaryotic cells in order to generate a cell which produces one of the polypeptides or proteins of the present invention.

The invention also relates to methods for producing a polypeptide comprising growing a culture of host cells of the invention in a suitable culture medium, and purifying the protein from the cells or the culture in which the cells are grown. For example, the methods of the invention include a process for producing a polypeptide in which a host cell containing a suitable expression vector that includes a polynucleotide of the invention is cultured under conditions that allow expression of the encoded polypeptide. The polypeptide can be recovered from the culture, conveniently from the culture medium, or from a lysate prepared from the host cells and further purified. Preferred embodiments include those in which the protein produced by such process is a full length or mature form of the protein.

In an alternative method, the polypeptide or protein is purified from bacterial cells which naturally produce the polypeptide or protein. One skilled in the art can readily follow known methods for isolating polypeptides and proteins in order to obtain one of the isolated polypeptides or proteins of the present invention. These include, but are not limited to, immunochromatography, HPLC, size-exclusion chromatography, ion-

exchange chromatography, and immuno-affinity chromatography. See, *e.g.*, Scopes, *Protein Purification: Principles and Practice*, Springer-Verlag (1994); Sambrook, *et al.*, in *Molecular Cloning: A Laboratory Manual*; Ausubel *et al.*, *Current Protocols in Molecular Biology*. Polypeptide fragments that retain biological/immunological activity
5 include fragments comprising greater than about 100 amino acids, or greater than about 200 amino acids, and fragments that encode specific protein domains.

The purified polypeptides can be used in *in vitro* binding assays which are well known in the art to identify molecules which bind to the polypeptides. These molecules include but are not limited to, for *e.g.*, small molecules, molecules from combinatorial
10 libraries, antibodies or other proteins. The molecules identified in the binding assay are then tested for antagonist or agonist activity in *in vivo* tissue culture or animal models that are well known in the art. In brief, the molecules are titrated into a plurality of cell cultures or animals and then tested for either cell/animal death or prolonged survival of the animal/cells.

15 In addition, the peptides of the invention or molecules capable of binding to the peptides may be complexed with toxins, *e.g.*, ricin or cholera, or with other compounds that are toxic to cells. The toxin-binding molecule complex is then targeted to a tumor or other cell by the specificity of the binding molecule for SEQ ID NO: 3-7.

The protein of the invention may also be expressed as a product of transgenic
20 animals, *e.g.*, as a component of the milk of transgenic cows, goats, pigs, or sheep which are characterized by somatic or germ cells containing a nucleotide sequence encoding the protein.

The proteins provided herein also include proteins characterized by amino acid sequences similar to those of purified proteins but into which modification are naturally
25 provided or deliberately engineered. For example, modifications, in the peptide or DNA sequence, can be made by those skilled in the art using known techniques. Modifications of interest in the protein sequences may include the alteration, substitution, replacement, insertion or deletion of a selected amino acid residue in the coding sequence. For example, one or more of the cysteine residues may be deleted or replaced with another
30 amino acid to alter the conformation of the molecule. Techniques for such alteration, substitution, replacement, insertion or deletion are well known to those skilled in the art

(see, *e.g.*, U.S. Pat. No. 4,518,584). Preferably, such alteration, substitution, replacement, insertion or deletion retains the desired activity of the protein. Regions of the protein that are important for the protein function can be determined by various methods known in the art including the alanine-scanning method which involved systematic substitution of single or strings of amino acids with alanine, followed by testing the resulting alanine-containing variant for biological activity. This type of analysis determines the importance of the substituted amino acid(s) in biological activity. Regions of the protein that are important for protein function may be determined by the eMATRIX program.

Other fragments and derivatives of the sequences of proteins which would be expected to retain protein activity in whole or in part and are useful for screening or other immunological methodologies may also be easily made by those skilled in the art given the disclosures herein. Such modifications are encompassed by the present invention.

The protein may also be produced by operably linking the isolated polynucleotide of the invention to suitable control sequences in one or more insect expression vectors, and employing an insect expression system. Materials and methods for baculovirus/insect cell expression systems are commercially available in kit form from, *e.g.*, Invitrogen, San Diego, Calif., U.S.A. (the MaxBat™ kit), and such methods are well known in the art, as described in Summers and Smith, Texas Agricultural Experiment Station Bulletin No. 1555 (1987), incorporated herein by reference. As used herein, an insect cell capable of expressing a polynucleotide of the present invention is "transformed."

The protein of the invention may be prepared by culturing transformed host cells under culture conditions suitable to express the recombinant protein. The resulting expressed protein may then be purified from such culture (*i.e.*, from culture medium or cell extracts) using known purification processes, such as gel filtration and ion exchange chromatography. The purification of the protein may also include an affinity column containing agents which will bind to the protein; one or more column steps over such affinity resins as concanavalin A-agarose, heparin-toyopearl™ or Cibacrom blue 3GA Sepharose™; one or more steps involving hydrophobic interaction chromatography using such resins as phenyl ether, butyl ether, or propyl ether; or immunoaffinity chromatography.

Alternatively, the protein of the invention may also be expressed in a form which will facilitate purification. For example, it may be expressed as a fusion protein, such as those of maltose binding protein (MBP), glutathione-S-transferase (GST) or thioredoxin (TRX), or as a His tag. Kits for expression and purification of such fusion proteins are commercially available from New England BioLab (Beverly, Mass.), Pharmacia (Piscataway, N.J.) and Invitrogen, respectively. The protein can also be tagged with an epitope and subsequently purified by using a specific antibody directed to such epitope. One such epitope ("FLAG®") is commercially available from Kodak (New Haven, Conn.).

Finally, one or more reverse-phase high performance liquid chromatography (RP-HPLC) steps employing hydrophobic RP-HPLC media, *e.g.*, silica gel having pendant methyl or other aliphatic groups, can be employed to further purify the protein. Some or all of the foregoing purification steps, in various combinations, can also be employed to provide a substantially homogeneous isolated recombinant protein. The protein thus purified is substantially free of other mammalian proteins and is defined in accordance with the present invention as an "isolated protein."

The polypeptides of the invention include analogs (variants). The polypeptides of the invention include KIRHy1 analogs. This embraces fragments of KIRHy1, as well KIRHy1 polypeptides which comprise one or more amino acids deleted, inserted, or substituted. Also, analogs of KIRHy1 embrace fusions of the KIRHy1 polypeptides or modifications of the KIRHy1 polypeptides, wherein the KIRHy1 polypeptide or analog is fused to another moiety or moieties, *e.g.*, targeting moiety or another therapeutic agent. Such analogs may exhibit improved properties such as activity and/or stability. Examples of moieties which may be fused to the KIRHy1 polypeptide or an analog include, for example, targeting moieties which provide for the delivery of polypeptide to hematopoietic or cancer cells.

5.6.1 HEMATOPOIESIS REGULATING ACTIVITY OF KIRHy1

KIRHy1 may be involved in regulation of hematopoiesis and, consequently, in the treatment of myeloid or lymphoid cell disorders. Even marginal biological activity in support of colony forming cells or of factor-dependent cell lines indicates involvement in

regulating hematopoiesis, *e.g.* in supporting the growth and proliferation of erythroid progenitor cells alone or in combination with other cytokines, thereby indicating utility, for example, in treating various anemias or for use in conjunction with irradiation/chemotherapy to stimulate the production of erythroid precursors and/or erythroid cells; in supporting the growth and proliferation of myeloid cells such as granulocytes and monocytes/macrophages (*i.e.*, traditional CSF activity) useful, for example, in conjunction with chemotherapy to prevent or treat consequent myelo-suppression; in supporting the growth and proliferation of megakaryocytes and consequently of platelets thereby allowing prevention or treatment of various platelet disorders such as thrombocytopenia, and generally for use in place of or complimentary to platelet transfusions; and/or in supporting the growth and proliferation of hematopoietic stem cells which are capable of maturing to any and all of the above-mentioned hematopoietic cells and therefore find therapeutic utility in various stem cell disorders (such as those usually treated with transplantation, including, without limitation, aplastic anemia and paroxysmal nocturnal hemoglobinuria), as well as in repopulating the stem cell compartment post irradiation/chemotherapy, either *in vivo* or *ex vivo* (*i.e.*, in conjunction with bone marrow transplantation or with peripheral progenitor cell transplantation (homologous or heterologous)) as normal cells or genetically manipulated for gene therapy.

Therapeutic compositions of the invention can be used in the following:

Suitable assays for proliferation and differentiation of various hematopoietic lines are cited above.

Assays for embryonic stem cell differentiation (which will identify, among others, proteins that influence embryonic differentiation hematopoiesis) include, without limitation, those described in: Johansson *et al. Cell. Biol.* 15:141-151, 1995; Keller *et al., Mol. and Cell. Biol.* 13:473-486, 1993; McClanahan *et al., Blood* 81:2903-2915, 1993.

Assays for stem cell survival and differentiation (which will identify, among others, proteins that regulate lympho-hematopoiesis) include, without limitation, those described in: Methylcellulose colony forming assays, Freshney, M. G. *In Culture of Hematopoietic Cells*. R. I. Freshney, *et al.* eds. Vol pp. 265-268, Wiley-Liss, Inc., New York, N.Y. 1994; Hirayama *et al., Proc. Natl. Acad. Sci. USA* 89:5907-5911, 1992;

Primitive hematopoietic colony forming cells with high proliferative potential, McNiece, I. K. and Briddell, R. A. *In Culture of Hematopoietic Cells*. R. I. Freshney, *et al.* eds. Vol pp. 23-39, Wiley-Liss, Inc., New York, N.Y. 1994; Neben *et al.*, *Exp. Hematol.* 22:353-359, 1994; Cobblestone area forming cell assay, Ploemacher, R. E. *In Culture of Hematopoietic Cells*. R. I. Freshney, *et al.* eds. Vol pp. 1-21, Wiley-Liss, Inc., New York, N.Y. 1994; Long term bone marrow cultures in the presence of stromal cells, Spooncer, E., Dexter, M. and Allen, T. *In Culture of Hematopoietic Cells*. R. I. Freshney, *et al.* eds. Vol pp. 163-179, Wiley-Liss, Inc., New York, N.Y. 1994; Long term culture initiating cell assay, Sutherland, H. J. *In Culture of Hematopoietic Cells*. R. I. Freshney, *et al.* eds. Vol pp. 139-162, Wiley-Liss, Inc., New York, N.Y. 1994.

5.6.2 IMMUNE STIMULATING OR SUPPRESSING ACTIVITY OF KIRHy1

KIRHy1 may also exhibit immune stimulating or immune suppressing activity, including without limitation the activities for which assays are described herein. A polynucleotide of the invention can encode a polypeptide exhibiting such activities. A protein may be useful in the treatment of various immune deficiencies and disorders (including severe combined immunodeficiency (SCID)), *e.g.*, in regulating (up or down) growth and proliferation of T and/or B lymphocytes, as well as effecting the cytolytic activity of NK cells and other cell populations. These immune deficiencies may be genetic or be caused by viral (*e.g.*, HIV) as well as bacterial or fungal infections, or may result from autoimmune disorders. More specifically, infectious diseases caused by viral, bacterial, fungal or other infection may be treatable using a protein of the present invention, including infections by HIV, hepatitis viruses, herpes viruses, mycobacteria, Leishmania spp., malaria spp. and various fungal infections such as candidiasis. Of course, in this regard, proteins of the present invention may also be useful where a boost to the immune system generally may be desirable, *i.e.*, in the treatment of cancer.

Autoimmune disorders which may be treated using a protein of the present invention include, for example, connective tissue disease, multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes mellitis,

myasthenia gravis, graft-versus-host disease and autoimmune inflammatory eye disease. Such a protein (or antagonists thereof, including antibodies) of the present invention may also to be useful in the treatment of allergic reactions and conditions (*e.g.*, anaphylaxis, serum sickness, drug reactions, food allergies, insect venom allergies, mastocytosis, 5 allergic rhinitis, hypersensitivity pneumonitis, urticaria, angioedema, eczema, atopic dermatitis, allergic contact dermatitis, erythema multiforme, Stevens-Johnson syndrome, allergic conjunctivitis, atopic keratoconjunctivitis, venereal keratoconjunctivitis, giant papillary conjunctivitis and contact allergies), such as asthma (particularly allergic asthma) or other respiratory problems. Other conditions, in which immune suppression is 10 desired (including, for example, organ transplantation), may also be treatable using a protein (or antagonists thereof) of the present invention. The therapeutic effects of the polypeptides or antagonists thereof on allergic reactions can be evaluated by *in vivo* animals models such as the cumulative contact enhancement test (Lastbom *et al.*, *Toxicology* 125: 59-66, 1998), skin prick test (Hoffmann *et al.*, *Allergy* 54: 446-54, 15 1999), guinea pig skin sensitization test (Vohr *et al.*, *Arch. Toxicol.* 73: 501-9), and murine local lymph node assay (Kimber *et al.*, *J. Toxicol. Environ. Health* 53: 563-79).

Using the proteins of the invention it may also be possible to modulate immune responses, in a number of ways. Down regulation may be in the form of inhibiting or blocking an immune response already in progress or may involve preventing the 20 induction of an immune response. The functions of activated T cells may be inhibited by suppressing T cell responses or by inducing specific tolerance in T cells, or both. Immunosuppression of T cell responses is generally an active, non-antigen-specific, process which requires continuous exposure of the T cells to the suppressive agent. Tolerance, which involves inducing non-responsiveness or anergy in T cells, is 25 distinguishable from immunosuppression in that it is generally antigen-specific and persists after exposure to the tolerizing agent has ceased. Operationally, tolerance can be demonstrated by the lack of a T cell response upon reexposure to specific antigen in the absence of the tolerizing agent.

Down regulating or preventing one or more antigen functions (including without 30 limitation B lymphocyte antigen functions (such as, for example, B7)), *e.g.*, preventing high level lymphokine synthesis by activated T cells, will be useful in situations of tissue,

skin and organ transplantation and in graft-versus-host disease (GVHD). For example, blockage of T cell function should result in reduced tissue destruction in tissue transplantation. Typically, in tissue transplants, rejection of the transplant is initiated through its recognition as foreign by T cells, followed by an immune reaction that destroys the transplant. The administration of a therapeutic composition of the invention may prevent cytokine synthesis by immune cells, such as T cells, and thus acts as an immunosuppressant. Moreover, a lack of costimulation may also be sufficient to anergize the T cells, thereby inducing tolerance in a subject. Induction of long-term tolerance by B lymphocyte antigen-blocking reagents may avoid the necessity of repeated administration of these blocking reagents. To achieve sufficient immunosuppression or tolerance in a subject, it may also be necessary to block the function of a combination of B lymphocyte antigens.

The efficacy of particular therapeutic compositions in preventing organ transplant rejection or GVHD can be assessed using animal models that are predictive of efficacy in humans. Examples of appropriate systems which can be used include allogeneic cardiac grafts in rats and xenogeneic pancreatic islet cell grafts in mice, both of which have been used to examine the immunosuppressive effects of CTLA4Ig fusion proteins *in vivo* as described in Lenschow *et al.*, *Science* 257:789-792 (1992) and Turka *et al.*, *Proc. Natl. Acad. Sci USA*, 89:11102-11105 (1992). In addition, murine models of GVHD (see Paul ed., *Fundamental Immunology*, Raven Press, New York, 1989, pp. 846-847) can be used to determine the effect of therapeutic compositions of the invention on the development of that disease.

Blocking antigen function may also be therapeutically useful for treating autoimmune diseases. Many autoimmune disorders are the result of inappropriate activation of T cells that are reactive against self-tissue and which promote the production of cytokines and autoantibodies involved in the pathology of the diseases. Preventing the activation of autoreactive T cells may reduce or eliminate disease symptoms. Administration of reagents which block stimulation of T cells can be used to inhibit T cell activation and prevent production of autoantibodies or T cell-derived cytokines which may be involved in the disease process. Additionally, blocking reagents may induce antigen-specific tolerance of autoreactive T cells which could lead to

long-term relief from the disease. The efficacy of blocking reagents in preventing or alleviating autoimmune disorders can be determined using a number of well-characterized animal models of human autoimmune diseases. Examples include murine experimental autoimmune encephalitis, systemic lupus erythmatosis in

5 MRL/lpr/lpr mice or NZB hybrid mice, murine autoimmune collagen arthritis, diabetes mellitus in NOD mice and BB rats, and murine experimental myasthenia gravis (see Paul ed., *Fundamental Immunology*, Raven Press, New York, 1989, pp. 840-856).

Upregulation of an antigen function (*e.g.*, a B lymphocyte antigen function), as a means of up regulating immune responses, may also be useful in therapy. Upregulation of
10 immune responses may be in the form of enhancing an existing immune response or eliciting an initial immune response. For example, enhancing an immune response may be useful in cases of viral infection, including systemic viral diseases such as influenza, the common cold, and encephalitis.

Alternatively, anti-viral immune responses may be enhanced in an infected patient
15 by removing T cells from the patient, costimulating the T cells *in vitro* with viral antigen-pulsed APCs either expressing a peptide of the present invention or together with a stimulatory form of a soluble peptide of the present invention and reintroducing the *in vitro* activated T cells into the patient. Another method of enhancing anti-viral immune responses would be to isolate infected cells from a patient, transfect them with a nucleic
20 acid encoding a protein of the present invention as described herein such that the cells express all or a portion of the protein on their surface, and reintroduce the transfected cells into the patient. The infected cells would now be capable of delivering a costimulatory signal to, and thereby activate, T cells *in vivo*.

A KIRHy1 polypeptide may provide the necessary stimulation signal to T cells to
25 induce a T cell mediated immune response against the transfected tumor cells. In addition, tumor cells which lack MHC class I or MHC class II molecules, or which fail to reexpress sufficient mounts of MHC class I or MHC class II molecules, can be transfected with nucleic acid encoding all or a portion of (*e.g.*, a cytoplasmic-domain truncated portion) of an MHC class I alpha chain protein and β_2 microglobulin protein or
30 an MHC class II alpha chain protein and an MHC class II beta chain protein to thereby express MHC class I or MHC class II proteins on the cell surface. Expression of the

appropriate class I or class II MHC in conjunction with a peptide having the activity of a B lymphocyte antigen (*e.g.*, B7-1, B7-2, B7-3) induces a T cell mediated immune response against the transfected tumor cell. Optionally, a gene encoding an antisense construct which blocks expression of an MHC class II associated protein, such as the invariant chain, can also be cotransfected with a DNA encoding a peptide having the activity of a B lymphocyte antigen to promote presentation of tumor associated antigens and induce tumor specific immunity. Thus, the induction of a T cell mediated immune response in a human subject may be sufficient to overcome tumor-specific tolerance in the subject.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Suitable assays for thymocyte or splenocyte cytotoxicity include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, W. Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, *In Vitro* assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Herrmann *et al.*, *Proc. Natl. Acad. Sci. USA* 78:2488-2492, 1981; Herrmann *et al.*, *J. Immunol.* 128:1968-1974, 1982; Handa *et al.*, *J. Immunol.* 135:1564-1572, 1985; Takai *et al.*, *J. Immunol.* 137:3494-3500, 1986; Takai *et al.*, *J. Immunol.* 140:508-512, 1988; Bowman *et al.*, *J. Virology* 61:1992-1998; Bertagnolli *et al.*, *Cellular Immunology* 133:327-341, 1991; Brown *et al.*, *J. Immunol.* 153:3079-3092, 1994.

Assays for T-cell-dependent immunoglobulin responses and isotype switching (which will identify, among others, proteins that modulate T-cell dependent antibody responses and that affect Th1/Th2 profiles) include, without limitation, those described in: Maliszewski, J. *Immunol.* 144:3028-3033, 1990; and Assays for B cell function: *In vitro* antibody production, Mond, J. J. and Brunswick, M. *In Current Protocols in Immunology*. J. E. e.a. Coligan eds. Vol 1 pp. 3.8.1-3.8.16, John Wiley and Sons, Toronto. 1994.

Mixed lymphocyte reaction (MLR) assays (which will identify, among others, proteins that generate predominantly Th1 and CTL responses) include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A. M.

Kruisbeek, D. H. Margulies, E. M. Shevach, W. Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, *In Vitro* assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Takai *et al.*, *J. Immunol.* 137:3494-3500, 1986; Takai *et al.*, *J. Immunol.* 140:508-512, 1988; Bertagnolli *et al.*, *J.*
5 *Immunol.* 149:3778-3783, 1992.

Dendritic cell-dependent assays (which will identify, among others, proteins expressed by dendritic cells that activate naive T-cells) include, without limitation, those described in: Guery *et al.*, *J. Immunol.* 134:536-544, 1995; Inaba *et al.*, *J. Exp. Med.* 173:549-559, 1991; Macatonia *et al.*, *J. Immunol.* 154:5071-5079, 1995; Porgador *et al.*,
10 *J. Exp. Med.* 182:255-260, 1995; Nair *et al.*, *J. Virology* 67:4062-4069, 1993; Huang *et al.*, *Science* 264:961-965, 1994; Macatonia *et al.*, *J. Exp. Med.* 169:1255-1264, 1989; Bhardwaj *et al.*, *J. Clin. Invest.* 94:797-807, 1994; and Inaba *et al.*, *J. Exp. Med.* 172:631-640, 1990.

Assays for lymphocyte survival/apoptosis (which will identify, among others,
15 proteins that prevent apoptosis after superantigen induction and proteins that regulate lymphocyte homeostasis) include, without limitation, those described in: Darzynkiewicz *et al.*, *Cytometry* 13:795-808, 1992; Gorczyca *et al.*, *Leukemia* 7:659-670, 1993; Gorczyca *et al.*, *Cancer Res.* 53:1945-1951, 1993; Itoh *et al.*, *Cell* 66:233-243, 1991; Zacharchuk, *J. Immunol.* 145:4037-4045, 1990; Zamai *et al.*, *Cytometry* 14:891-897,
20 1993; Gorczyca *et al.*, *Int. J. Oncology* 1:639-648, 1992.

Assays for proteins that influence early steps of T-cell commitment and development include, without limitation, those described in: Antica *et al.*, *Blood* 84:111-117, 1994; Fine *et al.*, *Cellular Immunology* 155:111-122, 1994; Galy *et al.*, *Blood* 85:2770-2778, 1995; Toki *et al.*, *Proc. Nat. Acad Sci. USA* 88:7548-7551, 1991.
25

5.6.3 ANTI-INFLAMMATORY ACTIVITY OF KIRHy1

Compositions of the present invention may also exhibit anti-inflammatory activity. The anti-inflammatory activity may be achieved by providing a stimulus to cells involved in the inflammatory response, by inhibiting or promoting cell-cell interactions
30 (such as, for example, cell adhesion), by inhibiting or promoting chemotaxis of cells involved in the inflammatory process, inhibiting or promoting cell extravasation, or by

stimulating or suppressing production of other factors which more directly inhibit or promote an inflammatory response. Compositions with such activities can be used to treat inflammatory conditions including chronic or acute conditions), including without limitation intimation associated with infection (such as septic shock, sepsis or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine-induced lung injury, inflammatory bowel disease, Crohn's disease or resulting from over production of cytokines such as TNF or IL-1. Compositions of the invention may also be useful to treat anaphylaxis and hypersensitivity to an antigenic substance or material. Compositions of this invention may be utilized to prevent or treat conditions such as, but not limited to, sepsis, acute pancreatitis, endotoxin shock, cytokine induced shock, rheumatoid arthritis, chronic inflammatory arthritis, pancreatic cell damage from diabetes mellitus type 1, graft versus host disease, inflammatory bowel disease, inflammation associated with pulmonary disease, other autoimmune disease or inflammatory disease, an antiproliferative agent such as for acute or chronic myelogenous leukemia or in the prevention of premature labor secondary to intrauterine infections.

The immunosuppressive effects of the compositions of the invention against rheumatoid arthritis is determined in an experimental animal model system. The experimental model system is adjuvant induced arthritis in rats, and the protocol is described by J. Holoshitz, *et al.*, 1983, *Science*, 219:56, or by B. Waksman *et al.*, 1963, *Int. Arch. Allergy Appl. Immunol.*, 23:129. Induction of the disease can be caused by a single injection, generally intradermally, of a suspension of killed *Mycobacterium tuberculosis* in complete Freund's adjuvant (CFA). The route of injection can vary, but rats may be injected at the base of the tail with an adjuvant mixture. The polypeptide is administered in phosphate buffered solution (PBS) at a dose of about 1-5 mg/kg. The control consists of administering PBS only.

The procedure for testing the effects of the test compound would consist of intradermally injecting killed *Mycobacterium tuberculosis* in CFA followed by immediately administering the test compound and subsequent treatment every other day until day 24. At 14, 15, 18, 20, 22, and 24 days after injection of *Mycobacterium* CFA, an overall arthritis score may be obtained as described by J. Holoskitz above. An analysis of

the data would reveal that the test compound would have a dramatic affect on the swelling of the joints as measured by a decrease of the arthritis score.

5.7 PEPTIDES

5 KIRHy1 peptides, such as fragments of the extracellular region, may be used to target toxins or radioisotopes to tumor cells *in vivo* by binding to or interacting with the cell surface antigens of the invention expressed on tumor or diseased cells. Much like an antibody, these fragments may specifically target cells expressing this antigen. Targeted delivery of these cytotoxic agents to the tumor cells would result in cell death and
10 suppression of tumor growth. An example of the ability of an extracellular fragment binding to and activating its intact receptor (by homophilic binding) has been demonstrated with the CD84 receptor (Martin *et al.*, *J. Immunol.* 167:3668-3676 (2001), herein incorporated by reference in its entirety).

Extracellular fragments of KIRHy1 may also be used to modulate immune cells
15 expressing the protein. Extracellular domain fragments of KIRHy1 may bind to and activate its own receptor on the cell surface, which may result in stimulating the release of cytokines (such as interferon gamma from NK cells, T cells, B cells or myeloid cells, for example) that may enhance or suppress the immune system. Additionally, binding of these fragments to cells bearing KIRHy1 of the invention may result in the activation of
20 these cells and also may stimulate proliferation. Some fragments may bind to the intact KIRHy1 and block activation signals and cytokine release by immune cells. These fragments would then have an immunosuppressive effect. Fragments that activate and stimulate the immune system may have anti-tumor properties. These fragments may stimulate an immunological response that can result in immune-mediated tumor cell
25 killing. The same fragments may result in stimulating the immune system to mount an enhanced response to foreign invaders such as viruses and bacteria. Fragments that suppress the immune response may be useful in treating lymphoproliferative disorders, auto-immune diseases, graft-vs-host disease, and inflammatory diseases, such as emphysema.

30

5.8 OTHER BINDING PEPTIDES OR SMALL MOLECULES

Screening of organic compound or peptide libraries with recombinantly expressed KIRHy1 protein of the invention may be useful for identification of therapeutic molecules that function to specifically bind to or even inhibit the activity of KIRHy1.

5 Synthetic and naturally occurring products can be screened in a number of ways deemed routine to those of skill in the art. Random peptide libraries are displayed on phage (phage display) or on bacteria, such as on *E. coli*. These random peptide display libraries can be used to screen for peptides which interact with a known target which can be a protein or a polypeptide, such as a ligand or receptor, a biological or synthetic
10 macromolecule, or organic or inorganic substances. By way of example, diversity libraries, such as random or combinatorial peptide or nonpeptide libraries can be screened for molecules that specifically bind to KIRHy1 polypeptides. Many libraries are known in the art that can be used, *i.e.* chemically synthesized libraries, recombinant (*i.e.* phage display libraries), and *in vitro* translation-based libraries. Techniques for creating and
15 screening such random peptide display libraries are known in the art (Ladner *et al.*, U.S. Patent No. 5,223, 409; Ladner *et al.*, U.S. Patent No. 4,946,778; Ladner *et al.*, U.S. Patent No. 5,403,484; Ladner *et al.*, U.S. Patent No. 5,571,698, all of which are herein incorporated by reference in their entirety) and random peptide display libraries and kits for screening such libraries are available commercially, for instance from Clontech (Palo
20 Alto, CA), Invitrogen Inc. (San Diego, CA), New England Biolabs, Inc. (Beverly, MA), and Pharmacia KLB Biotechnology Inc. (Piscataway, NJ). Random peptide display libraries can be screened using the KIRHy1 sequences disclosed herein to identify proteins which bind to KIRHy1.

Examples of chemically synthesized libraries are described in Fodor *et al.*,
25 *Science* 251:767-773 (1991); Houghten *et al.*, *Nature* 354:84-86 (1991); Lam *et al.*, *Nature* 354:82-84 (1991); Medynski, *Bio/Technology* 12:709-710 (1994); Gallop *et al.*, *J. Med. Chem.* 37:1233-1251 (1994); Ohlmeyer *et al.*, *Proc. Natl. Acad. Sci. USA* 90:10922-10926 (1993); Erb *et al.*, *Proc. Natl. Acad. Sci. USA* 91:11422-11426 (1994); Houghten *et al.*, *Biotechniques* 13:412 (1992); Jayawickreme *et al.*, *Proc. Natl. Acad. Sci.*
30 *USA* 91:1614-1618 (1994); Salmon *et al.*, *Proc. Natl. Acad. Sci. USA* 90:11708-11712 (1993); International Publication No. WO 93/20242; Brenner and Lerner, *Proc. Natl.*

Acad. Sci. USA 89:5381-5383 (1992), all of which are herein incorporated by reference in their entirety.

Examples of phage display libraries are described in Scott and Smith, *Science* 249:386-390 (1990); Devlin *et al.*, *Science* 249:404-406 (1990); Christian *et al.*, *J. Mol. Biol.* 227:711-718 (1992); Lenstra, *J. Immunol Meth.* 152:149-157 (1992); Kay *et al.*, *Gene* 128:59-65 (1993); International Publication No. WO 94/18318, all of which are herein incorporated by reference in their entirety.

In vitro translation-based libraries include but are not limited to those described in International Publication No. WO 91/05058, and Mattheakis *et al.*, *Proc. Natl. Acad. Sci. USA* 91:9022-9026 (1994), both of which are herein incorporated by reference in their entirety.

By way of examples of nonpeptide libraries, a benzodiazepine library (see for example, Bunin *et al.*, *Proc. Natl. Acad. Sci. USA* 91:4708-4712 (1994), herein incorporated by reference in its entirety) can be adapted for use. Peptoid libraries (Simon *et al.*, *Proc. Natl. Acad. Sci. USA* 89:9367-9371 (1992), herein incorporated by reference in its entirety) can also be used. Another example of a library that can be used, in which the amide functionalities in peptides have been permethylated to generate a chemically transformed combinatorial library, is described by Ostresh *et al.* (*Proc. Natl. Acad. Sci. USA* 91:11138-11142 (1994), herein incorporated by reference in its entirety).

Screening the libraries can be accomplished by any of a variety of commonly known methods. See, for example, the following references which disclose screening of peptide libraries: Parmley and Smith, *Adv. Exp. Med. Biol.* 251:215-218 (1989); Scott and Smith, *Science* 249:386-390 (1990); Fowlkes *et al.*, *Biotechniques* 13:422-427 (1992); Oldenburg *et al.*, *Proc. Natl. Acad. Sci. USA* 89:5393-5397 (1992); Yu *et al.*, *Cell* 76:933-945 (1994); Staudt *et al.*, *Science* 241:577-580 (1988); Bock *et al.*, *Nature* 355:564-566 (1992); Tuerk *et al.*, *Proc. Natl. Acad. Sci. USA* 89:6988-6992 (1992); Ellington *et al.*, *Nature* 355:850-852 (1992); Rebar and Pabo, *Science* 263:671-673 (1993); and International Publication No. WO 94/18318, all of which are herein incorporated by reference in their entirety.

In a specific embodiment, screening can be carried out by contacting the library members with a KIRHy1 protein (or nucleic acid or derivative) immobilized on a solid

phase and harvesting those library members that bind to the protein (or nucleic acid or derivative). Examples of such screening methods, termed “panning” techniques are described by way of example in Parmley and Smith, *Gene* 73:305-318 (1988); Fowlkes *et al.*, *Biotechniques* 13:422-427 (1992); International Publication No. WO 94/18318, all of which are herein incorporated by reference in their entirety, and in references cited hereinabove.

In another embodiment, the two-hybrid system for selecting interacting protein in yeast (Fields and Song, *Nature* 340:245-246 (1989); Chien *et al.*, *Proc. Natl. Acad. Sci. USA* 88:9578-9582 (1991), both of which are herein incorporated by reference in their entirety) can be used to identify molecules that specifically bind to KIRHy1 or a KIRHy1 derivative.

These “binding polypeptides” or small molecules which interact with KIRHy1 polypeptides can be used for tagging or targeting cells; for isolating homolog polypeptides by affinity purification; they can be directly or indirectly conjugated to drugs, toxins, radionuclides and the like. These binding polypeptides or small molecules can also be used in analytical methods such as for screening expression libraries and neutralizing activity, *i.e.*, for blocking interaction between ligand and receptor, or viral binding to a receptor. The binding polypeptides or small molecules can also be used for diagnostic assays for determining circulating levels of KIRHy1 polypeptides of the invention; for detecting or quantitating soluble KIRHy1 polypeptides as marker of underlying pathology or disease. These binding polypeptides or small molecules can also act as KIRHy1 “antagonists” to block KIRHy1 binding and signal transduction *in vitro* and *in vivo*. These anti-KIRHy1 binding polypeptides or small molecules would be useful for inhibiting KIRHy1 activity or protein binding.

Binding polypeptides can also be directly or indirectly conjugated to drugs, toxins, radionuclides and the like, and these conjugates used for *in vivo* diagnostic or therapeutic applications. Binding peptides can also be fused to other polypeptides, for example an immunoglobulin constant chain or portions thereof, to enhance their half-life, and can be made multivalent (through, *e.g.* branched or repeating units) to increase binding affinity for KIRHy1. For instance, binding polypeptides of the present invention can be used to identify or treat tissues or organs that express a corresponding anti-

complementary molecule (receptor or antigen, respectively, for instance). More specifically, binding polypeptides or bioactive fragments or portions thereof, can be coupled to detectable or cytotoxic molecules and delivered to a mammal having cells, tissues or organs that express the anti-complementary molecule.

5 Suitable detectable molecules may be directly or indirectly attached to the binding polypeptide, and include radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent markers, chemiluminescent markers, magnetic particles and the like. Suitable cytotoxic molecules may be directly or indirectly attached to the binding polypeptide, and include bacterial or plant toxins (for instance, diphtheria toxin, *Pseudomonas* exotoxin, 10 ricin, abrin and the like), as well as therapeutic radionuclides, such as iodine-131, rhenium-188, or yttrium-90 (either directly attached to the binding polypeptide, or indirectly attached through a means of a chelating moiety, for instance). Binding polypeptides may also be conjugated to cytotoxic drugs, such as adriamycin. For indirect attachment of a detectable or cytotoxic molecule, the detectable or cytotoxic molecule 15 can be conjugated with a member of a complementary/anticomplementary pair, where the other member is bound to the binding polypeptide. For these purposes, biotin/streptavidin is an exemplary complementary/anticomplementary pair.

 In another embodiment, binding polypeptide-toxin fusion proteins can be used for targeted cell or tissue inhibition or ablation (for instance, to treat cancer cells or tissues). 20 Alternatively, if the binding polypeptide has multiple functional domains (*i.e.*, an activation domain or a ligand binding domain, plus a targeting domain), a fusion protein including only the targeting domain may be suitable for directing a detectable molecule, a cytotoxic molecule, or a complementary molecule to a cell or tissue type of interest. In instances where the domain only fusion protein includes a complementary molecule, the 25 anti-complementary molecule can be conjugated to a detectable or cytotoxic molecule. Such domain-complementary molecule fusion proteins thus represent a generic targeting vehicle for cell/tissue-specific delivery of generic anti-complementary-detectable/cytotoxic molecule conjugates.

5.9 DISEASES AMENABLE TO ANTI-KIRHy1 TARGETING

In one aspect, the present invention provides reagents and methods useful for treating diseases and conditions wherein cells associated with the disease or disorder express KIRHy1. These diseases can include cancers, and other hyperproliferative conditions, such as hyperplasia, psoriasis, contact dermatitis, immunological disorders, wound healing, arthritis, and autoimmune disease. Whether the cells associated with a disease or condition express KIRHy1 can be determined using the diagnostic methods described herein.

Comparisons of KIRHy1 mRNA and protein expression levels between diseased cells, tissue or fluid (blood, lymphatic fluid, *etc.*) and corresponding normal samples are made to determine if the patient will be responsive to therapy targeting KIRHy1 antigens of the invention. Methods for detecting and quantifying the expression of KIRHy1 mRNA or protein use standard nucleic acid and protein detection and quantitation techniques that are well known in the art and are described in Sambrook, *et al.*, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory, NY (1989) or Ausubel, *et al.*, *Current Protocols in Molecular Biology*, John Wiley & Sons, New York, NY (1989), both of which are incorporated herein by reference in their entirety. Standard methods for the detection and quantification of KIRHy1 mRNA include *in situ* hybridization using labeled KIRHy1 riboprobes (Gemou-Engesaeth, *et al.*, *Pediatrics* 109: E24-E32 (2002), herein incorporated by reference in its entirety), Northern blot and related techniques using KIRHy1 polynucleotide probes (Kunzli, *et al.*, *Cancer* 94: 228 (2002), herein incorporated by reference in its entirety), RT-PCR analysis using KIRHy1-specific primers (Angchaiskisir, *et al.*, *Blood* 99:130 (2002), herein incorporated by reference in its entirety), and other amplification detection methods, such as branched chain DNA solution hybridization assay (Jardi, *et al.*, *J. Viral Hepat.* 8:465-471 (2001), herein incorporated by reference in its entirety), transcription-mediated amplification (Kimura, *et al.*, *J. Clin. Microbiol.* 40:439-445 (2002), herein incorporated by reference in its entirety), microarray products, such as oligos, cDNAs, and monoclonal antibodies, and real-time PCR (Simpson, *et al.*, *Molec. Vision*, 6:178-183 (2000), herein incorporated by reference in its entirety). Standard methods for the detection and quantification of KIRHy1 protein include western blot analysis (Sambrook, 1989 *supra*, Ausubel, 1989

supra)), immunocytochemistry (Racila, *et al.*, *Proc. Natl. Acad. Sci. USA* 95:4589-4594 (1998), herein incorporated by reference in its entirety), and a variety of immunoassays, including enzyme-linked immunosorbant assay (ELISA), radioimmuno assay (RIA), and specific enzyme immunoassay (EIA) (Sambrook, 1989 *supra*, Ausubel, 1989 *supra*).

- 5 Peripheral blood cells can also be analyzed for KIRHy1 expression using flow cytometry using, for example, immunomagnetic beads specific for KIRHy1 (Racila, 1998 *supra*) or biotinylated KIRHy1 antibodies (Soltys, *et al.*, *J. Immunol.* 168:1903 (2002), herein incorporated by reference in its entirety).

Yet another related aspect of the invention is directed to methods for gauging
10 tumor aggressiveness by determining the levels of KIRHy1 protein or mRNA in tumor cells compared to the corresponding normal cells (Orlandi, *et al.*, *Cancer Res.* 62:567 (2002), herein incorporated by reference in its entirety). In one embodiment, the disease or disorder is a cancer.

The diseases treatable by methods of the present invention preferably occur in
15 mammals. Mammals include, for example, humans and other primates, as well as pet or companion animals such as dogs and cats, laboratory animals such as rats, mice and rabbits, and farm animals such as horses, pigs, sheep, and cattle.

Tumors or neoplasms include growths of tissue cells in which the multiplication of the cells is uncontrolled and progressive. Some such growths are benign, but others
20 are termed "malignant" and may lead to death of the organism. Malignant neoplasms or "cancers" are distinguished from benign growths in that, in addition to exhibiting aggressive cellular proliferation, they may invade surrounding tissues and metastasize. Moreover, malignant neoplasms are characterized in that they show a greater loss of differentiation (greater "dedifferentiation"), and greater loss of their organization relative
25 to one another and their surrounding tissues. This property is also called "anaplasia."

Neoplasms treatable by the present invention also include solid phase tumors/malignancies, *i.e.*, carcinomas, locally advanced tumors and human soft tissue sarcomas. Carcinomas include those malignant neoplasms derived from epithelial cells that infiltrate (invade) the surrounding tissues and give rise to metastatic cancers,
30 including lymphatic metastases. Adenocarcinomas are carcinomas derived from glandular tissue, or which form recognizable glandular structures. Another broad

category or cancers includes sarcomas, which are tumors whose cells are embedded in a fibrillar or homogeneous substance like embryonic connective tissue. The invention also enables treatment of cancers of the myeloid or lymphoid systems, including leukemias, lymphomas and other cancers that typically do not present as a tumor mass, but are distributed in the vascular or lymphoreticular systems.

The type of cancer or tumor cells that may be amenable to treatment according to the invention include, for example, acute lymphocytic leukemia, acute nonlymphocytic leukemia, chronic lymphocytic leukemia, chronic myelocytic leukemia, cutaneous T-cell lymphoma, hairy cell leukemia, acute myeloid leukemia, erythroleukemia, chronic myeloid (granulocytic) leukemia, Hodgkin's disease, and non-Hodgkin's lymphoma, gastrointestinal cancers including esophageal cancer, stomach cancer, colon cancer, colorectal cancer, polyps associated with colorectal neoplasms, pancreatic cancer and gallbladder cancer, cancer of the adrenal cortex, ACTH-producing tumor, bladder cancer, brain cancer including intrinsic brain tumors, neuroblastomas, astrocytic brain tumors, gliomas, and metastatic tumor cell invasion of the central nervous system, Ewing's sarcoma, head and neck cancer including mouth cancer and larynx cancer, kidney cancer including renal cell carcinoma, liver cancer, lung cancer including small and non-small cell lung cancers, malignant peritoneal effusion, malignant pleural effusion, skin cancers including malignant melanoma, tumor progression of human skin keratinocytes, squamous cell carcinoma, basal cell carcinoma, and hemangiopericytoma, mesothelioma, Kaposi's sarcoma, bone cancer including osteomas and sarcomas such as fibrosarcoma and osteosarcoma, cancers of the female reproductive tract including uterine cancer, endometrial cancer, ovarian cancer, ovarian (germ cell) cancer and solid tumors in the ovarian follicle, vaginal cancer, cancer of the vulva, and cervical cancer; breast cancer (small cell and ductal), penile cancer, prostate cancer, retinoblastoma, testicular cancer, thyroid cancer, trophoblastic neoplasms, and Wilms' tumor.

The invention is particularly illustrated herein in reference to treatment of certain types of experimentally defined cancers. In these illustrative treatments, standard state-of-the-art *in vitro* and *in vivo* models have been used. These methods can be used to identify agents that can be expected to be efficacious in *in vivo* treatment regimens.

However, it will be understood that the method of the invention is not limited to the treatment of these tumor types, but extends to any cancer derived from any organ system. As demonstrated in the Examples, KIRHy1 is highly expressed in hematopoietic cells, specifically in the myeloid compartment (including for example, monocytes, macrophages, *etc.*), and in hematopoietic cell-related disorders. Leukemias can result from uncontrolled B cell proliferation initially within the bone marrow before disseminating to the peripheral blood, spleen, lymph nodes and finally to other tissues. Uncontrolled B cell proliferation also may result in the development of lymphomas that arise within the lymph nodes and then spread to the blood and bone marrow. Targeting KIRHy1 is useful in treating B cell malignancies, leukemias, lymphomas and myelomas including but not limited to multiple myeloma, Burkitt's lymphoma, cutaneous B cell lymphoma, primary follicular cutaneous B cell lymphoma, B lineage acute lymphoblastic leukemia (ALL), B cell non-Hodgkin's lymphoma (NHL), B cell chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia, hairy cell leukemia (HCL), acute myelogenous leukemia, acute myelomonocytic leukemia, chronic myelogenous leukemia, lymphosarcoma cell leukemia, splenic marginal zone lymphoma, diffuse large B cell lymphoma, B cell large cell lymphoma, malignant lymphoma, prolymphocytic leukemia (PLL), lymphoplasma cytoid lymphoma, mantle cell lymphoma, mucosa-associated lymphoid tissue (MALT) lymphoma, primary thyroid lymphoma, intravascular malignant lymphomatosis, splenic lymphoma, Hodgkin's Disease, and intragraft angiotropic large-cell lymphoma. Expression of KIRHy1 has also been demonstrated in Example 4 to be expressed in acute monocytic leukemia, acute myeloid leukemia, acute myelogenous leukemia, anaplastic large T cell lymphoma, B cell lymphoma, chronic myelogenous leukemia, diffuse large B cell lymphoma, follicular lymphoma, histiocytic lymphoma, Hodgkin's lymphoma, large B cell lymphoma, myeloma, non-Hodgkin's lymphoma, and plasmacytoma cell lines and tissue, and may be treated with KIRHy1 antibodies. Other diseases that may be treated by the methods of the present invention include multicentric Castleman's disease, primary amyloidosis, Franklin's disease, Seligmann's disease, primary effusion lymphoma, post-transplant lymphoproliferative disease (PTLD) [associated with EBV infection], paraneoplastic pemphigus, chronic lymphoproliferative disorders, X-linked lymphoproliferative syndrome (XLP), acquired angioedema,

angioimmunoblastic lymphadenopathy with dysproteinemia, Herman's syndrome, post-splenectomy syndrome, congenital dyserythropoietic anemia type III, lymphoma-associated hemophagocytic syndrome (LAHS), necrotizing ulcerative stomatitis, Kikuchi's disease, lymphomatoid granulomatosis, Richter's syndrome, polycythemic vera (PV), Gaucher's disease, Gougerot-Sjogren syndrome, Kaposi's sarcoma, cerebral lymphoplasmocytic proliferation (Bind and Neel syndrome), X-linked lymphoproliferative disorders, pathogen associated disorders such as mononucleosis (Epstein Barr Virus), lymphoplasma cellular disorders, post-transplantational plasma cell dyscrasias, and Good's syndrome.

Therapeutic compositions of the invention may be effective in adult and pediatric oncology including in solid phase tumors/malignancies, locally advanced tumors, human soft tissue sarcomas, metastatic cancer, including lymphatic metastases, blood cell malignancies, including multiple myeloma, acute and chronic leukemias and lymphomas, head and neck cancers, including mouth cancer, larynx cancer, and thyroid cancer, lung cancers including small cell carcinoma and non-small cell cancers, breast cancers including small cell carcinoma and ductal carcinoma, gastrointestinal cancers including esophageal cancer, stomach cancer, colon cancer, colorectal cancer and polyps associated with colorectal neoplasia, pancreatic cancers, liver cancer, urologic cancers including bladder cancer and prostate cancer, malignancies of the female genital tract including ovarian carcinoma, uterine (including endometrial) cancers, and solid tumor in the ovarian follicle, kidney cancers including renal cell carcinoma, brain cancers including intrinsic brain tumors, neuroblastoma, astrocytic brain tumors, gliomas, metastatic tumor cell invasion in the central nervous system, bone cancers including osteomas, sarcomas including fibrosarcoma and osteosarcoma, skin cancers including malignant melanoma, tumor progression of human skin keratinocytes, squamous cell carcinoma, basal cell carcinoma, hemangiopericytoma, and Kaposi's sarcoma.

Autoimmune diseases can be associated with hyperactive B cell activity that results in autoantibody production. Additionally, autoimmune diseases can be associated with uncontrolled protease activity (Wernike *et al.*, *Arthritis Rheum.* 46:64-74 (2002)) and aberrant cytokine activity (Rodenburg *et al.*, *Ann. Rheum. Dis.* 58:648-652 (1999), both of which are herein incorporated by reference in their entirety). Inhibition of the

development of autoantibody-producing cells or proliferation of such cells may be therapeutically effective in decreasing the levels of autoantibodies in autoimmune diseases. Inhibition of protease activity may reduce the extent of tissue invasion and inflammation associated with autoimmune diseases including but not limited to systemic lupus erythematosus, Hashimoto thyroiditis, Sjogren's syndrome, pericarditis luspus, Crohn's Disease, graft-verses-host disease, Graves' disease, myasthenia gravis, autoimmune hemolytic anemia, autoimmune thrombocytopenia, asthma, cryoglobulinemia, primary biliary sclerosis, pernicious anemia, Waldenstrom macroglobulinemia, hyperviscosity syndrome, macroglobulinemia, cold agglutinin disease, monoclonal gammopathy of undetermined origin, anetoderma and POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, M component, skin changes), connective tissue disease, multiple sclerosis, cystic fibrosis, rheumatoid arthritis, autoimmune pulmonary inflammation, psoriasis, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes mellitis, autoimmune inflammatory eye disease, Goodpasture's disease, Rasmussen's encephalitis, dermatitis herpetiformis, thyoma, autoimmune polyglandular syndrome type 1, primary and secondary membranous nephropathy, cancer-associated retinopathy, autoimmune hepatitis type 1, mixed cryoglobulinemia with renal involvement, cystoid macular edema, endometriosis, IgM polyneuropathy (including Hyper IgM syndrome), demyelinating diseases, angiomatosis, and monoclonal gammopathy.

Targeting KIRHy1 may also be useful in the treatment of allergic reactions and conditions *e.g.*, anaphylaxis, serum sickness, drug reactions, food allergies, insect venom allergies, mastocytosis, allergic rhinitis, hypersensitivity pneumonitis, urticaria, angioedema, eczema, atopic dermatitis, allergic contact dermatitis, erythema multiforme, Stevens-Johnson syndrome, allergic conjunctivitis, atopic keratoconjunctivitis, venereal keratoconjunctivitis, giant papillary conjunctivitis, allergic gastroenteropathy, inflammatory bowel disorder (IBD), and contact allergies, such as asthma (particularly allergic asthma), or other respiratory problems.

Targeting KIRHy1 may also be useful in the management or prevention of transplant rejection in patients in need of transplants such as stem cells, tissue or organ transplant. Thus, one aspect of the invention may find therapeutic utility in various

diseases (such as those usually treated with transplantation, including without limitation, aplastic anemia and paroxysmal nocturnal hemoglobinuria) as wells in repopulating the stem cell compartment post irradiation/chemotherapy, either *in vivo* or *ex vivo* (*i.e.* in conjunction with bone marrow transplantation or with peripheral progenitor cell transplantation (homologous or heterologous) as normal cells or genetically manipulated for gene therapy.

Targeting KIRHy1 may also be possible to modulate immune responses, in a number of ways. Down regulation may be in the form of inhibiting or blocking an immune response already in progress or may involve preventing the induction of an immune response. Down regulating or preventing one or more antigen functions (including without limitation B lymphocyte antigen functions, *e.g.*, modulating or preventing high level lymphokine synthesis by activated T cells, will be useful in situations of tissue, skin and organ transplantation and in graft-versus-host disease (GVHD). For example, blockage of T cell function should result in reduced tissue destruction in tissue transplantation. Typically, in tissue transplants, rejection of the transplant is initiated through its recognition as foreign by T cells, followed by an immune reaction that destroys the transplant. The administration of a therapeutic composition of the invention may prevent cytokine synthesis by immune cells, such as T cells, and thus acts as an immunosuppressant. Moreover, a lack of costimulation may also be sufficient to anergize the T cells, thereby inducing tolerance in a subject. Induction of long-term tolerance by B lymphocyte antigen-blocking reagents may avoid the necessity of repeated administration of these blocking reagents. To achieve sufficient immunosuppression or tolerance in a subject, it may also be necessary to block the function of a combination of B lymphocyte antigens.

The efficacy of particular therapeutic compositions in preventing organ transplant rejection or GVHD can be assessed using animal models that are predictive of efficacy in humans. Examples of appropriate systems which can be used include allogeneic cardiac grafts in rats and xenogeneic pancreatic islet cell grafts in mice, both of which have been used to examine the immunosuppressive effects of CTLA4Ig fusion proteins *in vivo* as described in Lenschow *et al.*, *Science* 257:789-792 (1992) and Turka *et al.*, *Proc. Natl. Acad. Sci USA*, 89:11102-11105 (1992), both of which are herein incorporated by

reference. In addition, murine models of GVHD (see Paul ed., *Fundamental Immunology*, Raven Press, New York, 1989, pp. 846-847, herein incorporated by reference) can be used to determine the effect of therapeutic compositions of the invention on the development of that disease.

5

5.10 ADMINISTRATION

The anti-KIRHy1 monoclonal antibodies used in the practice of a method of the invention may be formulated into pharmaceutical compositions comprising a carrier suitable for the desired delivery method. Suitable carriers include any material which
10 when combined with the anti-KIRHy1 antibodies retains the anti-tumor function of the antibody and is nonreactive with the subject's immune systems. Examples include, but are not limited to, any of a number of standard pharmaceutical carriers such as sterile phosphate buffered saline solutions, bacteriostatic water, and the like.

The anti-KIRHy1 antibody formulations may be administered via any route
15 capable of delivering the antibodies to the tumor site. Potentially effective routes of administration include, but are not limited to, intravenous, intraperitoneal, intramuscular, intratumor, intradermal, and the like. The preferred route of administration is by intravenous injection. A preferred formulation for intravenous injection comprises anti-KIRHy1 mAbs in a solution of preserved bacteriostatic water, sterile unpreserved water,
20 and/or diluted in polyvinylchloride or polyethylene bags containing 0.9% sterile sodium chloride for Injection, USP. The anti-KIRHy1 mAb preparation may be lyophilized and stored as a sterile powder, preferably under vacuum, and then reconstituted in bacteriostatic water containing, for example, benzyl alcohol preservative, or in sterile water prior to injection.

25 Treatment will generally involve the repeated administration of the anti-KIRHy1 antibody preparation via an acceptable route of administration such as intravenous injection (IV), typically at a dose in the range of about 0.1 to about 10 mg/kg body weight; however other exemplary doses in the range of 0.01 mg/kg to about 100 mg/kg are also contemplated. Doses in the range of 10-500 mg mAb per week may be effective
30 and well tolerated. Rituximab (Rituxan®), a chimeric CD20 antibody used to treat B-cell lymphoma, non-Hodgkin's lymphoma, and relapsed indolent lymphoma, is typically

administered at 375 mg/m² by IV infusion once a week for 4 to 8 doses. Sometimes a second course is necessary, but no more than 2 courses are allowed. An effective dosage range for Rituxan® would be 50 to 500 mg/m² (Maloney, *et al.*, *Blood* 84: 2457-2466 (1994); Davis, *et al.*, *J. Clin. Oncol.* 18: 3135-3143 (2000), both of which are herein
5 incorporated by reference in their entirety). Based on clinical experience with Trastuzumab (Herceptin®), a humanized monoclonal antibody used to treat HER2 (human epidermal growth factor 2)-positive metastatic breast cancer (Slamon, *et al.*, *Mol Cell Biol.* 9: 1165 (1989), herein incorporated by reference in its entirety), an initial loading dose of approximately 4 mg/kg patient body weight IV followed by weekly doses
10 of about 2 mg/kg IV of the anti-KIRHy1 mAb preparation may represent an acceptable dosing regimen (Slamon, *et al.*, *N. Engl. J. Med.* 344: 783(2001), herein incorporated by reference in its entirety). Preferably, the initial loading dose is administered as a 90 minute or longer infusion. The periodic maintenance dose may be administered as a 30 minute or longer infusion, provided the initial dose was well tolerated. However, as one
15 of skill in the art will understand, various factors will influence the ideal dose regimen in a particular case. Such factors may include, for example, the binding affinity and half life of the mAb or mAbs used, the degree of KIRHy1 overexpression in the patient, the extent of circulating shed KIRHy1 antigen, the desired steady-state antibody concentration level, frequency of treatment, and the influence of chemotherapeutic agents used in
20 combination with the treatment method of the invention.

Treatment can also involve anti-KIRHy1 antibodies conjugated to radioisotopes. Studies using radiolabeled-anticarcinoembryonic antigen (anti-CEA) monoclonal antibodies, provide a dosage guideline for tumor regression of 2-3 infusions of 30-80 mCi/m² (Behr, *et al.* *Clin. Cancer Res.* 5(10 Suppl.): 3232s-3242s (1999), Juweid, *et al.*,
25 *J. Nucl. Med.* 39:34-42 (1998), both of which are herein incorporated in their entirety).

Alternatively, dendritic cells transfected with mRNA encoding KIRHy1 can be used as a vaccine to stimulate T-cell mediated anti-tumor responses. Studies with dendritic cells transfected with prostate-specific antigen mRNA suggest a 3 cycles of intravenous administration of $1 \times 10^7 - 5 \times 10^7$ cells for 2-6 weeks concomitant with an
30 intradermal injection of 10^7 cells may provide a suitable dosage regimen (Heiser, *et al.*, *J. Clin. Invest.* 109:409-417 (2002); Hadzantonis and O'Neill, *Cancer Biother.*

Radiopharm. 1:11-22 (1999), both of which are herein incorporated in their entirety). Other exemplary doses of between 1×10^5 to 1×10^9 or 1×10^6 to 1×10^8 cells are also contemplated.

Naked DNA vaccines using plasmids encoding KIRHy1 can induce an
5 immunologic anti-tumor response. Administration of naked DNA by direct injection into the skin and muscle is not associated with limitations encountered using viral vectors, such as the development of adverse immune reactions and risk of insertional mutagenesis (Hengge, *et al.*, *J. Invest. Dermatol.* 116:979 (2001), herein incorporated in its entirety). Studies have shown that direct injection of exogenous cDNA into muscle
10 tissue results in a strong immune response and protective immunity (Ilan, *Curr. Opin. Mol. Ther.* 1:116-120 (1999), herein incorporated in its entirety). Physical (gene gun, electroporation) and chemical (cationic lipid or polymer) approaches have been developed to enhance efficiency and target cell specificity of gene transfer by plasmid DNA (Nishikawa and Huang, *Hum. Gene Ther.* 12:861-870 (2001), herein incorporated
15 in its entirety). Plasmid DNA can also be administered to the lungs by aerosol delivery (Densmore, *et al.*, *Mol. Ther.* 1:180-188 (2000)). Gene therapy by direct injection of naked or lipid – coated plasmid DNA is envisioned for the prevention, treatment, and cure of diseases such as cancer, acquired immunodeficiency syndrome, cystic fibrosis, cerebrovascular disease, and hypertension (Prazeres, *et al.*, *Trends Biotechnol.* 17:169-
20 174 (1999); Weihl, *et al.*, *Neurosurgery* 44:239-252 (1999), both of which are herein incorporated in their entirety). HIV-1 DNA vaccine dose-escalating studies indicate administration of 30-300 $\mu\text{g}/\text{dose}$ as a suitable therapy (Weber, *et al.*, *Eur. J. Clin. Microbiol. Infect. Dis.* 20: 800 (2001), herein incorporated in its entirety). Naked DNA injected intracerebrally into the mouse brain was shown to provide expression of a
25 reporter protein, wherein expression was dose-dependent and maximal for 150 μg DNA injected (Schwartz, *et al.*, *Gene Ther.* 3:405-411 (1996), herein incorporated in its entirety). Gene expression in mice after intramuscular injection of nanospheres containing 1 microgram of beta-galactosidase plasmid was greater and more prolonged than was observed after an injection with an equal amount of naked DNA or DNA
30 complexed with Lipofectamine (Truong, *et al.*, *Hum. Gene Ther.* 9:1709-1717 (1998), herein incorporated in its entirety). In a study of plasmid-mediated gene transfer into

skeletal muscle as a means of providing a therapeutic source of insulin, wherein four plasmid constructs comprising a mouse furin cDNA transgene and rat proinsulin cDNA were injected into the calf muscles of male Balb/c mice, the optimal dose for most constructs was 100 micrograms plasmid DNA (Kon, *et al. J. Gene Med.* 1:186-194 (1999), herein incorporated in its entirety). Other exemplary doses of 1-1000 µg/dose or 10-500 µg/dose are also contemplated.

Optimally, patients should be evaluated for the level of circulating shed KIRHy1 antigen in serum in order to assist in the determination of the most effective dosing regimen and related factors. Such evaluations may also be used for monitoring purposes throughout therapy, and may be useful to gauge therapeutic success in combination with evaluating other parameters.

5.10.1 KIRHy1 TARGETING COMPOSITIONS

Compositions for targeting KIRHy1-expressing cells are within the scope of the present invention. Pharmaceutical compositions comprising antibodies are described in detail in, for example, US Patent No. 6,171,586, herein incorporated in its entirety. Such compositions comprise a therapeutically or prophylactically effective amount an antibody, or a fragment, variant, derivative or fusion thereof as described herein, in admixture with a pharmaceutically acceptable agent. Typically, the KIRHy1 targeting agent will be sufficiently purified for administration to an animal.

The pharmaceutical composition may contain formulation materials for modifying, maintaining or preserving, for example, the pH, osmolarity, viscosity, clarity, color, isotonicity, odor, sterility, stability, rate of dissolution or release, adsorption or penetration of the composition. Suitable formulation materials include, but are not limited to, amino acids (such as glycine, glutamine, asparagine, arginine or lysine); antimicrobials; antioxidants (such as ascorbic acid, sodium sulfite or sodium hydrogen-sulfite); buffers (such as borate, bicarbonate, Tris-HCl, citrates, phosphates, other organic acids); bulking agents (such as mannitol or glycine), chelating agents [such as ethylenediamine tetraacetic acid (EDTA)]; complexing agents (such as caffeine, polyvinylpyrrolidone, beta-cyclodextrin or hydroxypropyl-beta-cyclodextrin); fillers; monosaccharides; disaccharides and other carbohydrates (such as glucose, mannose, or

dextrins); proteins (such as serum albumin, gelatin or immunoglobulins); coloring; flavoring and diluting agents; emulsifying agents; hydrophilic polymers (such as polyvinylpyrrolidone); low molecular weight polypeptides; salt-forming counterions (such as sodium); preservatives (such as benzalkonium chloride, benzoic acid, salicylic acid, thimerosal, phenethyl alcohol, methylparaben, propylparaben, chlorhexidine, sorbic acid or hydrogen peroxide); solvents (such as glycerin, propylene glycol or polyethylene glycol); sugar alcohols (such as mannitol or sorbitol); suspending agents; surfactants or wetting agents (such as pluronics, PEG, sorbitan esters, polysorbates such as polysorbate 20, polysorbate 80, triton, tromethamine, lecithin, cholesterol, tyloxapal); stability enhancing agents (sucrose or sorbitol); tonicity enhancing agents (such as alkali metal halides (preferably sodium or potassium chloride, mannitol sorbitol); delivery vehicles; diluents; excipients and/or pharmaceutical adjuvants. (*Remington's Pharmaceutical Sciences*, 18th Edition, Ed. A.R. Gennaro, Mack Publishing Company, (1990), herein incorporated in its entirety).

15 The optimal pharmaceutical composition will be determined by one skilled in the art depending upon, for example, the intended route of administration, delivery format, and desired dosage. *See*, for example, *Remington's Pharmaceutical Sciences, supra*. Such compositions may influence the physical state, stability, rate of *in vivo* release, and rate of *in vivo* clearance of the KIRHy1 immunotargeting agent.

20 The primary vehicle or carrier in a pharmaceutical composition may be either aqueous or non-aqueous in nature. For example, a suitable vehicle or carrier may be water for injection, physiological saline solution or artificial cerebrospinal fluid, possibly supplemented with other materials common in compositions for parenteral administration. Neutral buffered saline or saline mixed with serum albumin are further
25 exemplary vehicles. Other exemplary pharmaceutical compositions comprise Tris buffer of about pH 7.0-8.5, or acetate buffer of about pH 4.0-5.5, which may further include sorbitol or a suitable substitute therefor. In one embodiment of the present invention, KIRHy1 targeting agent compositions may be prepared for storage by mixing the selected composition having the desired degree of purity with optional formulation agents
30 (*Remington's Pharmaceutical Sciences, supra*) in the form of a lyophilized cake or an

aqueous solution. Further, the binding agent product may be formulated as a lyophilizate using appropriate excipients such as sucrose.

The pharmaceutical compositions can be selected for parenteral delivery. Alternatively, the compositions may be selected for inhalation or for delivery through the digestive tract, such as orally. The preparation of such pharmaceutically acceptable compositions is within the skill of the art. The formulation components are present in concentrations that are acceptable to the site of administration. For example, buffers are used to maintain the composition at physiological pH or at slightly lower pH, typically within a pH range of from about 5 to about 8. When parenteral administration is contemplated, the therapeutic compositions for use in this invention may be in the form of a pyrogen-free, parenterally acceptable aqueous solution comprising the KIRHy1 targeting agent in a pharmaceutically acceptable vehicle. A particularly suitable vehicle for parenteral injection is sterile distilled water in which a KIRHy1 targeting agent is formulated as a sterile, isotonic solution, properly preserved. Yet another preparation can involve the formulation of the desired molecule with an agent, such as injectable microspheres, bio-erodible particles, polymeric compounds (polylactic acid, polyglycolic acid), beads, or liposomes, that provides for the controlled or sustained release of the product which may then be delivered via a depot injection. Hyaluronic acid may also be used, and this may have the effect of promoting sustained duration in the circulation. Other suitable means for the introduction of the desired molecule include implantable drug delivery devices.

In another aspect, pharmaceutical formulations suitable for parenteral administration may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiologically buffered saline. Aqueous injection suspensions may contain substances that increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils, such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate, triglycerides, or liposomes. Non-lipid polycationic amino polymers may also be used for delivery. Optionally, the

suspension may also contain suitable stabilizers or agents to increase the solubility of the compounds and allow for the preparation of highly concentrated solutions.

In another embodiment, a pharmaceutical composition may be formulated for inhalation. For example, a KIRHy1 targeting agent may be formulated as a dry powder for inhalation. Polypeptide or nucleic acid molecule inhalation solutions may also be formulated with a propellant for aerosol delivery. In yet another embodiment, solutions may be nebulized. Pulmonary administration is further described in PCT Application No. PCT/US94/001875, herein incorporated in its entirety, which describes pulmonary delivery of chemically modified proteins.

It is also contemplated that certain formulations may be administered orally. In one embodiment of the present invention, KIRHy1 targeting agents that are administered in this fashion can be formulated with or without those carriers customarily used in the compounding of solid dosage forms such as tablets and capsules. For example, a capsule may be designed to release the active portion of the formulation at the point in the gastrointestinal tract when bioavailability is maximized and pre-systemic degradation is minimized. Additional agents can be included to facilitate absorption of the binding agent molecule. Diluents, flavorings, low melting point waxes, vegetable oils, lubricants, suspending agents, tablet disintegrating agents, and binders may also be employed.

Pharmaceutical compositions for oral administration can also be formulated using pharmaceutically acceptable carriers well known in the art in dosages suitable for oral administration. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.

Pharmaceutical preparations for oral use can be obtained through combining active compounds with solid excipient and processing the resultant mixture of granules (optionally, after grinding) to obtain tablets or dragee cores. Suitable auxiliaries can be added, if desired. Suitable excipients include carbohydrate or protein fillers, such as sugars, including lactose, sucrose, mannitol, and sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose, such as methyl cellulose, hydroxypropylmethyl-cellulose, or sodium carboxymethylcellulose; gums, including arabic and tragacanth; and proteins, such as gelatin and collagen. If desired, disintegrating or solubilizing agents

may be added, such as the cross-linked polyvinyl pyrrolidone, agar, and alginic acid or a salt thereof, such as sodium alginate.

Dragee cores may be used in conjunction with suitable coatings, such as concentrated sugar solutions, which may also contain gum arabic, talc,
5 polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound, *i.e.*, dosage.

Pharmaceutical preparations that can be used orally also include push-fit capsules
10 made of gelatin, as well as soft, sealed capsules made of gelatin and a coating, such as glycerol or sorbitol. Push-fit capsules can contain active ingredients mixed with fillers or binders, such as lactose or starches, lubricants, such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the KIRHy1 targeting agent may be dissolved or suspended in suitable liquids, such as fatty oils, liquid, or liquid polyethylene glycol with
15 or without stabilizers.

Another pharmaceutical composition may involve an effective quantity of KIRHy1 targeting agent in a mixture with non-toxic excipients that are suitable for the manufacture of tablets. By dissolving the tablets in sterile water, or other appropriate vehicle, solutions can be prepared in unit dose form. Suitable excipients include, but are
20 not limited to, inert diluents, such as calcium carbonate, sodium carbonate or bicarbonate, lactose, or calcium phosphate; or binding agents, such as starch, gelatin, or acacia; or lubricating agents such as magnesium stearate, stearic acid, or talc.

Additional pharmaceutical compositions will be evident to those skilled in the art, including formulations involving KIRHy1 targeting agents in sustained- or controlled-
25 delivery formulations. Techniques for formulating a variety of other sustained- or controlled-delivery means, such as liposome carriers, bio-erodible microparticles or porous beads and depot injections, are also known to those skilled in the art. *See*, for example, PCT/US93/00829, herein incorporated in its entirety, that describes controlled release of porous polymeric microparticles for the delivery of pharmaceutical
30 compositions. Additional examples of sustained-release preparations include semipermeable polymer matrices in the form of shaped articles, *e.g.* films, or

microcapsules. Sustained release matrices may include polyesters, hydrogels, polylactides (U.S. Patent No. 3,773,919; European Patent No. EP 58,481), copolymers of L-glutamic acid and gamma ethyl-L-glutamate (Sidman *et al.*, *Biopolymers*, 22:547-556 (1983)), poly (2-hydroxyethyl-methacrylate) (Langer *et al.*, *J Biomed Mater Res*, 15:167-277, (1981)) and (Langer *et al.*, *Chem Tech*, 12:98-105(1982)), ethylene vinyl acetate (Langer *et al.*, *supra*) or poly-D (-)-3-hydroxybutyric acid (European Patent No. EP 133,988, all of which are herein incorporated in their entirety). Sustained-release compositions also include liposomes, which can be prepared by any of several methods known in the art. See e.g., Epstein, *et al.*, *Proc Natl Acad Sci (USA)*, 82:3688-3692 (1985); European Patent Nos. EP 36,676, EP 88,046, and EP 143,949, all of which are herein incorporated by reference in their entirety.

The pharmaceutical composition to be used for *in vivo* administration typically must be sterile. This may be accomplished by filtration through sterile filtration membranes. Where the composition is lyophilized, sterilization using this method may be conducted either prior to or following lyophilization and reconstitution. The composition for parenteral administration may be stored in lyophilized form or in solution. In addition, parenteral compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

Once the pharmaceutical composition has been formulated, it may be stored in sterile vials as a solution, suspension, gel, emulsion, solid, or a dehydrated or lyophilized powder. Such formulations may be stored either in a ready-to-use form or in a form (*e.g.*, lyophilized) requiring reconstitution prior to administration.

In a specific embodiment, the present invention is directed to kits for producing a single-dose administration unit. The kits may each contain both a first container having a dried KIRHy1 immunotargeting agent and a second container having an aqueous formulation. Also included within the scope of this invention are kits containing single and multi-chambered pre-filled syringes (*e.g.*, liquid syringes and lyosyringes).

5.10.2 DOSAGE

An effective amount of a pharmaceutical composition to be employed therapeutically will depend, for example, upon the therapeutic context and objectives. One skilled in the art will appreciate that the appropriate dosage levels for treatment will thus vary depending, in part, upon the molecule delivered, the indication for which KIRHy1 targeting agent is being used, the route of administration, and the size (body weight, body surface or organ size) and condition (the age and general health) of the patient. Accordingly, the clinician may titer the dosage and modify the route of administration to obtain the optimal therapeutic effect. A typical dosage may range from about 0.1 mg/kg to up to about 100 mg/kg or more, depending on the factors mentioned above. In other embodiments, the dosage may range from 0.1 mg/kg up to about 100 mg/kg; or 0.01 mg/kg to 1 g/kg; or 1 mg/kg up to about 100 mg/kg or 5 mg/kg up to about 100 mg/kg. In other embodiments, the dosage may range from 10 mCi to 100 mCi per dose for radioimmunotherapy, from about 1×10^7 – 5×10^7 cells or 1×10^5 to 1×10^9 cells or 1×10^6 to 1×10^8 cells per injection or infusion, or from 30 μ g to 300 μ g naked DNA per dose or 1-1000 μ g/dose or 10-500 μ g/dose, depending on the factors listed above.

For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays or in animal models such as mice, rats, rabbits, dogs, or pigs. An animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

The exact dosage will be determined in light of factors related to the subject requiring treatment. Dosage and administration are adjusted to provide sufficient levels of the active compound or to maintain the desired effect. Factors that may be taken into account include the severity of the disease state, the general health of the subject, the age, weight, and gender of the subject, time and frequency of administration, drug combination(s), reaction sensitivities, and response to therapy. Long-acting pharmaceutical compositions may be administered every 3 to 4 days, every week, or biweekly depending on the half-life and clearance rate of the particular formulation.

The frequency of dosing will depend upon the pharmacokinetic parameters of the KIRHy1 targeting agent in the formulation used. Typically, a composition is

administered until a dosage is reached that achieves the desired effect. The composition may therefore be administered as a single dose, or as multiple doses (at the same or different concentrations/dosages) over time, or as a continuous infusion. Further refinement of the appropriate dosage is routinely made. Appropriate dosages may be
5 ascertained through use of appropriate dose-response data.

5.10.3 ROUTES OF ADMINISTRATION

The route of administration of the pharmaceutical composition is in accord with known methods, *e.g.* orally, through injection by intravenous, intraperitoneal,
10 intracerebral (intra-parenchymal), intracerebroventricular, intramuscular, intra-ocular, intra-arterial, intraportal, intralesional routes, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, urethral, vaginal, or rectal means, by sustained release systems, by implantation devices, or through inhalation. Where desired, the compositions may be administered by bolus
15 injection or continuously by infusion, or by implantation device.

Alternatively or additionally, the composition may be administered locally via implantation of a membrane, sponge, or another appropriate material on to which the KIRHy1 targeting agent has been absorbed or encapsulated. Where an implantation device is used, the device may be implanted into any suitable tissue or organ, and
20 delivery of the KIRHy1 targeting agent may be via diffusion, timed-release bolus, or continuous administration.

In some cases, it may be desirable to use pharmaceutical compositions in an *ex vivo* manner. In such instances, cells, tissues, or organs that have been removed from the patient are exposed to the pharmaceutical compositions after which the cells, tissues
25 and/or organs are subsequently implanted back into the patient.

In other cases, a KIRHy1 targeting agent can be delivered by implanting certain cells that have been genetically engineered to express and secrete the polypeptide. Such cells may be animal or human cells, and may be autologous, heterologous, or xenogeneic. Optionally, the cells may be immortalized. In order to decrease the chance of an
30 immunological response, the cells may be encapsulated to avoid infiltration of surrounding tissues. The encapsulation materials are typically biocompatible, semi-

permeable polymeric enclosures or membranes that allow the release of the protein product(s) but prevent the destruction of the cells by the patient's immune system or by other detrimental factors from the surrounding tissues.

5 5.11 COMBINATION THERAPY

KIRHy1 targeting agents of the invention can be utilized in combination with other therapeutic agents, and may enhance the effect of these other therapeutic agents such that a lesser daily amount, lesser total amount or reduced frequency of administration is required in order to achieve the same therapeutic effect at reduced toxicity. For cancer, these other therapeutics include, for example radiation treatment, chemotherapeutic agents, as well as other growth factors. For transplant rejection or autoimmune diseases, these other therapeutics include for example immunosuppressants such as cyclosporine, azathioprine corticosteroids, tacrolimus or mycophenolate mofetil.

In one embodiment, anti-KIRHy1 antibody is used as a radiosensitizer. In such embodiments, the anti-KIRHy1 antibody is conjugated to a radiosensitizing agent. The term "radiosensitizer," as used herein, is defined as a molecule, preferably a low molecular weight molecule, administered to animals in therapeutically effective amounts to increase the sensitivity of the cells to be radiosensitized to electromagnetic radiation and/or to promote the treatment of diseases that are treatable with electromagnetic radiation. Diseases that are treatable with electromagnetic radiation include neoplastic diseases, benign and malignant tumors, and cancerous cells.

The terms "electromagnetic radiation" and "radiation" as used herein include, but are not limited to, radiation having the wavelength of 10^{-20} to 100 meters. Preferred embodiments of the present invention employ the electromagnetic radiation of: gamma-radiation (10^{-20} to 10^{-13} m), X-ray radiation (10^{-12} to 10^{-9} m), ultraviolet light (10 nm to 400 nm), visible light (400 nm to 700 nm), infrared radiation (700 nm to 1.0 mm), and microwave radiation (1 mm to 30 cm).

Radiosensitizers are known to increase the sensitivity of cancerous cells to the toxic effects of electromagnetic radiation. Many cancer treatment protocols currently employ radiosensitizers activated by the electromagnetic radiation of X-rays. Examples of X-ray activated radiosensitizers include, but are not limited to, the following:

metronidazole, misonidazole, desmethylmisonidazole, pimonidazole, etanidazole, nimorazole, mitomycin C, RSU 1069, SR 4233, EO9, RB 6145, nicotinamide, 5-bromodeoxyuridine (BUdR), 5-iododeoxyuridine (IUdR), bromodeoxycytidine, fluorodeoxyuridine (FUdR), hydroxyurea, cisplatin, and therapeutically effective analogs and derivatives of the same.

Photodynamic therapy (PDT) of cancers employs visible light as the radiation activator of the sensitizing agent. Examples of photodynamic radiosensitizers include the following, but are not limited to: hematoporphyrin derivatives, Photofrin(r), benzoporphyrin derivatives, NPe6, tin etioporphyrin (SnET2), pheoborbide-a, bacteriochlorophyll-a, naphthalocyanines, phthalocyanines, zinc phthalocyanine, and therapeutically effective analogs and derivatives of the same.

Chemotherapy treatment can employ anti-neoplastic agents including, for example, alkylating agents including: nitrogen mustards, such as mechlorethamine, cyclophosphamide, ifosfamide, melphalan and chlorambucil; nitrosoureas, such as carmustine (BCNU), lomustine (CCNU), and semustine (methyl-CCNU); ethylenimines/methylmelamine such as triethylenemelamine (TEM), triethylene, thiophosphoramidate (thiotepa), hexamethylmelamine (HMM, altretamine); alkyl sulfonates such as busulfan; triazines such as dacarbazine (DTIC); antimetabolites including folic acid analogs such as methotrexate and trimetrexate, pyrimidine analogs such as 5-fluorouracil, fluorodeoxyuridine, gemcitabine, cytosine arabinoside (AraC, cytarabine), 5-azacytidine, 2,2'-difluorodeoxycytidine, purine analogs such as 6-mercaptopurine, 6-thioguanine, azathioprine, 2'-deoxycoformycin (pentostatin), erythrohydroxynonyladenine (EHNA), fludarabine phosphate, and 2-chlorodeoxyadenosine (cladribine, 2-CdA); natural products including antimitotic drugs such as paclitaxel, vinca alkaloids including vinblastine (VLB), vincristine, and vinorelbine, taxotere, estramustine, and estramustine phosphate; podophyllotoxins such as etoposide and teniposide; antibiotics such as actinomycin D, daunomycin (rubidomycin), doxorubicin, mitoxantrone, idarubicin, bleomycins, plicamycin (mithramycin), mitomycinC, and actinomycin; enzymes such as L-asparaginase; biological response modifiers such as interferon-alpha, IL-2, G-CSF and GM-CSF; miscellaneous agents including platinum coordination complexes such as cisplatin and

carboplatin, anthracenediones such as mitoxantrone, substituted urea such as hydroxyurea, methylhydrazine derivatives including N-methylhydrazine (MIH) and procarbazine, adrenocortical suppressants such as mitotane (o,p'-DDD) and aminoglutethimide; hormones and antagonists including adrenocorticosteroid antagonists
5 such as prednisone and equivalents, dexamethasone and aminoglutethimide; progestin such as hydroxyprogesterone caproate, medroxyprogesterone acetate and megestrol acetate; estrogen such as diethylstilbestrol and ethinyl estradiol equivalents; antiestrogen such as tamoxifen; androgens including testosterone propionate and fluoxymesterone/equivalents; antiandrogens such as flutamide, gonadotropin-releasing
10 hormone analogs and leuprolide; and non-steroidal antiandrogens such as flutamide.

Combination therapy with growth factors can include cytokines, lymphokines, growth factors, or other hematopoietic factors such as M-CSF, GM-CSF, TNF, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IFN, TNF0, TNF1, TNF2, G-CSF, Meg-CSF, GM-CSF,
15 thrombopoietin, stem cell factor, and erythropoietin. Other compositions can include known angiopoietins, for example, vascular endothelial growth factor (VEGF). Growth factors include angiogenin, bone morphogenic protein-1, bone morphogenic protein-2, bone morphogenic protein-3, bone morphogenic protein-4, bone morphogenic protein-5, bone morphogenic protein-6, bone morphogenic protein-7, bone morphogenic protein-8,
20 bone morphogenic protein-9, bone morphogenic protein-10, bone morphogenic protein-11, bone morphogenic protein-12, bone morphogenic protein-13, bone morphogenic protein-14, bone morphogenic protein-15, bone morphogenic protein receptor IA, bone morphogenic protein receptor IB, brain derived neurotrophic factor, ciliary neurotrophic factor, ciliary neurotrophic factor receptor, cytokine-induced neutrophil chemotactic factor
25 1, cytokine-induced neutrophil chemotactic factor 2, endothelial cell growth factor, endothelin 1, epidermal growth factor, epithelial-derived neutrophil attractant, fibroblast growth factor 4, fibroblast growth factor 5, fibroblast growth factor 6, fibroblast growth factor 7, fibroblast growth factor 8, fibroblast growth factor 8b, fibroblast growth factor 8c, fibroblast growth factor 9, fibroblast growth factor 10, fibroblast growth factor acidic,
30 fibroblast growth factor basic, glial cell line-derived neurotrophic factor receptor 2, growth related protein, heparin binding epidermal growth factor, hepatocyte growth factor,

hepatocyte growth factor receptor, insulin-like growth factor I, insulin-like growth factor receptor, insulin-like growth factor II, insulin-like growth factor binding protein, keratinocyte growth factor, leukemia inhibitory factor, leukemia inhibitory factor receptor, nerve growth factor, nerve growth factor receptor, neurotrophin-3, neurotrophin-4, placenta growth factor, placenta growth factor 2, platelet-derived endothelial cell growth factor, platelet derived growth factor, platelet derived growth factor A chain, platelet derived growth factor AA, platelet derived growth factor AB, platelet derived growth factor B chain, platelet derived growth factor BB, platelet derived growth factor receptor, pre-B cell growth stimulating factor, stem cell factor, stem cell factor receptor, transforming growth factor, transforming growth factor 1, transforming growth factor 1.2, transforming growth factor 2, transforming growth factor 3, transforming growth factor 5, latent transforming growth factor 1, transforming growth factor binding protein I, transforming growth factor binding protein II, transforming growth factor binding protein III, tumor necrosis factor receptor type I, tumor necrosis factor receptor type II, urokinase-type plasminogen activator receptor, vascular endothelial growth factor, and chimeric proteins and biologically or immunologically active fragments thereof.

5.12 DIAGNOSTIC USES OF KIRHy1

20 5.12.1 ASSAYS FOR DETERMINING KIRHy1-EXPRESSION STATUS

Determining the status of KIRHy1 expression patterns in an individual may be used to diagnose cancer and may provide prognostic information useful in defining appropriate therapeutic options. Similarly, the expression status of KIRHy1 may provide information useful for predicting susceptibility to particular disease stages, progression, and/or tumor aggressiveness. The invention provides methods and assays for determining KIRHy1 expression status and diagnosing cancers that express KIRHy1.

In one aspect, the invention provides assays useful in determining the presence of cancer in an individual, comprising detecting a significant increase or decrease, as applicable, in KIRHy1 mRNA or protein expression in a test cell or tissue or fluid sample relative to expression levels in the corresponding normal cell or tissue. In one embodiment, the presence of KIRHy1 mRNA is evaluated in tissue samples of a

lymphoma. The presence of significant KIRHy1 expression may be useful to indicate whether the lymphoma is susceptible to KIRHy1 targeting using a targeting composition of the invention. In a related embodiment, KIRHy1 expression status may be determined at the protein level rather than at the nucleic acid level. For example, such a method or
5 assay would comprise determining the level of KIRHy1 expressed by cells in a test tissue sample and comparing the level so determined to the level of KIRHy1 expressed in a corresponding normal sample. In one embodiment, the presence of KIRHy1 is evaluated, for example, using immunohistochemical methods. KIRHy1 antibodies capable of detecting KIRHy1 expression may be used in a variety of assay formats well known in
10 the art for this purpose.

Peripheral blood may be conveniently assayed for the presence of cancer cells, including lymphomas and leukemias, using RT-PCR to detect KIRHy1 expression. The presence of RT-PCR amplifiable KIRHy1 mRNA provides an indication of the presence of one of these types of cancer. A sensitive assay for detecting and characterizing
15 carcinoma cells in blood may be used (Racila, *et al.*, *Proc. Natl. Acad. Sci. USA* 95: 4589-4594 (1998), herein incorporated by reference in its entirety). This assay combines immunomagnetic enrichment with multiparameter flow cytometric and immunohistochemical analyses, and is highly sensitive for the detection of cancer cells in blood, reportedly capable of detecting one epithelial cell in 1 ml of peripheral blood.

20 A related aspect of the invention is directed to predicting susceptibility to developing cancer in an individual. In one embodiment, a method for predicting susceptibility to cancer comprises detecting KIRHy1 mRNA or KIRHy1 in a tissue sample, its presence indicating susceptibility to cancer, wherein the degree of KIRHy1 mRNA expression present is proportional to the degree of susceptibility.

25 Yet another related aspect of the invention is directed to methods for assessment of tumor aggressiveness (Orlandi, *et al.*, *Cancer Res.* 62:567 (2002), herein incorporated by reference in its entirety). In one embodiment, a method for gauging aggressiveness of a tumor comprises determining the level of KIRHy1 mRNA or KIRHy1 protein expressed by cells in a sample of the tumor, comparing the level so determined to the
30 level of KIRHy1 mRNA or KIRHy1 protein expressed in a corresponding normal tissue taken from the same individual or a normal tissue reference sample, wherein the degree

of KIRHy1 mRNA or KIRHy1 protein expression in the tumor sample relative to the normal sample indicates the degree of aggressiveness.

Methods for detecting and quantifying the expression of KIRHy1 mRNA or protein are described herein and use standard nucleic acid and protein detection and quantification technologies well known in the art. Standard methods for the detection and quantification of KIRHy1 mRNA include *in situ* hybridization using labeled KIRHy1 riboprobes (Gemou-Engesaeth, *et al.*, *Pediatrics*, 109:E24-E32 (2002)), Northern blot and related techniques using KIRHy1 polynucleotide probes (Kunzli, *et al.*, *Cancer* 94:228 (2002)), RT-PCR analysis using primers specific for KIRHy1 (Angchaiskisir, *et al.*, *Blood* 99:130 (2002)), and other amplification type detection methods, such as, for example, branched DNA (Jardi, *et al.*, *J. Viral Hepat.* 8:465-471 (2001)), SISBA, TMA (Kimura, *et al.*, *J. Clin. Microbiol.* 40:439-445 (2002)), and microarray products of a variety of sorts, such as oligos, cDNAs, and monoclonal antibodies. In a specific embodiment, real-time RT-PCR may be used to detect and quantify KIRHy1 mRNA expression (Simpson, *et al.*, *Molec. Vision* 6:178-183 (2000)). Standard methods for the detection and quantification of protein may be used for this purpose. In a specific embodiment, polyclonal or monoclonal antibodies specifically reactive with the wild-type KIRHy1 may be used in an immunohistochemical assay of biopsied tissue (Ristimaki, *et al.*, *Cancer Res.* 62:632 (2002), herein incorporated by reference in its entirety).

5.12.2 DIAGNOSTIC ASSAYS AND KITS

The present invention further provides methods to identify the presence or expression of KIRHy1, or homolog thereof, in a test sample, using a nucleic acid probe or antibodies of the present invention, optionally conjugated or otherwise associated with a suitable label.

In general, methods for detecting a KIRHy1 polynucleotide can comprise contacting a sample with a compound that binds to and forms a complex with the polynucleotide for a period sufficient to form the complex, and detecting the complex, so that if a complex is detected, a polynucleotide of the invention is detected in the sample. Such methods can also comprise contacting a sample under stringent hybridization conditions with nucleic acid primers that anneal to a polynucleotide of the invention

under such conditions, and amplifying annealed polynucleotides, so that if a polynucleotide is amplified, a polynucleotide of the invention is detected in the sample.

In general, methods for detecting a polypeptide of the invention can comprise contacting a sample with a compound that binds to and forms a complex with the polypeptide for a period sufficient to form the complex, and detecting the complex, so that if a complex is detected, a polypeptide of the invention is detected in the sample.

In detail, such methods comprise incubating a test sample with one or more of the antibodies or one or more of the nucleic acid probes of the present invention and assaying for binding of the nucleic acid probes or antibodies to components within the test sample.

Conditions for incubating a nucleic acid probe or antibody with a test sample vary. Incubation conditions depend on the format employed in the assay, the detection methods employed, and the type and nature of the nucleic acid probe or antibody used in the assay. One skilled in the art will recognize that any one of the commonly available hybridization, amplification or immunological assay formats can readily be adapted to employ the nucleic acid probes or antibodies of the present invention. Examples of such assays can be found in Chard, T., *An Introduction to Radioimmunoassay and Related Techniques*, Elsevier Science Publishers, Amsterdam, The Netherlands (1986); Bullock, G.R. et al., *Techniques in Immunocytochemistry*; Academic Press, Orlando, FL Vol. 1 (1982), Vol. 2 (1983), Vol. 3 (1985); Tijssen, P., *Practice and Theory of immunoassays: Laboratory Techniques in Biochemistry and Molecular Biology*, Elsevier Science Publishers, Amsterdam, The Netherlands (1985). The test samples of the present invention include cells, protein or membrane extracts of cells, or biological fluids such as sputum, blood, serum, plasma, or urine. The test sample used in the above-described method will vary based on the assay format, nature of the detection method and the tissues, cells or extracts used as the sample to be assayed. Methods for preparing protein extracts or membrane extracts of cells are well known in the art and can be readily be adapted in order to obtain a sample which is compatible with the system utilized.

In another embodiment of the present invention, kits are provided which contain the necessary reagents to carry out the assays of the present invention. Specifically, the invention provides a compartment kit to receive, in close confinement, one or more containers which comprises: (a) a first container comprising one of the probes or

antibodies of the present invention; and (b) one or more other containers comprising one or more of the following: wash reagents, reagents capable of detecting presence of a bound probe or antibody.

In detail, a compartment kit includes any kit in which reagents are contained in
5 separate containers. Such containers include small glass containers, plastic containers or strips of plastic or paper. Such containers allows one to efficiently transfer reagents from one compartment to another compartment such that the samples and reagents are not cross-contaminated, and the agents or solutions of each container can be added in a quantitative fashion from one compartment to another. Such containers will include a
10 container which will accept the test sample, a container which contains the antibodies used in the assay, containers which contain wash reagents (such as phosphate buffered saline, Tris-buffers, *etc.*), and containers which contain the reagents used to detect the bound antibody or probe. Types of detection reagents include labeled nucleic acid probes, labeled secondary antibodies, or in the alternative, if the primary antibody is labeled, the
15 enzymatic, or antibody binding reagents which are capable of reacting with the labeled antibody. One skilled in the art will readily recognize that the disclosed probes and antibodies of the present invention can be readily incorporated into one of the established kit formats which are well known in the art.

20 **5.12.3 MEDICAL IMAGING**

KIRHy1 antibodies that recognize KIRHy1 and fragments thereof are useful in medical imaging of sites expressing KIRHy1. Such methods involve chemical attachment of a labeling or imaging agent, such as a radioisotope, which include ⁶⁷Cu, ⁹⁰Y, ¹²⁵I, ¹³¹I, ¹⁸⁶Re, ¹⁸⁸Re, ²¹¹At, ²¹²Bi, administration of the labeled antibody and
25 fragment to a subject in a pharmaceutically acceptable carrier, and imaging the labeled antibody and fragment *in vivo* at the target site. Radiolabelled anti-KIRHy1 antibodies or fragments thereof may be particularly useful in *in vivo* imaging of KIRHy1 expressing cancers, such as lymphomas or leukemias. Such antibodies may provide highly sensitive methods for detecting metastasis of KIRHy1-expressing cancers.

30 Upon consideration of the present disclosure; one of skill in the art will appreciate that many other embodiments and variations may be made in the scope of the present

invention. Accordingly, it is intended that the broader aspects of the present invention not be limited to the disclosure of the following examples.

5 **6. EXAMPLES**

EXAMPLE 1

ISOLATION OF SEQ ID NO: 1 FROM A cDNA LIBRARY OF HUMAN CELLS

The novel nucleic acids of SEQ ID NO: 1 were obtained from various human cDNA libraries using standard PCR, sequencing by hybridization sequence signature
10 analysis, and Sanger sequencing techniques. The inserts of the library were amplified with PCR using primers specific for vector sequences flanking the inserts. These samples were spotted onto nylon membranes and interrogated with oligonucleotide probes to give sequence signatures. The clones were clustered into groups of similar or identical sequences, and single representative clones were selected from each group for gel
15 sequencing. The 5' sequence of the amplified inserts were then deduced using the reverse M13 sequencing primer in a typical Sanger sequencing protocol. PCR products were purified and subjected to fluorescent dye terminator cycle sequencing. Single-pass gel sequencing was done using a 377 Applied Biosystems (ABI) sequencer. These inserts was identified as a novel sequence not previously obtained from this library and not
20 previously reported in public databases. This sequence is designated as SEQ ID NO: 1 in the attached sequence listing.

EXAMPLE 2

ASSEMBLAGE OF SEQ ID NO: 2

25 The novel nucleic acids (SEQ ID NO: 2) of the invention were assembled from sequences that were obtained from various cDNA libraries by methods described in Example 1 above, and in some cases obtained from one or more public databases. The final sequence was assembled using the EST sequence as seed. Then a recursive algorithm was used to extend the seed into an extended assemblage, by pulling additional sequences from
30 different databases (*i.e.* Hyseq's database containing EST sequences, dbEST, gb pri, and UniGene) that belong to this assemblage. The algorithm terminated when there was no additional sequences from the above databases that would extend the assemblage. Inclusion

of component sequences into the assemblage was based on a BLASTN hit to the extending assemblage with BLAST score greater than 300 and percent identity greater than 95%.

Table 1

SEQ ID NO.	Corresponding SEQ ID NO. in U.S.S.N. 09/631,451	Corresponding SEQ ID NO. in U.S.S.N. 09/491,404	Accession No.	Description	Smith-Waterman Score	Percent Identity
3	156	2882	AJ010101	Homo sapiens IRC1a (NK cell IRC1a gene)	334	37

5

EXAMPLE 3

TISSUE EXPRESSION ANALYSIS OF KIRHY1 POLYNUCLEOTIDES AND CHROMOSOMAL LOCALIZATION

10 By checking Hyseq proprietary database established from screening by hybridization, SEQ ID NO: 2 was found to be expressed in following human tissue/cell cDNA:

Table 2

Library Name	No. of Positive Clones	Total No. of Clones in the Library	Tissue Origin
LUC001	26	210372	Leukocytes
ASP001	3	32114	Adult spleen
LUC003	2	30296	Leukocytes
SPLc01	6	110573	Spleen
FLG001	1	28154	Whole organ
ALG001	1	28271	Adult lung
CLN001	1	28708	Colon
UTR001	1	29595	Uterus
ABR001	1	30163	Adult brain
BMD002	2	75816	Bone marrow
LGT002	4	158948	Lung tumor
PLA003	1	80877	Placenta
DGD004	1	91423	Lymphocytes/Myeloma
THMc02	1	96791	Thymus
SIN001	1	142562	Whole organ
STM001	1	181899	Bone Marrow
AOV010	1	259409	Ovary
FLS002	1	709733	Fetal liver/spleen

15 The gene corresponding to SEQ ID NO: 2 was mapped to human chromosome 17 by BLAST analysis with human genome sequences.

EXAMPLE 4

KIRHy1 mRNA IS HIGHLY EXPRESSED IN B-CELL CELL LINES AND TISSUES

Figure 3 shows the relative expression of mRNA derived from B-cell cell lines, healthy tissues, and tumor tissues derived from B cell lymphomas, follicular lymphomas, and myelomas.

Total mRNA derived from tissues and cells lines was subjected to quantitative real-time PCR (TaqMan) (Simpson, *et al.*, *Molec. Vision*, 6:178-183 (2000) herein incorporated by reference) to determine the relative expression of KIRHy1 mRNA. Total mRNA derived from cell lines (obtained from ATCC, Manassas, VA) was isolated using standard protocols. The cell lines were derived from acute myelogenous leukemia (AML193), acute myeloid leukemia (AM565), acute myelogenous leukemia (KG1), anaplastic large T cell lymphoma (L5664), B cell lymphoma (RA1), chronic myelogenous leukemia (K562), diffuse large B cell lymphoma (L22601), follicular lymphoma grade II/III (L5856), histiocytic lymphoma (U937), Hodgkin's lymphoma (HD5664), large B cell lymphoma (DB), non-Hodgkin's lymphoma (RL), and plasmacytoma (RPMI).

The mRNA derived from the tumor tissues was prepared from malignant B cells that had been isolated from the tumors. Tumor samples were obtained from different patients suffering from B cell lymphomas (H02-85T, H02-86T, H02-87T, H02-88T, H02-89T), follicular lymphoma (H02-74T, H02-75T, H02-76T, H02-77T, H02-78T), and myeloma (H02-79T, H02-80T, H02-81T, H02-82T, H02-83T, H02-84T). DNA sequences encoding Elongation Factor 1 were used as a positive control and normalization factors in all samples. All assays were performed in duplicate with the resulting values averaged. The y-axis shows the relative expression of the KIRHy1 mRNA, wherein the lowest expression was set as equal to 1 and the rest of the values are expressed as relative to 1.

Figure 3 shows that relatively little expression of the KIRHy1 gene was found in healthy tissues with the exception of tissues that either produce or are infiltrated by B lymphocytes, namely lymph node and small intestine. The results show that KIRHy1 is upregulated in B cell lymphoma, follicular lymphoma, myeloma, acute monocytic leukemia, histiocytic lymphoma, acute myelogenous leukemia, and acute myeloid

leukemia, indicating that KIRHy1 may be used as a therapeutic target or as a diagnostic marker for these types of disorders.

EXAMPLE 5

PRODUCTION OF KIRHY1-SPECIFIC ANTIBODIES

Cells expressing KIRHy1 are identified using antibodies to KIRHy1. Polyclonal antibodies are produced by DNA vaccination or by injection of peptide antigens into rabbits or other hosts. An animal, such as a rabbit, is immunized with a peptide from the extracellular region of KIRHy1 conjugated to a carrier protein, such as BSA (bovine serum albumin) or KLH (keyhole limpet hemocyanin). The rabbit is initially immunized with conjugated peptide in complete Freund's adjuvant, followed by a booster shot every two weeks with injections of conjugated peptide in incomplete Freund's adjuvant. Anti-KIRHy1 antibody is affinity purified from rabbit serum using KIRHy1 peptide coupled to Affi-Gel 10 (Bio-Rad), and stored in phosphate-buffered saline with 0.1% sodium azide.

One such polyclonal antibody was made using KLH conjugated to an immunogenic KIRHy1 peptide having the amino acid sequence Glu-Glu-Pro-Thr-Glu-Tyr-Ser-Thr-Ile-Ser-Arg-Pro (SEQ ID NO: 11). The anti-KIRHy1 peptide polyclonal antibody is herein denoted as 10458a. To determine that 10458a was KIRHy1-specific, an expression vector encoding a V5/His tagged-KIRHy1 (pIntron-KIRHy1, Nuvelo Inc.) was introduced into mammalian COS-7 cells. Western blot analysis of protein extracts of non-transfected cells and the KIRHy1-containing cells was performed using 10458a as the primary antibody and a horseradish peroxidase-labeled anti-rabbit antibody (donkey anti-rabbit IgG) as the secondary antibody. Detection of an approximately 48 kD band in the KIRHy1-containing cells and lack thereof in the control cells indicated that 10458a was specific for KIRHy1.

Monoclonal antibodies are produced by injecting mice with a KIRHy1 peptide, with or without adjuvant. Subsequently, the mouse is boosted every 2 weeks until an appropriate immune response has been identified (typically 1-6 months), at which point the spleen is removed. The spleen is minced to release splenocytes, which are fused (in the presence of polyethylene glycol) with murine myeloma cells. The resulting cells (hybridomas) are grown in culture and selected for antibody production by clonal

selection. The antibodies are secreted into the culture supernatant, facilitating the screening process, such as screening by an enzyme-linked immunosorbent assay (ELISA). Alternatively, humanized monoclonal antibodies are produced either by engineering a chimeric murine/human monoclonal antibody in which the murine-specific antibody regions are replaced by the human counterparts and produced in mammalian cells, or by using transgenic “knock out” mice in which the native antibody genes have been replaced by human antibody genes and immunizing the transgenic mice as described above.

EXAMPLE 6

DIAGNOSTIC METHODS USING KIRHY1-SPECIFIC ANTIBODIES TO DETECT KIRHY1 EXPRESSION

Expression of KIRHy1 in leukemia and myeloma cell lines was detected by Western blot analysis using the anti-KIRHy1 peptide polyclonal antibody 10458a (see Example 5 for Western details). The cell lines were derived from acute myelogenous leukemia (U-937, KG-1, Kasumi-3, GDM-1), acute monocytic leukemia (THP-1), acute promyelocytic leukemia (HL-60), and myeloma (U-266). All samples with the exception of HL-60 cells were positive for KIRHy1 expression (see Table 3).

Table 3

Cell Line	KIRHy1 protein expression
HL-60	-
U-266	+
THP-1	+
U-937	++
KG-1	++
Kasumi-3	++
GDM-1	++

The results show that KIRHy1 is highly expressed in acute myelogenous leukemia (AML) and to a lesser extent in myeloma and acute monocytic leukemia. In addition, these results are consistent with the relative expression of KIRHy1 mRNA (see Example 4), indicating that KIRHy1 targeting may be useful as a therapeutic treatment or diagnostic assay for these disorders.

Expression of KIRHy1 in tissue samples (normal or acute myelogenous leukemia (AML) bone marrow) was detected using the anti-KIRHy1 peptide polyclonal antibody, 10458a (see Example 5). Samples were prepared for immunohistochemical (IHC) analysis (LifeSpan Biosciences, Inc., Seattle, WA) by fixing the tissue in 10% formalin embedding in paraffin, and sectioning using standard techniques. Sections were stained using 10458a followed by incubation with a secondary horse radish peroxidase (HRP)-conjugated antibody and visualized by the product of the HRP enzymatic reaction. Data as seen in Table 4 shows that KIRHy1 is highly expressed on the cell surface of AML bone marrow tissues (in 5 out of 5 patient samples). No expression of KIRHy1 was observed on the cell surface of normal bone marrow samples (5 out of 5 patient samples). These data show that KIRHy1 expression is found in AML tissues and are consistent with the relative expression of KIRHy1 mRNA (see Example 4).

Table 4

Tissue	Positive	Total
Acute myelogenous leukemia bone marrow	5	5
Normal bone marrow	0	5

Additionally, antibody blocking assays were performed and analyzed by IHC. Normal and AML bone marrow tissue samples were prepared for IHC as stated above; however, before the samples were incubated with 10458a, 10458a was pre-treated with an excess of SEQ ID NO: 11 and then processed as stated above. In all the samples tested (5 out of 5), SEQ ID NO: 11 blocked the reactivity of 10458a in the AML bone marrow samples (see Table 5).

Table 5

Tissue	Positive	Total
AML bone marrow	5	5
AML bone marrow blocked with SEQ ID NO: 11	0	5
Normal bone marrow	0	5

Expression of KIRHy1 on the surface of cells within a blood sample is detected by flow cytometry. Peripheral blood mononuclear cells (PBMC) are isolated from a blood sample using standard techniques. The cells are washed with ice-cold PBS and incubated on ice with the KIRHy1-specific polyclonal antibody for 30 min. The cells are

gently pelleted, washed with PBS, and incubated with a fluorescent anti-rabbit antibody for 30 min. on ice. After the incubation, the cells are gently pelleted, washed with ice cold PBS, and resuspended in PBS containing 0.1% sodium azide and stored on ice until analysis. Samples are analyzed using a FACScalibur flow cytometer (Becton Dickinson) and CELLQuest software (Becton Dickinson). Instrument setting are determined using FACS-Brite calibration beads (Becton-Dickinson).

Tumors expressing KIRHy1 is imaged using KIRHy1-specific antibodies conjugated to a radionuclide, such as ^{123}I , and injected into the patient for targeting to the tumor followed by X-ray or magnetic resonance imaging.

EXAMPLE 7

IN VITRO ANTIBODY-DEPENDENT CYTOTOXICITY ASSAY

The ability of a KIRHy1-specific antibody to induce antibody-dependent cell-mediated cytotoxicity (ADCC) is determined *in vitro*. ADCC is performed using the CytoTox 96 Non-Radioactive Cytotoxicity Assay (Promega; Madison, WI) (Hornick *et al.*, *Blood* 89:4437-4447, (1997)) as well as effector and target cells. Peripheral blood mononuclear cells (PBMC) or neutrophilic polymorphonuclear leukocytes (PMN) are two examples of effector cells that can be used in this assay. PBMC are isolated from healthy human donors by Ficoll-Paque gradient centrifugation, and PMN are purified by centrifugation through a discontinuous percoll gradient (70% and 62%) followed by hypotonic lysis to remove residual erythrocytes. RA1 B cell lymphoma cells (for example) are used as target cells.

RA1 cells are suspended in RPMI 1640 medium supplemented with 2% fetal bovine serum and plated in 96-well V-bottom microtiter plates at 2×10^4 cells/well.

KIRHy1-specific antibody is added in triplicate to individual wells at 1 $\mu\text{g}/\text{ml}$, and effector cells are added at various effector:target cell ratios (12.5:1 to 50:1). The plates are incubated for 4 hours at 37°C. The supernatants are then harvested, lactate dehydrogenase release determined, and percent specific lysis calculated using the manufacture's protocols.

EXAMPLE 8

TOXIN-CONJUGATED KIRHy1-SPECIFIC ANTIBODIES

Antibodies to KIRHy1 are conjugated to toxins and the effect of such conjugates in animal models of cancer is evaluated. Chemotherapeutic agents, such as calicheamycin and carboplatin, or toxic peptides, such as ricin toxin, are used in this approach. Antibody-toxin conjugates are used to target cytotoxic agents specifically to cells bearing the antigen. The antibody-toxin binds to these antigen-bearing cells, becomes internalized by receptor-mediated endocytosis, and subsequently destroys the targeted cell. In this case, the antibody-toxin conjugate targets KIRHy1-expressing cells, such as B cell lymphomas, and deliver the cytotoxic agent to the tumor resulting in the death of the tumor cells.

One such example of a toxin that may be conjugated to an antibody is carboplatin. The mechanism by which this toxin is conjugated to antibodies is described in Ota *et al.*, *Asia-Oceania J. Obstet. Gynaecol.* 19: 449-457 (1993). The cytotoxicity of carboplatin-conjugated KIRHy1-specific antibodies is evaluated *in vitro*, for example, by incubating KIRHy1-expressing target cells (such as the RA1 B cell lymphoma cell line) with various concentrations of conjugated antibody, medium alone, carboplatin alone, or antibody alone. The antibody-toxin conjugate specifically targets and kills cells bearing the KIRHy1 antigen, whereas, cells not bearing the antigen, or cells treated with medium alone, carboplatin alone, or antibody alone, show no cytotoxicity.

The antitumor efficacy of carboplatin-conjugated KIRHy1-specific antibodies is demonstrated in *in vivo* murine tumor models. Five to six week old, athymic nude mice are engrafted with tumors subcutaneously or through intravenous injection. Mice are treated with the KIRHy1-carboplatin conjugate or with a non-specific antibody-carboplatin conjugate. Tumor xenografts in the mouse bearing the KIRHy1 antigen are targeted and bound to by the KIRHy1-carboplatin conjugate. This results in tumor cell killing as evidenced by tumor necrosis, tumor shrinkage, and increased survival of the treated mice.

Other toxins are conjugated to KIRHy1-specific antibodies using methods known in the art. An example of a toxin conjugated antibody in human clinical trials is CMA-

676, an antibody to the CD33 antigen in AML which is conjugated with calicheamicin toxin (Larson, *Semin. Hematol.* 38(Suppl 6):24-31 (2001)).

EXAMPLE 9

5 RADIO-IMMUNOTHERAPY USING KIRHY1-SPECIFIC ANTIBODIES

Animal models are used to assess the effect of antibodies specific to KIRHy1 as vectors in the delivery of radionuclides in radio-immunotherapy to treat lymphoma, hematological malignancies, and solid tumors. Human tumors are propagated in 5-6 week old athymic nude mice by injecting a carcinoma cell line or tumor cells
10 subcutaneously. Tumor-bearing animals are injected intravenously with radio-labeled anti-KIRHy1 antibody (labeled with 30-40 μ Ci of 131 I, for example) (Behr, *et al.*, *Int. J. Cancer* 77: 787-795 (1988)). Tumor size is measured before injection and on a regular basis (*i.e.* weekly) after injection and compared to tumors in mice that have not received treatment. Anti-tumor efficacy is calculated by correlating the calculated mean tumor
15 doses and the extent of induced growth retardation. To check tumor and organ histology, animals are sacrificed by cervical dislocation and autopsied. Organs are fixed in 10% formalin, embedded in paraffin, and thin sectioned. The sections are stained with hematoxylin-eosin.

20 EXAMPLE 10

IMMUNOTHERAPY USING KIRHY1-SPECIFIC ANTIBODIES

Animal models are used to evaluate the effect of KIRHy1-specific antibodies as targets for antibody-based immunotherapy using monoclonal antibodies. Human myeloma cells are injected into the tail vein of 5-6 week old nude mice whose natural
25 killer cells have been eradicated. To evaluate the ability of KIRHy1-specific antibodies in preventing tumor growth, mice receive an intraperitoneal injection with KIRHy1-specific antibodies either 1 or 15 days after tumor inoculation followed by either a daily dose of 20 μ g or 100 μ g once or twice a week, respectively (Ozaki, *et al.*, *Blood* 90:3179-3186 (1997)). Levels of human IgG (from the immune reaction caused by the human
30 tumor cells) are measured in the murine sera by ELISA.

The effect of KIRHy1-specific antibodies on the proliferation of myeloma cells is examined *in vitro* using a ^3H -thymidine incorporation assay (Ozaki *et al.*, *supra*). Cells are cultured in 96-well plates at 1×10^5 cells/ml in 100 μl /well and incubated with various amounts of KIRHy1 antibody or control IgG (up to 100 $\mu\text{g}/\text{ml}$) for 24 h. Cells are
5 incubated with 0.5 μCi ^3H -thymidine (New England Nuclear, Boston, MA) for 18 h and harvested onto glass filters using an automatic cell harvester (Packard, Meriden, CT). The incorporated radioactivity is measured using a liquid scintillation counter.

The cytotoxicity of the KIRHy1 monoclonal antibody is examined by the effect of complements on myeloma cells using a ^{51}Cr -release assay (Ozaki *et al.*, *supra*).
10 Myeloma cells are labeled with 0.1 mCi ^{51}Cr -sodium chromate at 37°C for 1 h. ^{51}Cr -labeled cells are incubated with various concentrations of KIRHy1 monoclonal antibody or control IgG on ice for 30 min. Unbound antibody is removed by washing with medium. Cells are distributed into 96-well plates and incubated with serial dilutions of baby rabbit complement at 37°C for 2 h. The supernatants are harvested from each well
15 and the amount of ^{51}Cr released is measured using a gamma counter. Spontaneous release of ^{51}Cr is measured by incubating cells with medium alone, whereas maximum ^{51}Cr release is measured by treating cells with 1% NP-40 to disrupt the plasma membrane. Percent cytotoxicity is measured by dividing the difference of experimental and spontaneous ^{51}Cr release by the difference of maximum and spontaneous ^{51}Cr
20 release.

Antibody-dependent cell-mediated cytotoxicity (ADCC) for the KIRHy1 monoclonal antibody is measured using a standard 4 h ^{51}Cr -release assay (Ozaki *et al.*, *supra*). Splenic mononuclear cells from SCID mice are used as effector cells and cultured with or without recombinant interleukin-2 (for example) for 6 days. ^{51}Cr -labeled
25 target myeloma cells (1×10^4 cells) are placed in 96-well plates with various concentrations of anti-KIRHy1 monoclonal antibody or control IgG. Effector cells are added to the wells at various effector to target ratios (12.5:1 to 50:1). After 4 h, culture supernatants are removed and counted in a gamma counter. The percentage of cell lysis is determined as above.

30

EXAMPLE 11

KIRHy1-SPECIFIC ANTIBODIES AS IMMUNOSUPPRESSANTS

Animal models are used to assess the effect of KIRHy1-specific antibodies block signaling through the KIRHy1 receptor to suppress autoimmune diseases, such as arthritis or other inflammatory conditions, or rejection of organ transplants. Immunosuppression is tested by injecting mice with horse red blood cells (HRBCs) and assaying for the levels of HRBC-specific antibodies (Yang, *et al.*, *Int. Immunopharm.* 2:389-397 (2002)). Animals are divided into five groups, three of which are injected with anti-KIRHy1 antibodies for 10 days, and 2 of which receive no treatment. Two of the experimental groups and one control group are injected with either Earle's balanced salt solution (EBSS) containing $5-10 \times 10^7$ HRBCs or EBSS alone. Anti-KIRHy1 antibody treatment is continued for one group while the other groups receive no antibody treatment. After 6 days, all animals are bled by retro-orbital puncture, followed by cervical dislocation and spleen removal. Splenocyte suspensions are prepared and the serum is removed by centrifugation for analysis.

Immunosuppression is measured by the number of B cells producing HRBC-specific antibodies. The Ig isotype (for example, IgM, IgG1, IgG2, *etc.*) is determined using the IsoDetect™ Isotyping kit (Stratagene, La Jolla, CA). Once the Ig isotype is known, murine antibodies against HRBCs are measured using an ELISA procedure. 96-well plates are coated with HRBCs and incubated with the anti-HRBC antibody-containing sera isolated from the animals. The plates are incubated with alkaline phosphatase-labeled secondary antibodies and color development is measured on a microplate reader (SPECTRAmax 250, Molecular Devices) at 405 nm using *p*-nitrophenyl phosphate as a substrate.

Lymphocyte proliferation is measured in response to the T and B cell activators concanavalin A and lipopolysaccharide, respectively (Jiang, *et al.*, *J. Immunol.* 154:3138-3146 (1995)). Mice are randomly divided into 2 groups, 1 receiving anti-KIRHy1 antibody therapy for 7 days and 1 as a control. At the end of the treatment, the animals are sacrificed by cervical dislocation, the spleens are removed, and splenocyte suspensions are prepared as above. For the *ex vivo* test, the same number of splenocytes are used, whereas for the *in vivo* test, the anti-KIRHy1 antibody is added to the medium

at the beginning of the experiment. Cell proliferation is also assayed using the ^3H -thymidine incorporation assay described above (Ozaki, *et al.*, *Blood* 90: 3179 (1997)).

EXAMPLE 12

5 CYTOKINE SECRETION IN RESPONSE TO KIRHY1 PEPTIDE FRAGMENTS

Assays are carried out to assess activity of fragments of the KIRHy1 protein, such as the Ig domain, to stimulate cytokine secretion and to stimulate immune responses in NK cells, B cells, T cells, and myeloid cells. Such immune responses can be used to stimulate the immune system to recognize and/or mediate tumor cell killing or
10 suppression of growth. Similarly, this immune stimulation can be used to target bacterial or viral infections. Alternatively, fragments of the KIRHy1 that block activation through the KIRHy1 receptor may be used to block immune stimulation in natural killer (NK), B, T, and myeloid cells.

Fusion proteins containing fragments of the KIRHy1, such as the Ig domain
15 (KIRHy1-Ig), are made by inserting a CD33 leader peptide, followed by a KIRHy1 domain fused to the Fc region of human IgG1 into a mammalian expression vector, which is stably transfected into NS-1 cells, for example. The fusion proteins are secreted into the culture supernatant, which is harvested for use in cytokine assays, such as interferon- γ (IFN- γ) secretion assays (Martin, *et al.*, *J. Immunol.* 167:3668-3676 (2001)).

20 PBMCs are activated with a suboptimal concentration of soluble CD3 and various concentrations of purified, soluble anti-KIRHy1 monoclonal antibody or control IgG. For KIRHy1-Ig cytokine assays, anti-human Fc Ig at 5 or 20 $\mu\text{g/ml}$ is bound to 96-well plates and incubated overnight at 4°C. Excess antibody is removed and either KIRHy1-Ig or control Ig is added at 20-50 $\mu\text{g/ml}$ and incubated for 4 h at room temperature. The
25 plate is washed to remove excess fusion protein before adding cells and anti-CD3 to various concentrations. Supernatants are collected after 48 h of culture and IFN- γ levels are measured by sandwich ELISA, using primary and biotinylated secondary anti-human IFN- γ antibodies as recommended by the manufacturer.

EXAMPLE 13

TUMOR IMAGING USING KIRHy1-SPECIFIC ANTIBODIES

KIRHy1-specific antibodies are used for imaging KIRHy1-expressing cells *in vivo*. Six-week-old athymic nude mice are irradiated with 400 rads from a cesium source.

5 Three days later the irradiated mice are inoculated with 4×10^7 RA1 cells and 4×10^6 human fetal lung fibroblast feeder cells subcutaneously in the thigh. When the tumors reach approximately 1 cm in diameter, the mice are injected intravenously with an inoculum containing 100 $\mu\text{Ci}/10 \mu\text{g}$ of ^{131}I -labeled KIRHy1-specific antibody. At 1, 3, and 5 days postinjection, the mice are anesthetized with a subcutaneous injection of 0.8
10 mg sodium pentobarbital. The immobilized mice are then imaged in a prone position with a Spectrum 91 camera equipped with a pinhole collimator (Raytheon Medical Systems; Melrose Park, IL) set to record 5,000 to 10,000 counts using the Nuclear MAX Plus image analysis software package (MEDX Inc.; Wood Dale, IL) (Hornick, *et al.*, *Blood* 89:4437-4447 (1997)).

15

EXAMPLE 14

IN VIVO TUMOR MODELS

The tumor suppressing activity of KIRHy1 targeting molecules is tested by taking groups of 4-10 nude, athymic male mice are injected subcutaneously with 10^6 cells, either
20 a control (M12pcDNA), KIRHy1 expressing clones, or low expressing clones (Spenger *et al.*, *Cancer Research* 59:2370-2375 (1999), incorporated herein by reference in its entirety). The clones the lowest levels of KIRHy1 are used as the comparison benchmark. Mice are monitored for 8 weeks for weight gain/loss and tumor formation. Tumor volume is calculated using the formula $(l \times w^2)/2$ (where l = length and w = width of the tumor)
25 (*Id.*).

Statistical analysis using the Kruskal-Wallis method for comparing tumor formation, and the Mann-Whitney U test for comparing tumor volume are performed to determine any statistical significance amongst groups.

After 8 weeks, the mice are sacrificed, and the tumors removed and digested with
30 0.1% collagenase (Type I) and 50 $\mu\text{g}/\text{ml}$ DNase (Worthington Biochemical Corp., Freehold, NJ). Dispersed cells are plated in ITS medium/5% FBS at % CO_2 at 37°C for

24 hours to allow attachment. After 24 hours, the cultures are switched to serum-free medium. The cells are split, the media and RNA collected, and Western immunoblots and Northern blots are done to detect KIRHy1.

5

EXAMPLE 15

***IN VITRO* ASSAY OF CELL PROLIFERATION AND MIGRATION**

The effect of KIRHy1-specific antibodies or therapeutic peptides on the proliferation of myeloma cells is examined *in vitro* using a ³H-thymidine incorporation assay (Ozaki *et al.*, *Blood* 90:3179-3186 (1997), herein incorporated by reference in its entirety. Tumor cells are cultured in 96-well plates at 1×10^5 cells/ml in 100 μ l/well and incubated with various amounts of antibody or control IgG (up to 100 μ g/ml) for 24 h. Cells are incubated with 0.5 μ Ci ³H-thymidine (New England Nuclear, Boston, MA) for 18 h and harvested onto glass filters using an automatic cell harvester (Packard, Meriden, CT). The incorporated radioactivity is measured using a liquid scintillation counter.

15 Cell migration is conducted in 24-well, 6.5-mm internal diameter Transwell cluster plates (Corning Costar, Cambridge, MA). Briefly, 10^5 cells/75 μ l are loaded onto fibronectin (5 μ M)-coated polycarbonate membranes (8- μ m pore size) separating two chambers of a transwell (Tai *et al.*, *Blood* 99:1419-1427 (2002), herein incorporated by reference in its entirety. Medium with or without anti-KIRHy1 antibodies is added to the lower chamber

20 of the Transwell cluster plates. After 8-16 h, cells migrating to the lower chamber are counted using a Coulter counter ZBII (Beckman Coulter) and by hemacytometer.